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ABSTRACT
Q-GRIFFITHSIN INTERACTIONS AND UTILITY FOR THE PREVENTION AND
TREATMENT OF MUCOSAL INFECTIONS
Henry Nabeta
September 30, 2021
Griffithsin (GRFT) is a carbohydrate binding agent (lectin) that was originally
identified in the red alga Griffithsia sp. Q-Griffithsin (Q-GRFT) is an oxidation stable
analog of GRFT. GRFT has demonstrated inhibitory activity against HIV-1,
Coronaviruses, Hepatitis C, influenza and Ebola viruses. The broad-spectrum activity
suggests the potential utility of this lectin in a wide range of viral infections. However,
the lectin’s activity in mucosal infections has not been extensively studied. Using in vitro,
ex vivo and in vivo assays, we have demonstrated that Q-GRFT maintains the ability to
bind glycosylated ligands following incubation in murine, macaque and human rectal
fluids. Additionally, we demonstrated the first reported in vitro findings of antifungal
activity by Q-GRFT. Furthermore, in murine prophylaxis and therapeutic infection
models, Q-GRFT was efficacious against vaginal candidiasis. In response to the ongoing
COVID-19 pandemic, we have demonstrated that in engineered human cornea and
airway epithelia, repeated topical application resulted in Q-GRFT accumulation in
mucosal tissues. In addition, in a human cadaver study, intranasal administration resulted
in adequate drug dispersion on the nasal, nasopharyngeal and oropharyngeal cavities,
with the drug detected in fluids collected from these anatomic sites. These findings
support the development of a protocol for a Phase 1a first-in-human intranasal Q-GRFT
administration to evaluate safety, tolerability, and pharmacokinetics of the drug product
for pre-exposure prophylaxis against coronaviruses.
Altogether, these data demonstrated Q-GRFT’s stability in the mucosal
environment and support its incorporation in multipurpose STI prevention modalities
v

given the novel antifungal activity. Epithelial accumulation and ability to detect Q-GRFT
in nasal specimens supports the feasibility of successfully performing the Phase 1a study
and future drug development as a prophylaxis against coronaviruses.

TABLE OF CONTENTS
DEDICATION .................................................................................................................... ii
ACKNOWLEDGEMENTS ............................................................................................... iv
ABSTRACT.........................................................................................................................v
LIST OF TABLES ........................................................................................................... viii
LIST OF FIGURES .............................................................................................................x
CHAPTER 1: INTRODUCTION AND BACKGROUND .................................................1
INTRODUCTION ............................................................................................................1
ENDOGENOUS LECTINS AND THEIR ROLES IN MUCOSAL INFECTIONS .......2
EXOGENOUS LECTINS AND THEIR ROLES IN MUCOSAL INFECTIONS ........21
CONCLUSION ..............................................................................................................29
CHAPTER 2: STABILITY OF Q-GRIFFITHSIN IN THE RECTAL MUCOSAL
ENVIRONMENT ..............................................................................................................30
INTRODUCTION ..........................................................................................................30
MATERIALS AND METHODS ...................................................................................31
RESULTS.......................................................................................................................34
DISCUSSION ................................................................................................................38
CHAPTER 3: IMPACT OF Q-GRFT ON THE GROWTH OF GUT AND RECTAL
MICROBIOME, AND MYCOBIOME COMPONENTS .................................................42
INTRODUCTION ..........................................................................................................42
MATERIALS AND METHODS ...................................................................................43
RESULTS.......................................................................................................................51
DISCUSSION ................................................................................................................78
CHAPTER 4: EFFICACY AND IMMUNOLOGICAL CONSEQUENCE OF Q-GRFT
IN VAGINAL CANDIDIASIS..........................................................................................84
INTRODUCTION ..........................................................................................................84
MATERIALS AND METHODS ...................................................................................86
RESULTS.......................................................................................................................89
DISCUSSION ................................................................................................................99

CHAPTER 5: DEVELOPMENT OF Q-GRFT AS AN INTRANASAL SPRAY FOR
BROAD-SPECTRUM CORONAVIRUSES PROPHYLAXIS ......................................104
INTRODUCTION ........................................................................................................104
PRE-CLINICAL EXPERIMENTAL STUDY RESULTS ..........................................110
PHASE 1A CLINICAL STUDY PROTOCOL DESIGN............................................117
DISCUSSION ..............................................................................................................134
CHAPTER 6: CONCLUSION AND FUTURE DIRECTIONS .....................................137
REFERENCES ................................................................................................................151
CURRICULUM VITAE ..................................................................................................188

LIST OF TABLES
Table 1.1 Endogenous lectins and their binding ligands on mucosal pathogens .................3
Table 1.2 GRFT effective concentrations to inhibit 50% virus infection (EC50). .............23
Table 1.3 Mucosal pathogen binding ligands for Griffithsin .............................................23
Table 2.1 Physicochemical properties of murine rectal fluids .......................................... 35
Table 2.2 Physicochemical properties of human rectal fluids ...........................................36
Table 3.1 Sample and Barcode Information ......................................................................50
Table 3.2 MIC50 results for Q-GRFT against Chlamydia trachomatis and Neisseria
gonorrhea...........................................................................................................................54
Table 3.3 Competition ELISA assay values (EC50 and 95% CI) for Q-GRFT binding to
α-mannan, chitin and β-glucan. .........................................................................................60
Table 3.4 MIC50s and MIC90s of Q-GRFT against different Candida species ..................67
Table 3.5 The top 20 down-regulated DEGs for 7.8 µM Q-GRFT treated C. albicans
(1QG) vs non-treated control (VC) cells.......................................................................... 71
Table 3.6 The top 20 down-regulated DEGs for 0.78 µM Q-GRFT treated C. albicans
(2QG) vs non-treated control (VC) cells. ..........................................................................72
Table 3.7 The top 20 down-regulated DEGs for 7.8 µM Q-GRFTlec neg treated C. albicans
(3QG) vs non-treated control (VC) cells. ..........................................................................73
Table 3.8 Comparison of differentially expressed genes following C. albicans growth at
different conditions ............................................................................................................76
Table 3. 9 Q-GRFT specific differentially expressed genes following C. albicans
treatment for 4 hours at 37°C .............................................................................................77
Table 5.1 P-values for EpiAirway tissues treatment with Q-GRFT. ...............................111
Table 5.2 P-values for EpiAirway tissues treatment with Q-GRFT. ...............................112
Table 5.3 Phase 1a study arms . .......................................................................................119
Table 5.4 Schedule of Phase 1a study visits and evaluations .........................................130
Table 5.5 Analysis of Safety Event Frequency for Arms of Size 12 (Q-GRFT nasal spray)
..........................................................................................................................................132
Table 5.6 Analysis of Safety Event Frequency for Arms of Size 6 (placebo spray). ......133
Table 5.7 Analysis of safety event frequency for both arms of size 18 ...........................134

ix

LIST OF FIGURES
Figure 1.1 Sequence and structure of Griffithsin ...............................................................22
Figure 2.1 Stability of Q-GRFT in rectal fluids and seminal plasma ................................37
Figure 3.1 Bioinformatics analysis workflow diagram .....................................................50
Figure 3.2 Q-GRFT inhibits HIV PsV QH069 replication ............................................... 51
Figure 3.3 The effect of Q-GRFT on the growth of rectal microbiome (bacterial)
components ........................................................................................................................53
Figure 3.4 Effect of on the growth of C. albicans ............................................................55
Figure 3.5 Q-GRFT binds to C. albicans ..........................................................................57
Figure 3.6 Q-GRFT binds to C. albicans cell wall ...........................................................59
Figure 3.7 Effect of Q-GRFT on C. albicans' cell integrity and oxidative status .............62
Figure 3. 8 C. albicans surface phenotype following treatment with Q-GRFT ...............64
Figure 3. 9 Impact of Q-GRFT on growth of non-C. albicans species ............................66
Figure 3. 10 C. albicans RNA expression profile following treatment with Q-GRFT ....70
Figure 3.11 C. albicans RNA expression profile following treatment with Q-GRFT .....73
Figure 3. 12 Top 20 enriched GO functions/ biological processes of DEGs with the
adjusted P-values (FDR) ....................................................................................................75
Figure 3. 13 Experimental plan to determine early RNA expression following C. albicans
treatment at different conditions. .......................................................................................76
Figure 4. 1 Q-GRFT significantly inhibits vaginal fungal infection in a prophylaxis model
of murine candidiasis. ........................................................................................................91
Figure 4. 2 Efficacy of Q-GRFT in a murine model of vaginal candidiasis. .....................93
Figure 4.3 Q-GRFT treatment is associated with lower levels of vaginal inflammation in
candidiasis ..........................................................................................................................97
Figure 4.4 Histological evaluation of vaginal candidiasis following treatment with QGRFT .................................................................................................................................99
Figure 5.1 Q-GRFT accumulation by dose in epithelial tissues following treatment .....111
Figure 5.2 Q-GRFT does not affect basal expression of inflammatory cytokines in airway
epithelium ........................................................................................................................113
Figure 5.3 Q-GRFT does not affect basal expression of inflammatory cytokines in cornea
epithelium ........................................................................................................................114

Figure 5.4 Q-GRFT is detectable in the human nasal cavity, nasopharynx, and
oropharynx .......................................................................................................................116
Figure 5.5 Q-GRFT is quantifiable in the human nasal cavity, nasopharynx, and
oropharynx .......................................................................................................................117
Figure 5.6 Phase 1a study design .....................................................................................119

xi

CHAPTER 1: INTRODUCTION AND BACKGROUND
THE ROLE OF LECTINS IN THE IMMUNE RESPONSE TO MUCOSAL
INFECTIONS
INTRODUCTION
Lectins are proteins that recognize and interact with carbohydrate moieties (1).
Endogenous lectins, encoded by the mammalian genome, include the collectin and
galectin families. Collectins are collagenous C-type lectins (which require calcium for
binding) and consist of a carbohydrate recognition domain (CRD) and a collagen-like
domain. Examples include surfactant protein A (SP-A), surfactant protein D (SP-D) and
mannose-binding lectin (MBL) (2, 3). Galectins consist of a CRD with β-sandwich fold
and β-galactosidase-binding ability (4). Endogenous lectins play a major role in the
innate immune system’s recognition of microbial pathogens and commensal organisms.
Presumably GRFT plays a similar role in its parent organism, a marine red alga of the
genus Griffithsia. GRFT is a 25kDa domain swapped homodimer with a beta prism
structure that has three binding sites recognizing oligomannose structures on either side
of the homodimer, Figure 1.1 (5-9). GRFT displays an unusually potent antiviral activity
against HIV-1 and some other viral pathogens in vitro (8, 10, 11).
There is a rising trend in Candida species isolated from human subjects that
demonstrate resistance to antifungal agents (12). The Candida sp. cell wall comprises of
mannose sugar moieties in α-mannan, that interact with GRFT (13). We have made a
novel discovery of GRFT’s ability to interact with several Candida species, inhibiting
fungal growth (13). GRFT binds to glycan structures in coronaviruses envelope,
inhibiting viral replication (10). In response to the ongoing COVID-19 pandemic, our
laboratory is developing GRFT as a potential intranasal spray application to prevent
coronaviruses transmission and infection.
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This chapter reviews the role of both endogenous and exogenous lectins in
mucosal infections. A summary of endogenous lectins and their major target molecules
sugar binding specificity on mucosal pathogens is presented in Table 1.1. Binding targets
of GRFT is summarized in Table 1.3.
ENDOGENOUS LECTINS AND THEIR ROLES IN MUCOSAL INFECTIONS
COLLECTINS: SP-A and SP-D
SP-A and SP-D are lung C-type lectins secreted into the alveolar fluid by type II
alveolar epithelial cells (AEC), and into the airway lumen by submucosal- and Club cells
(2). These lectins also immunoprotective in the trachea and nasal mucosa (14, 15),
through their role as anti-infectious and immunomodulatory agents (16). By keeping the
lungs free of infections and inflammation, SP-A and SP-D ensure effective gaseous
exchange (16).
Numerous mechanisms have been proposed for the enhancement of pathogen
clearance by lung collectins. These include: (i) Lung collectins binding simultaneously to
bacteria and neutrophil extracellular traps (NET)-DNA, enhancing bacterial trapping by
the NETs (17); (ii) Collectins’ binding to and aggregating pathogens prevents cell entry,
resulting in their removal through either mucocilliary clearance or phagocytosis by
alveolar macrophages and neutrophils (2, 14, 18-20); (iii) Collectins upregulate the
expression of microbial recognition receptors-mannose receptors and scavenger receptor
SR-AI/II on the cell surface (21, 22); (iv) Collectins enhance the phagocytosis of
complement-coated particles and Ig-G-opsonized microbes (18, 23, 24).
SP-A and SP-D are involved in critical processes in the lung immune response to
pathogens, and recognize numerous respiratory microbes including viruses like
respiratory syncytial virus, adenovirus, influenza A virus and coronaviruses; fungi like
Aspergillus fumigatus, Cryptococcus neoformans, Pneumocystis jiroveci; bacteria like
Mycobacterium tuberculosis, Hemophilus influenzae and Pseudomonas aeruginosa;
helminths like Nippostrongylus brasiliensis and Schistosoma (14, 18, 20, 25-27).
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Table 1. 1 Endogenous lectins and their binding ligands on mucosal pathogens.
Endogenous lectin
Collectins
SP-A, SP-D

Pathogen

Binding ligand

Pneumocystis sp.

Nippostrongylus
brasiliensis
Influenza A virus
SP-A

SP-D

Galectins
Gal-1, Gal-3
Gal-1, Gal-9
Gal-1

Gal-3

Gal-9
Mannose-binding
lectin
MBL

Aspergillus fumigatus
Pseudomonas
aeruginosa
Hemophilus influenza
type A
HIV-1
SARS-CoV
Cryptococcus
neoformans
Mycobacterium
tuberculosis
Schistosoma mansoni

Citrobacter rodentium
Trichomonas vaginalis
Helicobacter pylori
Chlamydia trachomatis

HIV-1
Cryptococcus
neoformans
Paracoccidiodes
brasiliensis
Francisella novicida

Reference

Major surface glycoprotein
(MSG)

(28-30)

Glycoprotein A (GpA)
Nonspecific

(14, 30, 31)
(25)

Neuraminidase, HA1
component of hemaglutinin
Glycoproteins gp45, gp55
Outer membrane protein OprH

(32)

Major outer protein

(35)

gp120
Spike (S) protein
Mannoprotein 1,
glucuronoxylomannan
Lipoarabinomannan (LAM)

(36)
(37)
(38)

Fucα1-3GalNAc, Fucα13GlcNAc

(27)

Non-specific
Lipophosphoglycan (LPG)
Non-specific
Poly β-D-galactopyranosyl-(14)N-acetyl-D-glucosamine, β1-6-N-acetylglucosamine
gp120, X4, X4R5, R5
-

(40)
(41, 42)
(43)
(44, 45)

-

(48)

-

(49)

Spike (S) protein

(50)

SARS-CoV

(33)
(34)

(39)

(46)
(47)

Respiratory antiviral roles of SP-A and SP-D
Both SP-A and SP-D bind to human coronavirus 229E (HCoV-229E) virions in a
dose-dependent manner (26). SP-D binds to the severe acute respiratory syndrome
3

(SARS-CoV) glycosylated spike (S) protein in a calcium-dependent fashion (37). Both
SP-A and SP-D inhibited infection of human bronchial epithelial cells in a concentrationdependent manner, with SP-D demonstrating the greatest reduction in infection at similar
concentrations of lectin used. However, the inhibitory impact of SP-A and SP-D on
coronaviruses infection is likely dependent on the virus and pulmonary cell type being
infected. This is because pre-treatment with SP-A, but not SP-D, significantly reduced
infection of alveolar macrophages with HCoV-29E (26). Systemic SP-D levels have
previously been shown to corelate with infectious lung injury (51, 52), and may be
utilized as a biosignature of alveolar integrity in coronaviruses infection (53). In a study
that enrolled participants with pulmonary infections, 16 patients who had been
hospitalized with SARS-CoV type pneumonia exhibited significantly elevated serum SPD levels (53). In addition, they demonstrated a significant correlation between serum SPD and anti-SARS-CoV N protein IgG (53). Kerget et al., have proposed that SP-D may
be a surrogate marker for predicting the course and planning treatment in COVID-19
(54). In their study, they identify that SARS-CoV-2 infection was associated with higher
serum SP-D levels at admission, and among patients who developed macrophage
activation syndrome and acute respiratory distress than those who did not. Similarly,
Atsushi Saito et al. (55), have observed that serum SP-A and SP-D positively corelate
with COVID-19 severity in SARS-CoV-2 pneumonia.
By binding to SARS-CoV-2, SP-A and SP-D may modulate the inflammatory
response and/ or probably hinder human cell entry (16, 56). To support this hypothesis,
studies with recombinant human SP-D (rfhSP-D) have demonstrated initial success in
inhibiting cell entry and infection. In in vitro assays, rfhSP-D bound to S1 spike protein
of SARS-CoV-2 in a dose-responsive manner, and protected HEK293T cells against
infection with pseudotyped viral particles (57). Using human clinical samples, rfhSP-D
inhibited the binding between the S1 subunit receptor binding domain of SARS-CoV-2
spike protein and human angiotensin converting enzyme-2 (hACE-2) receptor,
attenuating viral infection and replication (58). These findings suggest the need for
further exploration of the role of lung collectins as potential and/or surrogate diagnostic
and therapeutic biosignatures for the severity and prognosis of COVID-19 in
symptomatic patients.
4

SP-D uses its CRD to bind to mannosylated, N-linked carbohydrates on
neuraminidase and the HA1 component of hemagglutinin (HA) of Influenza A virus
(IAV), mediating viral hemagglutination and infectivity (32). SP-A neutralizes IAV by
interacting with the virus via its sialic acid residues in the CRD (59). Animal studies
using mice deficient in SP-A and SP-D have demonstrated that when challenged
intranasally with IAV, collectin-deficient mice developed more severe disease when
compared to wild-type controls. In addition, SP-A and SP-D deficient mice displayed
attenuated viral clearance, with increased production of proinflammatory cytokines in
comparison to the controls (60, 61). Exogenous administration of the collectins in lungs
of SP-A- and SP-D- deficient mice resulted in decreased epithelial injury, a lower viral
load and attenuated production of proinflammatory cytokines like tumor necrosis factor
(TNF), interleukin-6 (IL-6) and interferon gamma (IFN-ɤ) following challenge with IAV
(62). However, because of differences in N-glycosylation patterns of viral HA, some
pandemic pH1N1 strains are resistant to SP-A neutralization (63).
Unlike a complete SP-A molecule that provides protection against IAV, a
recombinant/ truncated human surfactant protein A, rfhSP-A molecule was found to
enhance pH1N1 and H3N2 infection of A549 lung epithelial cells (63). This was
associated with increased transcription of proinflammatory cytokines TNF-α, IL-12, IL-6,
IFN-α and Regulated upon Activation, Normal T Cell Expressed and Presumably
Secreted (RANTES) (63). This response contrasts that observed with rfhSP-D, which
upon binding HA reduced expression of proinflammatory cytokines (64). A therapeutic
role of rfhSP-D has also been demonstrated by the ability to attenuate transduction of
Madine Darby canine kidney (MDCK) cells by H1 + N1 pseudotyped lentivirus particles,
hindering viral entry (64). Altogether, these results delineate that while still complex,
further studies still need to be undertaken to better understand the full potential of SP-A,
SP-D, and rfhSP-D for utility as therapeutics against IAV infection.
SP-A and SP-D interaction with respiratory fungal pathogens
Through its carbohydrate recognition domain, SP-D blocks immunoglobulin E
(IgE)’s specific binding to A. fumigatus, enhancing fungal phagocytosis by human
neutrophils and alveolar macrophages (33, 65). Interestingly, Madan et. al, (66) have also
5

demonstrated that SP-D protects against A. fumigatus-induced pulmonary
hypersensitivity in mice. Similarly, Haczku et al. (51) found that SP-D levels in lung
lavage fluids of BALB/c mice were elevated nine-fold during an allergic response to A.
fumigatus-induced airway inflammation. Additionally, the elevated SP-D levels
positively correlated with total serum IgE concentrations (51). Mice deficient in SP-D
gene are generally more susceptible to invasive pulmonary aspergillosis (IPA) and
display more severe disease symptoms compared to SP-A gene deficient rodents that are
resistant to disease (67).
A. fumigatus secretes N-glycosylated fungal ligands gp45 and gp55, as
glycoprotein antigens, which are recognized by SP-A. The secretory property and the
ligands’ recovery in culture filtrates has enabled their utility in aspergillosis
immunodiagnostics (33). In developing anti-Aspergillosis respiratory therapeutic agents,
Madan et al. have found that a recombinant protein containing an SP-D homotrimeric
neck region and CRD domains (rSP-D), and purified human proteins when administered
intranasally protect immunosuppressed mice from severe outcomes of lethal challenge
with A. fumigatus conidia (68). Similarly, intranasal treatment with recombinant fulllength (hSP-D) or truncated human SP-D (rhSP-D) improved survival in
immunocompromised mice with IPA, reduced lung fungal growth and increased
expression of TNF-alpha (TNF-α) and IFN-gamma (IFN-ɤ) in respiratory fluids. In
addition, macrophage inflammatory protein-1 alpha (MIP-1α) was elevated in these fluids
(69). These findings delineate the potential therapeutic benefits of recombinant forms of
SP-D in protection against infection with A. fumigatus conidia (69).
SP-A binds to encapsulated and non-capsulated Cryptococcus neoformans yeast
forms in a concentration dependent manner. In contrast to encapsulated strain binding,
recognition of non-encapsulated variants did not enhance phagocytosis by monocytederived macrophages and human-alveolar macrophages (70). In a study by Giles et al.,
SP-A binding to C. neoformans is IgG dependent and subsequently inhibits alveolar
macrophage IgG-mediated fungal phagocytosis (71). Using an inhalation challenge
mouse model, they found that SP-A binding had no impact on host defense immune
mechanisms against pulmonary C. neoformans infection. On the other hand, SP-D binds
6

to cryptococcal capsular components mannoprotein 1 and glucuronoxylomannan (38).
Despite interactions with both encapsulated and non-encapsulated cryptococci, only nonencapsulated binding resulted in aggregation by SP-D (38). Geunes-Boyer et al. have
demonstrated that SP-D facilitates C. neoformans infection in vivo (72). They found that
SP-D -deficient mice are partially protected from infection, displaying a lower fungal
burden compared to wild-type controls. Furthermore, in both in vitro and in vivo studies,
SP-D binding protected yeast cells against macrophage-mediated destruction mechanisms
and hydrogen peroxide-induced oxidative stress (72).
SP-A and SP-D bind the major surface glycoprotein (MSG), a predominant
membrane protein rich in mannose residues, and used by Pneumocystis sp. to attach to
alveolar epithelium (28). SP-D also binds to β-glucans found on cystic forms of
Pneumocystis (29, 30). Interestingly, SP-A and SP-D demonstrate divergent outcomes
upon interacting with P. jiroveci. Upon binding to the mannose-rich glycoprotein (GPA)
in the cell wall, SP-D blocks Pneumocystis’ interaction with macrophage mannose
receptors, inhibiting phagocytosis (14, 30, 31). In contrast, SP-A binds to GPA and
enhances Pneumocystis’s interaction with alveolar macrophages. In demonstrating this
phenomenon, Atochina et al. found that mice lacking SP-A were more susceptible to P.
carinii infection, and produced lower quantities of reactive oxygen-nitrogen species and
proinflammatory cytokines compared to wild-type controls(73). It has been proposed that
differences in the tertiary structure of these collectins may contribute to the contrasting
outcomes despite binding to the same receptor (74).
Interaction of SP-A and SP-D with respiratory bacterial pathogens
Purified SP-D derived from healthy- human donor bronchoalveolar lavage fluids
was demonstrated to bind Mycobacterium tuberculosis, resulting in bacterial
agglutination (39). This binding was predominantly specific to lipoarabinomannan
(LAM) and led to bacterial adherence to macrophages. Bacterial adherence to monocytederived macrophages was also significantly increased upon binding to SP-A. Similarly,
Kazumi et al. have demonstrated that SP-D and SP-A bind to Mycobacterium avium in a
concentration- dependent manner (75). Both collectins enhanced M. avium phagocytosis
by rat alveolar- and human monocyte-derived macrophages. Upon binding, SP-A and SP7

D upregulated the expression of mannose receptors on monocyte-derived macrophages,
enhancing phagocytosis. The alanine-and proline-rich antigenic (Apa) glycoprotein has
also been identified as a binding target for SP-A on the M. tuberculosis cell wall. The
binding is calcium-and mannose-dependent (76). However, the impact of binding to this
receptor and its role on bacteria phagocytosis has not yet been explored or demonstrated.
A recombinant protein comprising of the neck-region and CRD of bovine SP-D
was expressed in E. coli by Lim et al. (77). This protein displayed similar carbohydratebinding specificity as the native protein and bound to lipopolysaccharides of
Pseudomonas aeruginosa and Klebsiella pneumoniae (77). Using Pseudomonsa
aeruginosa isolates from patients with cystic fibrosis, Qadi et al. identified outer
membrane protein OprH as a ligand for SP-A (34). They demonstrated that phagocytic
killing by macrophages was increased upon SP-A binding to OprH.
SP-A has also been shown to bind to the major outer membrane protein of
Hemophilus influenzae type A in a calcium-dependent fashion. The resultant
opsonization enhanced killing by alveolar macrophages in bactericidal assays (35).
Distinct immune roles have been proposed for SP-A and SP-D during pulmonary
infection with Hemophilus influenza (78). When challenged with H. influenza
intratracheally, SP-D-deficient (SP-D-/-) mice cleared infection, while SP-A -deficient
(SP-A-/-) animals demonstrated decreased bacterial killing. Mice deficient in either
collectin demonstrated decreased bacteria uptake by macrophages and increased
pulmonary inflammatory cell recruitment with inflammation-associated cytokines.
However, a significantly greater production of oxidants, superoxide and hydrogen
peroxide was associated with SP-D-/- -derived macrophages, while a lower production
was associated with SP-A-/- -isolated macrophages, when compared to wild-type mice
alveolar macrophages. It is likely that increased superoxides and peroxides contribute to
H. influenza killing in SP-D-/- mice.
Anti-helminthic role of SP-A and SP-D in pulmonary infections
Using mice lacking SP-A, Minuutti et al. have shown that IL-4-dependent
macrophage proliferation and activation in response to lung migratory helminth
Nippostrongylus brasiliensis infection is enhanced by the collectin (79). SP-A was
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associated with accelerated lung parasite clearance and lower pulmonary injury following
N. brasiliensis infection. Type 2 immunity is enhanced by pulmonary epithelial
responses, controlling nematode infections (25). Thawer et al. (25) have also
demonstrated that SP-D concentrations are elevated in respiratory fluids following N.
brasiliensis pulmonary infection. The host innate immune response to helminths was
impaired in SP-D-/- mice, resulting in persistence of infection. Administering pulmonary
SP-D prior to infection resulted in improved parasite clearance and enhanced expression
of cells and cytokines modulating the type 2 immune responses, like IL-13 -producing
type 2 innate lymphoid cells, increased markers of alternative activation of alveolar
macrophages, and elevated IL-4 and IL-13. Additionally, when naïve mice received
adoptively transferred alveolar macrophages from SP-D-treated helminth infected mice,
there was evidence of enhanced immunity to N. brasiliensis. The enhanced parasitic
killing was modulated by SP-D binding to the helminth via the CRD.
Fucosylated glycoconjugates Fucα1-3GalNAc and Fucα1-3GlcNAc are expressed
on the surface of Schistosoma mansoni, a blood fluke that transiently resides in the lung
during its life cycle and development (27). SP-D has been found to bind to S. mansoni
cercariae and schistosomula via the CRD, in a calcium-dependent manner, during the
pulmonary stage (27). However, the impact of this binding to worm elimination is yet to
be extensively studied.
Interaction of SP-A and SP-D with genitourinary mucosal virus pathogens
Herpes simplex virus (HSV), human papillomavirus (HPV) and human
immunodeficiency virus (HIV) are viral pathogens that may enter the human body via the
genitourinary mucosa. SP-A and SP-D are expressed in genitourinary tissues including
the vaginal epithelium, uterus, testis, prostate gland and kidneys (16, 80-82). These
collectins may bind and neutralize viral pathogens, preventing entry and replication in the
genitourinary mucosa.
Ujma et al., following findings that SP-A binds HPV16-PsV and impairs murine
infection, have proposed the collectin’s potential utility as a topical microbicide (83).
They showed that phagocytosis of HPV16-PsV by RAW264.7 murine macrophages was
enhanced by the HPV16-PsV/SP-A complex formed when SP-A bound pseudovirus
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(PsV) particles. Interestingly, recombinant SP-D bound HPV16-PsV, albeit weakly and
did not impact macrophage uptake. In a cervicovaginal challenge model, pre-incubation
of HPV16-PsV with purified human SP-A significantly attenuated murine pseudoviral
infection.
In binding assays, Iwaarden et. al demonstrated that SP-A recognized and
interacted with HSV-1 via the carbohydrate moiety in a concentration- dependent manner
(84). Additionally, in an in vitro study, SP-A, acting as an opsonin, enhanced
phagocytosis (85), demonstrating the lectin’s potential immune role in anti-HSV activity.
SP-A binds to the HIV envelope glycoprotein (gp120) in a calcium-dependent
manner (36). However, a dual modulatory role of both infection attenuation and
enhancement has been demonstrated upon SP-A interaction with different immune cells.
By binding gp120, SP-A inhibited infection of CD4+ T cells by HIV strains Bal and IIIB.
On the contrary, SP-A promoted gp120-dendritic cells (DCs) interaction, increased the
uptake of viral particles and significantly enhanced virus transfer from DCs to CD4+ T
cells (36). Similarly, SP-D inhibited HIV infectivity in in vitro assays, and enhanced viral
binding and capture by immature monocyte derived dendritic cells (iMDDCs).
Furthermore, lectin binding enhanced the transfer of HIV from iMDDCs to T-cell like
line PM1 (86). Alistar et al. posit that following HIV binding at the CRD, SP-A and SP-D
interact with other host receptors via the lectin’s N-terminus (16). They further delineate
that an engineered recombinant SP-A or SP-D molecule that is able to bind HIV, but
devoid of the N-terminus would be effective in virus neutralization, while avoiding
interaction with other immune cells (16), and impede transfer to lymphoid tissues (87).
Indeed, Dodagatta et al. have reported a direct protein-protein interaction between rfhSPD and Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin
(DC-SIGN) via C-type lectin domains (87). They demonstrated that SP-D and DC-SIGN
compete for binding to HIV-1 gp120, and the recombinant lectin significantly attenuated
HIV-1 transfer to activated peripheral blood monocytes. Given the paucity of data
available, more studies are needed to investigate interactions between collectins- SP-A
and SP-D, recombinant molecules- rfhSP-A and rfhSP-D, and HIV, and to establish their
impact on infectivity and virus transfer to other immune cells (16).
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GALECTINS
Galectins are animal lectins that share consensus amino acid sequences in the
CRD and possess a high affinity for β-galactosides (88). The galectin family is classified
based on the organization of CRD domains, namely:- (1) Prototype (galectins-1, -2, -5, 7, -10, -11, -13 and -14), consisting of monomers and homodimers of one CRD; (2)
Tandem Repeat group (galectins -4, -6, -8, -9 and -12), a two-CRD type that consists of
two distinct, yet homologous CRDs in a single polypeptide chain formation; (3) Chimeric
type (galectin-3), consisting of a non-lectin proline component and glycine-rich short
tandem repeats connected to a CRD (88, 89). Galectins are synthesized on cytosolic
ribosomes and may be packaged and delivered to intracellular vesicles and compartments
or secreted/ and translocated to the extracellular space (90, 91). Expression of these
lectins varies from one cell type to another and may depend on the individual cell’s
activation status (91).
Antimicrobial properties of galectins in respiratory mucosal infections
Using both in vitro assays and murine influenza virus infection models, Yang et
al. have demonstrated an innate immunity role for Gal-1 in respiratory viral pathogenesis
(92). Gal-1 bound to IAV in a dose-dependent manner, and inhibited virus-induced
hemagglutination activity in vitro. Additionally, Gal-1 protected MDCK cells from
infection with various subtypes of IAV. Intranasal challenge with IAV resulted in
enhanced Gal-1 expression in infected rodents. Furthermore, following infection, when
mice treated intranasally with Gal-3 were compared with vehicle-treated controls, they
had lower weight loss, a decreased viral burden, lower pulmonary inflammation, and
better survival, despite challenge with a lethal dose of IAV. Similarly, Gal-1 -deficient
mice had lower rates of survival after challenge with IAV compared to wild-type
controls.
Following pulmonary Francisella novicida infection, a novel alarmin role for
Gal-9 has been proposed, as the galectin enhances inflammation and modulates the
immune response in the resultant sepsis (49). Pulmonary Gal-9 expression peaked at the
onset of sepsis, was secreted extracellularly, and was associated with infiltration of lungs
with neutrophils and inflammatory cytokines (TNF-α, IL-6) in response to infection. Gal11

9 response and disease modulation during F. novicida murine infection exhibited
properties consistent with alarmin molecules. Upon infection, Gal-9 expression and
extracellular secretion were enhanced, the galectin stimulated an increased inflammatory
response to pathogens, while disease severity was attenuated in Gal-9 – deficient mice
(49).
Fungal pathogens Cryptococcus neoformans and Paracoccidioides brasiliensis
gain entry into the body via inhalation of infectious spores and conidia, respectively (93,
94). These fungal infections may manifest as pneumonia in susceptible
immunocompromised individuals (47, 95). In in vitro experiments, Gal-3 binds to ligands
in encapsulated C. neoformans strains and disrupts fungal viability of extracellular
vesicles through lysis (47). In both human and murine disease, pulmonary Gal-3 levels
are elevated following infection. Compared to wild-type controls, upon challenge with C.
neoformans, mice deficient in Gal-3 were more susceptible to infection, displayed a
higher fungal burden and succumbed to death earlier (47). Similarly, Gal-3 expression is
enhanced in human and murine P. brasiliensis infection (48). The galectin impeded
fungal growth through inhibition of budding and promoted denaturation and lysis of P.
brasiliensis extracellular vesicles. In addition, Gal-3 enhanced macrophage
internalization of extracellular vesicles (48).
Role of galectins in gastrointestinal mucosal infections
Galectin-1 (Gal-1) and galectin-3 (Gal-3) are significantly expressed in colonic
mucosal epithelial cells (96, 97). While Gal-3 mediates pro-inflammatory activity like
immune cell mobilization and maintenance, Gal -1 is anti-inflammatory, modulates
regulatory T cell recruitment and attenuates the inflammatory response (97-99). These
contrasting roles may be harnessed by the host to promote an inflammatory response to
pathogens while maintaining an immune homeostatic state (40). Using a colonic mouse
model of infection with the non-invasive Citrobacter rodentium, Curciarello et al.
determined that Gal-1 and Gal-3 contributed only minimally to immunity against the gut
pathogen (40). Upon challenge with C. rodentium, mice deficient in Gal-1 exhibited
reduced macrophage and T cell responses. Bacterial challenge in Gal-3 deficient animals
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was associated with delayed infection establishment, a prolonged duration of disease and
delayed colonic migration of T cells, macrophages, and dendritic cells.
In a human study of patients with chronic gastritis and positive for Helicobacter
pylori, Gal-3 and Gal-9 were significantly expressed in gastric epithelial mucosal cells,
while Gal-1 was found in elevated amounts in the stroma (43). H. pylori infection was
significantly associated with pro-inflammatory Gal-3 expression. Furthermore,
expression of Gal-9, a galectin with immunomodulatory and regulatory functions was
attenuated in epithelia of patients with chronic and chronic active gastritis. These data
demonstrate that further studies are needed to explore and understand the mechanisms of
galectins in modulation of gut mucosal infections.
Humoral mucosal immunity, largely driven by IgA is critical in the prevention of
colonization and establishment of pathogenic gut mucosal infections (100). Gal-9 may
modulate and contribute to the development of a mucosal adaptive immune response by
IgA through communication with T helper 17 (Th17) cells (101). Liang et al. have
demonstrated that following mucosal immunization, deficiency of Gal-9 in murine
models is associated with an impaired gut mucosal antigen-specific IgA response (101).
Immunized Gal-9 deficient mice exhibited an attenuated immune response to high dose
cholera toxin (CT) and had lower rates of survival in comparison with wild-type controls.
The paucity of lamina propria Th17 cells, attenuated IL17 gene expression, and lower
IgA in immunized Gal-9- deficient mice in comparison with wild-type controls,
underscores the role of this galectin in the Th-17-IgA axis (101).
Interaction of galectins with genitourinary mucosal pathogens
Gal-1 and Gal-3, expressed by human cervical and vaginal epithelial cells, bind
the protozoan parasite Trichomonas vaginalis via lipophosphoglycan (LPG), a
glycoconjugate rich in galactose (41, 42). Interestingly, modulation of immunity by these
galectins results in contrasting inflammatory responses, a feature that is exploited by the
protozoan parasite for its survival (42). Gal-1 attenuates the proinflammatory response,
resulting in reduced expression of phagocyte chemoattractant, IL-8, required to recruit
immune cells that eliminate the parasite. In addition, Gal-1 suppresses the expression of
Chemokine (C-C motif) ligand 20 (CCL20) and RANTES, chemokines that bridge the
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innate immune response to adaptive immunity (42). Conversely, Gal-3 enhances the
expression of chemokine IL-8 in the cervical-vagina environment. Moreover, in in vivo
studies, T. vaginalis was observed to deplete Gal-3 from the extracellular milieu (42).
Hence, the parasite manipulates and skews the immune response towards a Gal-1
predominant state, promoting its survival in cervico-vaginal tissues.
Endogenous, intracellularly expressed Gal-1 facilitates Chlamydia trachomatiscervicovaginal host cell interactions, while promoting pathogen adhesion and immune
evasion (44). Gal-1 interacts with C. trachomatis via numerous glycosylated ligands
expressed on the bacteria surface including poly β-D-galactopyranosyl-(1-4)-N-acetyl-Dglucosamine [poly-LacNAc]-enriched glycan epitopes and β1-6-N-acetylglucosamine
(β1-6GlcNAc)-branched complex N-glycans (44, 45). Furthermore, unlike the uniform
diffuse pattern, upon cellular infection, Gal-1 redistributes to localize around chlamydial
inclusion bodies. In HeLa cells, Gal-1 enhanced infection and formation of inclusion
bodies. Similarly, exogenous addition of the lectin during vaginal challenge of wild type
mice enhanced genital infection and promoted the formation of infectious bodies (44).
These results demonstrate Gal-1’s role in facilitating C. trachomatis infectivity.
The majority of HIV infections worldwide are sexually transmitted and occur
across mucosal epithelial barriers (102). Gal-1 is significantly expressed by immune
tissues and cells including lymphoid epithelial cells, activated B and T cells,
macrophages, follicular dendritic cells and CD4+CD25+ T regulatory cells (103-105). In
addition, T-helper subtype 1 (Th1) cells secrete substantial amounts of Gal-1 (55). CD4+
T cells, known to be highly susceptible to HIV-1 are localized in the lamina muscularis
mucosae, a region where Gal-1 is highly expressed (106, 107). In fact, Gal-1, by
crosslinking immune cell receptors (X4, X4R5 and R5) and glycoprotein 120 (Gp120)
enhances the initial virus binding and adsorption kinetics (46), directly promoting HIV-1
infectivity of CD4+ T cells and macrophages (46, 106). Additionally, upon HIV-1
binding the T cell receptor, intracellular galectin-3 translocates to the virological synapse,
co-localizing with G antigen (Gag), envelope (Env) and ALG-2-interacting protein X
(Alix) proteins (108, 109). This interaction promotes HIV-1 transfer and augments virus
transmission efficacy (108). Alix protein is critical in HIV-1 replication and working in
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concert with the endosomal sorting complex required for transport (ESCRFT), stimulates
virion propagation (109, 110). Moreover, Gal-3 enhances Alix-Gag association, an
interaction that amplifies HIV-1 budding, promoting infectivity (109). Definitive studies
will be imperative in establishing the potential efficacy and utility of galectin-blockade as
a modality in the prevention of HIV-1 infection and transmission in murine and human
subjects.
Role of galectins in ocular mucosal infections and immunity
The therapeutic potential and the ability of galectins to modulate the immune
response, tolerance, and inflammation in immune privileged sites, including the eye (111115), has been explored. Gal-1 may regulate the immune response via its
immunosuppressive impact on T cells including T-cell adhesion to extracellular milieu,
T-cell activation and Th1 cytokine release (114, 116-118). Gal-1’s probable role in
establishing immune privilege in the eye has been demonstrated by the lectin’s secretion
from retinal pigment epithelium, with the resultant suppression of T-cell activation (113,
114). Indeed, anti-retinal-Gal-1 antibodies (IgE, IgG and IgA) are significantly elevated
in the sera of patients with infectious uveitis, including toxoplasmic retinochoroiditis,
bacterial and retinochoroiditis (119). Moreover, the levels of these antibodies positively
correlated with progression and poor outcome of disease. Galectin-1 is likely secreted
into ocular tissues and aqueous humor in particular to perform an immunosuppressive
role in response to ocular inflammation (120).
A glycocalyx coat, rich in transmembrane mucins containing O-linked
carbohydrates, provides a protective barrier in the cornea and conjunctiva against
pathogen adhesion and ocular infection (121, 122). Gal-3 binds to and cross-links
mucins, including mucin1 (MUC1) and mucin16 (MUC16), in a carbohydrate-dependent
manner (123, 124). Repression of galectin-3 biosynthesis in human ocular cornea
epithelium impedes the tight intercellular junctions with a resultant loss of the protective
barrier function (115). Interestingly, HSV-1 binds to and employs Gal-3 as an entry
receptor into ocular tissues. By masking and impeding viral attachment to Gal-3 in the
apical glycocalyx, corneal keratinocyte infection by herpesvirus is abrogated (125).

15

Undoubtedly, there is a promising therapeutic potential for galectins and /or
galectin-inhibitory molecules in the treatment of ocular infections. However, this area is
still not fully explored and will require more studies to be designed. Interestingly, initial
studies have demonstrated the utility of Gal-1 in ocular herpetic lesions. Rajasagi et al.
(126) have shown that following HSV-1 infection, recombinant Gal-1 diminished the
severity of stromal keratitis, a chronic inflammatory lesion, and attenuated corneal
neovascularization, pathologies that often result in blindness. Recombinant Gal-1 was
associated with decreased corneal infiltration of proinflammatory cells and cytokines, and
an increased production of immunosuppressive IL-10 and neovascularization-inhibitory
molecules.

MANNOSE-BINDING LECTIN
Mannose-binding lectin (MBL) is a collectin produced mainly by hepatocytes and
secreted into the systemic circulation (3). MBL activates the lectin complement pathway,
enhances phagocytosis of microorganisms and modulates inflammation (127).
Role of MBL in fungal gastrointestinal mucosal infections
Complement activation occurs upon recognition of microorganisms through
CRDs, that sense pathogen associated molecular patterns (PAMPs), that include
pathogen associated glycan structures such as D-mannose, L-fucose and Nacetylglucosamine (128). These domains are expressed on the surface of microorganisms
including Candida albicans (127, 129, 130). C. albicans is an opportunistic infection in
the gastrointestinal tract and often results in invasive infection when epithelial and host
immune functions are compromised or breached. MBL promotes C. albicans’
opsonophagocytosis by neutrophils (131). Through the MBL-MBL-associated serine
proteases (MASP) complex, MBL binds to C3b activating the complement system and
opsonizing C. albicans (132). Following recognition by CR1 on the leukocyte surface,
MBL may directly opsonize C. albicans (133). MBL expression is induced in response to
C. albicans sensing in the gut and contributes to intestinal homeostasis and host defense
(127). MBL has been identified as critical in the host’s first line of defense against
16

invasive candidiasis, with a significant decrease in the lectin levels 2 days before positive
blood cultures (131). In wild type mice, blocking MBL by feeding rodents with mannan
resulted in increased C. albicans colonization. Furthermore, in MBL-deficient mice,
dextran sodium sulfate-induced colitis promoted dissemination of C. albicans to kidneys
and lungs, while deficient mice also predominantly expressed cytokines including IL-17
(127), a cytokine thought to be of little consequence in eliminating invasive candidiasis
(134).
Impact of MBL on immunity and response to bacterial respiratory mucosal infections
There is vast literature about MBL binding to microorganisms and MBL-mediated
complement activation following binding to mannan- coated polystyrene surfaces (132).
The exact role of MBL in promoting phagocytosis has only recently been explored (132).
Studies estimate that MBL2 polymorphisms occur in about 5% of the population
worldwide (135), with the associated MBL deficiency contributing to increased
susceptibility to infections (136). Interestingly, polymorphism of MBL homozygous
variant genotypes rs1800451 was associated with reduced pulmonary tuberculosis (PTB)
risk, while that of allele rs5030737 demonstrated increased risk of PTB. Alleles
rs1800450, rs7096206 and rs11003125 did not demonstrate any association with PTB
susceptibility (137). Numerous publications describe a role for MBL in C3 deposition in
S. aureus but scant data is available for the uptake of opsonized S. aureus by human
neutrophils. Neth and colleagues reported that opsonophagocytosis of S. aureus was
increased when exogenous MBL-MASP was added to MBL-deficient serum (138).
Additionally, infection with S. aureus CP5 in an MBL knockout mouse model resulted in
decreased C4b deposition and greater mortality (139). In contrast, Krarup et al. showed
that MBL did not bind to encapsulated S. aureus (140). Brouwer et al. report a dose
dependent MBL binding to S. aureus and S. pnuemoniae (132). However, they observed
that this binding had no influence on the uptake of these bacterial species by human
neutrophils. It is likely that the lectin pathway of complement activation has only a
limited contribution in opsonophagocytosis of these bacteria. Clinical studies reported by
Moen et al., and Roy et al., demonstrated a small but significant risk of increased
invasive pneumococcal disease in patients homozygous for the MBL structural codon
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variant allelles -52, -54, -57, and -221(141, 142). In contrast, Kronborg et al., and
Brouwer et al., did not demonstrate any role of MBL in the pathogenesis of S.
pneumoniae infection in clinical and in vitro studies, respectively (132, 143). Similarly,
Kazumi Kudo et. al demonstrated that MBL binds to M. avium in a calcium-independent
and concentration- dependent manner. However, the binding did not enhance bacteria
phagocytosis by rat alveolar- and human monocyte-derived macrophages (75). Overall,
these findings suggest that MBL substitution therapy may have a protective value for
fungal rather than bacterial infections (132).
Interactions and role of MBL in respiratory coronaviruses infection
There is increasing evidence that suggests that MBL may be protective in the
initial stages of SARS-CoV-2 infection (144). Serum mannose-binding protein (MBP)
levels are highest in childhood and gradually decrease as individuals age. At birth, MBP
levels are about 1 µg/mL, attaining a lifetime peak of approximately 2.5 µg/mL within 5
days post birth (145), and are significantly lower in centenarians, octo-and nonagenarians
when compared to the general population (146). A bimodal peak pattern of serum MBP
levels has also been described, with the initial peak in childhood and the latter peak
gradually declining with advancing age (147). In addition, in analyzing MBL2 gene
variants, the frequency of high and null activity haplotypes was significantly lower in the
elderly compared to the general population. Furthermore, individuals between 80 and 99
years displayed a higher frequency of intermediate activity haplotypes than the general
population in the same geographic area (146). In children, sustained low levels of serum
MBL and reduced levels at birth are associated with recurrent respiratory infections and
otitis media (148).
Polymorphisms in the MBL2 structural gene result in low serum levels,
predisposing to coronaviruses infections (144). A genetic polymorphism in codon 54 of
MBL exon 1 (A/B variant) results in a low-MBL-producing B allele and an increased risk
of severe acute respiratory syndrome coronavirus (SARS-CoV) infection (149).
Hongxing et al. observed that MBL gene polymorphisms significantly increase the
susceptibility to SARS-CoV infection (150). They show that among infected and control
subjects, SARS-CoV infected subjects significantly displayed haplotype pairs that were
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associated with medium or low expression of MBL, including the codon 54 variant. In
another case-control study, Ip et al., demonstrate MBL’s role as a first-line host defense
against coronaviruses and that the lectin’s deficiency is a susceptibility factor for SARSCoV infection (50). They report that a higher frequency of haplotypes is associated with
low or deficient serum MBL levels in SARS-CoV infection than in control subjects.
Serum MBL levels were significantly lower in infected patients compared to the controls.
In complementary in vitro experiments, they show that deposition of complement C4 on
SARS-CoV is enhanced by MBL, and the lectin inhibits infection of fetal rhesus kidney
cells (FRhK-4). The lectin’s binding to SARS-CoV is dose- and calcium -dependent, and
inhibited by mannan, suggesting that it occurs through the carbohydrate recognition
domains.
SARS-CoV-2 comprises of glycosylated sites in both the S1 region and the N234
region found next to the ACE2-binding site, that are enriched with mannose sugars
(151). Because MBL binds to glycosylated residues, it is likely that the lectin may bind
and inhibit the S1-ACE2 interaction in SARS-CoV-2, as previously observed with
SARS-CoV (144, 152). MBL interacts with SARS-S glycoprotein and blocks viral
binding to the C-type lectin, DC-SIGN and this interaction is postulated to interfere with
early pre- or post-receptor-binding events necessary for efficient viral entry (152). Given
that polymorphisms in MBL have been linked to susceptibility to coronaviruses
infections (50, 149), it is likely that this may be one of the mechanisms through which
MBL may interfere with SARS-CoV-2 infection. Whether the heavy glycan shield may
actually be a decoy for ‘immune evasion’ is still being investigated (144, 151). However,
what is clear is that there is a role of MBL in the immune response to infection with
SARS-CoV-2. Ting et al. established that the N proteins of SARS-CoV, Middle East
respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 bind to MASP-2, a
key serine protease in the lectin complement pathway of activation, aggravating lung
injury (153). Interestingly, blockade of the N protein: MASP-2 interaction significantly
alleviated the hyper-activation and reduced lung injury in vitro and in vivo.
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Failure of MBL to maintain adequate control of infection and immunity
Low serum plasma levels of MBL have been associated with susceptibility to
invasive infections. The low levels are as a result of genetic influences on MBL
expression (154, 155). Nonetheless, scenarios have been described in which MBL results
in worsening infection or failure to adequately eliminate pathogens (154). Excessive
MBL activation is responsible for imbalances in inflammatory and coagulation responses
observed in transplant rejections, inflammatory diseases, and diabetic nephropathy (156,
157). In addition, by upregulating the inflammatory response, MBL appears to worsen
pandemic H1N1 (pdmH1N1) and avian H9N2 infections (157, 158). Despite binding to
the virus, the interaction with pdmH1N1 is insufficient to allow antiviral activity (158). A
single potential glycosylation site is located at the base of the HA globular head of
PdmH1N1, however, the virus lacks potential glycosylation sites on the HA globular
head region (159). Absence of this glycosylation site in pdmH1N1 and H9N2 results in
MBL failure to interfere with viral binding to target cells, despite its binding to virus
(158).
Paradoxically, MBL has been reported to predispose to infectious diseases,
leprosy and visceral leishmaniasis, infections caused by intracellular parasites (160-162).
In fact, patients with these infections had higher MBL levels when compared with
controls (162). The high prevalence of variant alleles in control subjects than in patients
suggested the benefits of functional MBL efficiency in this group (162). Intracellular
parasites rely on phagocytosis to invade host cells, and opsonization by complement
further facilitates host cell entry by use of complement receptors. Hence, low MBL levels
in the control subjects diminishes the likelihood of complement-mediated phagocytosis
(160). These findings however, warrant further study because some other reports have
indicated no significant difference in MBL levels of cases and controls, including those
with infectious and parasitic pathogens (163, 164).
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EXOGENOUS LECTINS AND THEIR ROLES IN MUCOSAL INFECTIONS
GRIFFITHSIN
Griffthsin (GRFT) was discovered during an anti-HIV natural products screen by
researchers at the National Cancer Institute (NCI) (165). GRFT, a carbohydrate-binding
lectin, is comprised of 121 amino acid residues, and exists as a homodimer complex,
Figure 1.1A. Each monomer contains three carbohydrate-binding domains that are
attachment ligands for microbes and pathogens that express high-mannose compounds in
their structure (165, 166), Figure 1.1B. The GRFT domain-swapped dimer presents as a
near perfect three-fold symmetry, with three repeats of an antiparallel four-stranded βsheet that resembles a β-prism-I motif in the jacalin lectin family (5, 165). GRFT
preferentially interacts with terminal sugars when binding with oligosaccharides (7).
Structural experiments have demonstrated that all GRFT binding sites are almost
identical, and each contains aspartic acid (Asp) residues that interact with mannose (5,
165). Aspartic acid 30, Asp70 and Asp112 interact with mannose O5 and O6 via
hydrogen bonding linkages (5). Interestingly, mutations that result in Asp to Alanine
(Ala) changes weaken GRFT binding to a mannose column, but do not affect protein
folding (167).
Originally extracted from the red algae Griffithsia sp. (8), a recombinant form
may be expressed and purified from the tobacco plant, Nicotiana benthamiana (168), rice
endosperm (169), and Escherichia coli (170). This has proved essential in making the
drug available for testing in clinical studies (165). Expression of GRFT in Nicotiana
benthamiana using a tobacco mosaic virus -based vector yields gram amounts of the
lectin (165, 168, 171). The expressed GRFT is purified using ceramic filtration, two-stage
chromatography, and a combination of heat, magnesium chloride and bentonite, followed
subsequently by a single chromatographic step (165, 168, 172). Although not as potent as
the native dimeric lectin, engineered GRFT monomeric tandemers have also been
constructed and investigated for their antiviral activity (9).
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A.

B.

Figure 1.1 Sequence and structure of Griffithsin. (A) Sequence of wild-type GRFT
demonstrating amino acids within beta strands (red) and black arrows denoting secondary
structure. X is the unknown amino acid in the natural alga-derived extract. The three Asp
residues found in the mannose-binding sites are identified in bold. (B) Ribbon trace of a
Griffithsin homodimer. Monomer 1 is colored blue while monomer 2 is green. The Nterminal extension that resulted from the cloning procedure is colored red. Amino acid
sequence and GRFT image are adapted from Lusvarghi et al. (165), and Ziolkowska et al.
(5), respectively.

Broad-spectrum antiviral activity of Griffithsin
GRFT demonstrates antiviral activity against numerous enveloped viruses. This
inhibition is attributed to carbohydrate-mediated binding of GRFT to various envelope
glycoproteins, despite differences in the predicted glycan quantities in different viral
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structures (165). A list of viruses to which GRFT binds, and the respective effective
concentrations that inhibit 50% viral replication (EC50) is summarized in Table 1.2
below.

Table 1. 2 GRFT effective concentrations to inhibit 50% virus infection (EC50).
GRFT sample

Virus type

EC50 (nM)

Reference

Native GRFT

HIV-1RF

0.043

(8)

Recombinant GRFT

HIV-1RoJo

0.63

(8)

Native GRFT

HIV-1ADA

0.5

(8)

Recombinant GRFT

SARS-CoV200300592

280

(5)

Recombinant GRFT

SARS-CoVUrbani

48

(10)

Recombinant GRFT

SARS-CoVCuHK

61

(10)

Recombinant GRFT

HCVJFH1

13.9

(173)

Recombinant GRFT

JEV

20

(174)

Recombinant GRFT

HSV-2

230

(175)

HIV-1: human immunodeficiency virus type 1; SARS-CoV: severe acute respiratory
syndrome corona virus; HCV: hepatitis C virus; JEV: Japanese encephalitis virus; HSV2: herpes simplex virus type 2.

Below, we review GRFT’s utility and activity against mucosal infections. An
abbreviated list of some of the mucosal pathogens to which GRFT binds, with the
respective ligands is presented in Table 1.3.
Table 1. 3 Mucosal pathogen binding ligands for Griffithsin.
Lectin

Pathogen

Binding ligand

Reference

Griffithsin

SARS-CoV-2

Spike (S) protein

(176)

HIV-1

gp120, gp41, gp160

(8)

Trichomonas vaginalis

Surface N-glycans

(177)

Candida albicans

Cell wall α-mannan

(13)
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Role of Griffithsin in the modulation of respiratory mucosal infections
Human coronaviruses are enveloped positive-sense single-stranded viruses, that
utilize the glycosylated spike (S) protein to interact with host receptors, prior to gaining
entry into cells (178). These heavily glycosylated sites (O- and N-linked) are critical in
triggering the host immune response to infection (178, 179). Human coronaviruses
HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 largely cause seasonal and
predominantly mild respiratory illnesses (180). HCoV-229E and HCoV-NL63 bind to
human aminopeptidase N (APN) and angiotensin-converting enzyme 2 (ACE2),
respectively (181, 182). The highly pathogenic and infectious SARS-CoV, MERS-CoV,
and SARS-CoV-2 cause life-threatening severe pulmonary injury and pathology (183185). MERS-CoV binds dipeptidyl peptidase 4 (DPP4) while SARS-CoV and SARSCoV-2 interact with ACE2 (186-188). GRFT has been shown to bind MERS-CoV spike
protein. GRFT inhibits the initial steps in the MERS-CoV infectivity process, and
impedes cell entry in a dose-dependent manner (189). In in vitro studies, O’Keefe et al.
have demonstrated that GRFT inhibits cell infectivity with HCoV-OC43, HCoV-229E
and HCoV-NL63 (10). Furthermore, they determined that the lectin inhibits a postbinding step during SARS-CoV cell entry. Intriguingly, in their murine studies, compared
to non-treated controls, intranasal GRFT attenuated SARS-CoV -induced respiratory
disease severity and pathology, and resulted in lower inflammatory cytokines during
infection. These results confirmed the initial experimental findings by Ziolkowska et al.,
who by using three distinct in vitro assays, demonstrated that GRFT inhibited SARSCoV replication and virus-induced cytopathic effects (5). We have demonstrated that QGriffithsin (Q-GRFT), an oxidation-resistant variant of GRFT binds to SARS-CoV-2
spike protein. A Phase 1a clinical trial to determine the pharmacokinetics and tolerability
of Q-GRFT, as an intranasal spray application for prophylaxis against COVID-19, is
planned. Enrollment of volunteers is anticipated to be completed by the end of 2021.
Hantavirus [Andes virus (ANDV) and Sin Nombre virus (SNV)] infections are
rodent-borne (deer mice) infections that may transmit to humans following aerosolization
of infected murine urine, feces and saliva (190, 191). These viruses express fusion
glycoproteins Gc and Gn in their envelope (192, 193). Hantaviruses infection results in
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hantavirus pulmonary syndrome and/ or hemorrhagic fever with renal syndrome (194). In
in vitro studies, GRFT inhibited ANDV and SNV infectivity in Vero-E6 cells (195).
Furthermore, pre-incubation of GRFT with pseudovirions (PsV) revealed that inhibition
of infection is likely due to the interaction between hantaviruses and the lectin. Similarly,
this study revealed that the trimeric tandemer 3mGRFT inhibited the entry of PsV
particles into cells, albeit with a higher potency than GRFT. It remains to be seen if these
results will be replicated in in vivo models.
Interactions of Griffithsin with the gastrointestinal and rectal mucosal microbiome,
pathogens, and immunity
Oral administration of GRFT did not result in any detectable lectin levels in the
serum of treated animals, despite the low fecal drug concentrations observed. Regardless,
drug levels in the fecal material ably neutralized HIV-Env PsV in in vitro assays (196).
The gastrointestinal tract secretes various proteases (197) that have the potential to
degrade and denature GRFT, given the lectin’s peptide nature (165). In in vitro studies
using commercially available gut proteases, GRFT resisted degradation by the majority
of proteases and was only degraded by elastase (198). The lectin resisted proteolytic
activity by enzymes pepsin, papain, leucine aminopeptidase, pronase, α-chymotrypsin,
proteinase K, endoproteinase, lys-C and trypsin (198). Similarly, we have demonstrated
the presence of protease enzymatic activity in human and murine rectal fluids in in vitro
assays. However, we have determined that Q-GRFT resists proteolytic degradation by
proteases in human, mice and macaque rectal fluids (199). It is likely that high stomach
acidity may be the most predominant contributor to the denaturation of orally
administered GRFT (196). Additionally, the potential for bile salts to degrade GRFT in
the gut may warrant investigation.
Condom-less receptive anal intercourse among men who have sex with men is the
predominant mode of transmission of new HIV infections in the Western world (200202). In preliminary studies during the development of GRFT as a microbicide to
prevent HIV infection, Girard et al. describe the impact of rectal application of the lectin
on Rhesus macaques’ mucosa and proteome (203). There were no significant detectable
changes in the rectal proteome associated with GRFT gel application. Small and likely
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inconsequential changes in the rectal microbiome were detected. These results were
indicative of GRFT’s tolerability in the rectal environment and further supported the
relevancy for its development as a microbicide. In keeping with these findings, using in
vitro assays, we have demonstrated that Q-GRFT does not inhibit the growth of gut and
rectal microbiome components-Lactobacillus acidophilus, Lactobacillus casei,
Bifidobacterium longum longum, Clostridium difficile and Bacteroides fragilis
(manuscript in preparation) (199). Furthermore, Gunaydin et al. (204), have established
that rectal Q-GRFT gel application is associated with a stable expression of E-cadherin+
cells, responsible for maintaining epithelial integrity. Interestingly, administration of a
high GRFT gel concentration was associated with slightly elevated intra-epithelial CD4+
T cells. Repeated dosing resulted in significantly elevated lamina propria CD4+ T cells,
targets for HIV infection. The elevated CD4-T cells may not potentiate HIV-1
transmission because a similar study with a hyperosmolar lubricant resulted in elevated
rectal mucosal mononuclear cells and cytokines but did not increase the risk of SHIV
infection in macaques (205). However, repeat studies using HIV-1 virus infection assays
will help in determining the infectivity of these CD4-T cells.
GRFT’s binding to HIV-1 glycoproteins gp120, gp41 and gp160 is dependent on
glycosylation of these viral coat structures (8). GRFT has demonstrated activity against
HIV-1 clades A, B and C (168), is highly potent, blocking CXCR4- and CCR5-tropic
viruses and impedes cell-to-cell viral transmission (206). Dimeric GRFT is more potent
and efficacious at binding and preventing viral transmission than the monomeric form
(207). When combined with tenofovir, maraviroc or enfuvirtide, GRFT exhibited
excellent synergistic inhibitory activity against infection of peripheral blood
mononuclear cells (PBMCs) and CD4+ MT-4 cells with HIV-1 clade B and C isolates
(208). In addition, synergistic and complementary inhibition of viral activity has been
demonstrated with broadly neutralizing anti-HIV-1 monoclonal antibodies (mAb)
VRC01, PGT121 and PGT126 (209, 210).
Monoclonal antibodies kill HIV-infected cells by targeting relatively conserved
epitopes and mediating antibody-dependent cellular cytotoxicity (211). However, viruses
often conceal features that would make them susceptible targets of antibody
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neutralization (165). Through oligomerization or conformational occlusion, they may
hide fundamental structural motifs that are critical for antibody binding. Additionally,
viruses may undergo rapid mutation rates leading to high sequence variability in nonessential regions like variable loops, or undergo extensive posttranslational glycosylation,
evading antibody detection (165). Because enveloped viruses employ the heavy glycan
shield to elude neutralizing antibodies (212), this makes GRFT an ideal strategy that
binds to these glycans, ultimately preventing cell infection. Additionally, glycosylation
maintains viral fitness following antibody escape mutations (213, 214), further
predisposing them to GRFT anti-viral activity.
Against this background and findings, our group is currently recruiting
participants in a first-in-humans Phase I clinical trial to determine the pharmacokinetics
and tolerability of Q-GRFT for utility as a rectal microbicide against HIV-1 infection and
transmission (215).
Impact of Griffithsin on genitourinary mucosal immunity and infections
Like the gastrointestinal and rectal environment, cervicovaginal fluids are
comprised of enzymes and are capable of proteolytic degradation of proteins (216).
GRFT has demonstrated stability in cervicovaginal secretions and maintains its anti-HIV1 potency in this environment (206). In human cervical explant assays and in the in vivo
rabbit vaginal irritation model, GRFT did not induce any significant expression of
proinflammatory cytokines and chemokines (168). GRFT binds to N-glycans of
Trichomonas vaginalis (177). Topical murine treatment was associated with lower
recovery of the bacterial pathogen in vaginal fluids, suggesting a potential therapeutic
role in Trichomonas infections (177). Contrastingly, we did not demonstrate any
inhibitory activity of GRFT against STI-causative pathogens C. trachomatis and
Neisseria gonorrhea in in vitro assays (199). Vulvovaginal candidiasis is one of the
leading causes of vaginitis (217) and recurrent Candida sp. infections predispose to drug
resistance (218). We have demonstrated a novel finding that Q-GRFT binds to α-mannan,
a glycosylated component of the C. albicans cell wall, in a concentration-dependent
manner. Additionally, we have identified that Q-GRFT inhibits the growth of other
Candida species C. krusei, C. parapsilosis and C. glabrata, including some strains of the
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multi-drug resistant C. auris. We determined that upon binding, Q-GRFT induces a break
down in fungal cell wall integrity, with formation of intracellular reactive oxidative
species (13).
GRFT inhibits HIV-1 infection in human vaginal explant models (168).
Furthermore, a Griffithsin/ Carrageenan (GRFT/CG) combination formulated as a freezedried fast dissolving insert for on-demand use was protective against a vaginal simian
immunodeficiency HIV chimeric virus (SHIV) challenge in rhesus macaques (219).
Comparably, GRFT/CG was protective against vaginal HPV and HSV-2 PsV challenges
in murine models (219). Similarly, sustained GRFT delivery, formulated in nanoparticleelectrospun fiber composites was protective against a lethal vaginal challenge of HSV-2
in murine models (220).
Potential role of Griffithsin in ocular mucosal infections
Numerous respiratory viruses have been identified to have tropism for ocular
epithelial tissues, including adenovirus, influenza virus, coronaviruses, rhinovirus and
respiratory syncytial virus (221-226). Additionally, increasing evidence for SARS-CoV-2
infection and transmission via ocular tissues in the ongoing COVID-19 pandemic has
been documented, although more confirmatory categorical data and studies are needed
(227-229). Given GRFT’s ability to bind and inhibit infectivity with coronaviruses (as
discussed above), there is potential utility of an ocular formulation in preventing
transmission. Indeed, Wang et al. in their review, hypothesize that contact lenses able to
sustain delivery of GRFT probably via nanoparticles may be protective among health
workers and others in close contact with patients (230). However, given the
cumbersomeness of daily use of contact lenses, this may not be practical for the majority
of users. Given the tendency for GRFT to accumulate and persist in tissues during
chronic use (196), further studies are warranted to establish drug levels in ocular
epithelial tissues. Befittingly, we have hypothesized that a Q-GRFT ocular eye
suspension administered daily may be adequate in preventing coronavirus infection
among people at risk of infection. Our initial in vitro assays confirm that daily treatment
of corneal epithelium results in detectable Q-GRFT levels and does not enhance any
expression of proinflammatory cytokines and chemokines (chapter 5).
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CONCLUSION
Lectins interact with a diverse array of ligands on microbes and pathogens,
mediating a variety of functions. Here, we have summarized the relevant functions of
lectins pertinent to mucosal infections and immunity. The rapidly changing scope of
discoveries and studies into the function of these molecules, and the need for a wider
breadth of antimicrobial agents to counter the rising antimicrobial drug resistance has
pushed for the exploration of new molecules and drugs. Indeed, this has resulted in more
knowledge about mechanisms and potential roles of lectins in this field. Whether these
discoveries and knowledge culminate into new therapeutics and novel diagnostic
approaches for utility against current and emerging mucosal infectious diseases and
pathogens is yet to be determined.
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CHAPTER 2: STABILITY OF Q-GRIFFITHSIN IN THE RECTAL MUCOSAL
ENVIRONMENT

INTRODUCTION
In 2019, 1.7 million people were estimated to have acquired new HIV infections
worldwide. Sixty two percent (62%) of these infections were among key-at risk
populations (including gay men, other men who have sex with men (MSM), transgender
people, sex workers, injection drug users and prisoners) (231, 232). In the United States,
there were 36,400 new HIV infections in 2018, with the largest percentage of
transmission (67%) attributed to male-to-male sexual contact (233). Unprotected
receptive anal intercourse (URAI) is associated with a 1.7% HIV transmission risk per
coital act, and is higher than that in unprotected vaginal intercourse, 0.08% (234). The
vulnerability of the rectal environment to infection is due to the anatomical presence of a
single columnar epithelial layer, with predominant expression of activated CD4+ T cells
that express CCR5 co-receptor, a binding ligand for HIV-1 (235).
Pre-exposure prophylaxis (PrEP) strategies have been developed and deployed,
with a multitude of other approaches still under investigation, to provide on-demand
modalities like injectables and topical products, as alternatives to daily PrEP, and
improve adherence (236). These include microneedles, electrospun fibers, vaginal films
and rings, subdermal implants, microbicide gels, enema and mucoadhesive tablets (237244). These products deliver potent anti-HIV drugs/ agents to mucosal epithelium
involved in sexual contact (245).
Q-GRFT, a virucidal and non- cell entry inhibitor of HIV has also demonstrated
potency against other sexually transmitted viruses like HSV-2 and HPV in vitro and in
vivo (175, 219). GRFT binds to glycoproteins in the HIV envelope blocking interaction
with CXCR4 and CCR5 receptors, and subsequent cell entry and cell-to-cell transmission
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(8, 168). Initially extracted from red sea algae, recombinant forms of the lectin are
currently produced in Nicotiana benthamiana plants following transduction with GRFTexpressing tobacco mosaic virus vectors (168). GRFT has been demonstrated to be stable
in cervical/ vaginal lavage fluids, maintaining its anti-HIV activity and potency in this
environment (206).
Our laboratory has developed an oxidation-resistant variant of GRFT, GriffithsinM78Q (Q-GRFT), for use as a multipurpose topical microbicide to protect people at risk
of HIV- and superinfection with STIs like HSV-2 and HPV. Healthy volunteers are
currently being enrolled in a first-in-human Phase1 study to determine pharmacokinetics
in the rectal environment (246). Because of its protein nature, Q-GRFT may be
susceptible to enzymatic degradation and the lectin’s activity may be affected by hostand microbiome-derived compounds in the rectum. The activity of Q-GRFT in the rectal
environment remains unknown. In this study, we investigated the stability and activity of
Q-GRFT in mice, macaque and human rectal fluids and seminal plasma.

MATERIALS AND METHODS
Specimen:
Human rectal fluids and seminal plasma. Human rectal fluids were eluted from rectal
swabs that were collected at Magee-Womens Research Institute, University of Pittsburgh,
Pittsburgh, Pennsylvania from healthy subjects participating in the PREVENT Phase 1
clinical trial that is developing Griffithsin-M78Q as a rectal microbicide against HIV
infection and transmission (246). This study was approved by the University of
Pittsburgh Institutional Review Board and was listed as ClinicalTrials.gov Identifier:
NCT04032717. At collection, the swabs were placed in the rectum for a few minutes and
then stored at -80°C in a LDMS labeled cryogenic vial. To elute the rectal fluids, the
frozen rectal swab was thawed at room temperature (20-25°C). One Spin-x
microcentrifuge tube (0.45μm cellulose acetate filter) and 1-1.5 mL microcentrifuge tube
per sample were used to spin the sponge. The excess handle of the swab/ sponge was
removed and discarded using dissection scissors and the swab placed in the upper
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chamber of the Spin-X filter unit. Three hundred microliters of Phosphate buffered saline
(PBS) were added to the upper chamber. The chamber and collection tube were then
centrifuged at 12,000 rpm for 20 minutes at 2-8°C. The filtered solution was aliquoted
into 1.5 mL microcentrifuge tubes and stored at -80°C until when assays were performed.
Seminal fluids (sperm cell-free semen) were commercially purchased from Lee
BioSolutions, Inc Maryland Heights, MO USA.
Macaque rectal fluids. Rectal fluids were collected from six Rhesus Macaques (Macaca
mulatta) that were housed at the Centers of Disease Control and Prevention (CDC; Atlanta,
GA). Animals were housed in accordance with the Guide for the Care and Use of
Laboratory Animals (8th Edition) in an AALAC-accredited facility, according to
institutional standard operating procedures. These were adult female Indian-origin
macaques with average age of 8.7 years, that were part of a study to evaluate the
pharmacokinetics (PK) of Q-GRFT formulated as a 0.3% (w/w), 1.0% and 3.0% Carbopol
gel upon intrarectal administration. Rectal fluids used in our study were collected at various
times in untreated control animals. All study procedures were performed on anesthetized
animals according to methods and procedures approved by CDC’s Institutional Animal
Care and Use Committee. For the rectal fluids collection, Weck-cel swabs or Merocel
sponges, Beaver Visitec Intl Ltd, Fischer Scientific #NC0240644 were used, as described
previously (247). Briefly, the swabs or sponges were pre-wet with cold PBS and inserted
into the rectum. They were then removed after 5 minutes, and the excess feces scrapped
off. The swabs/ sponges were then placed in a Costar Spin-X centrifuge filter (Sigma Cat.
#CLS8160) and centrifuged with PBS at 4 °C for 30 minutes at 16000 rpm to elute fluids.
The eluates were placed in new Spin-X tubes and stored at -80 °C until when analysis was
performed.
Mice rectal fluids. Mice were euthanized and rectal fluids collected following a protocol
previously described (248). Briefly, 200 μL of PBS were introduced into the anal canal
with a disposable pipette tip. The rinse was gently pipetted in and out of the anal canal a
few times and the fluid collected in a microcentrifuge tube. The fluid was stored at -80°C
until when analysis was performed.
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Physicochemical properties of human and mice rectal fluids. Stored rectal fluids were
thawed at room temperature and the aliquots assessed visually for any color intensity and
suspended materials. The pH was determined using MColorpHastTM (Merck KGaA,
Darmstadt, Germany) universal indicator strips.
Murine and human rectal fluids’ protein concentration was determined by the
bicinchoninic acid (BCA) assay using the PierceTM BCA Protein Assay kit. Briefly, the
Diluted Albumin (BSA) standards and Working reagents (WR) were prepared following
kit instructions. Twenty-five microliters (25μl) of each of the standard and rectal fluid
samples were pipetted to a 96-well microplate followed by 200μl of the WR and mixed
thoroughly using a plate shaker. The plate was incubated for 30 minutes, and absorbance
read at 562nm using a BioTek Synergy plate reader running Gen5 software. A standard
curve was plotted (for the BSA standard) and the slope used to determine the protein
concentration of the unknown rectal fluid samples.
Protease concentration of murine and human rectal fluids was determined by the
casein colorimetric assay using the Pierce Protease Assay kit. Briefly, the assay buffer,
Succinylated casein Solution, Trypsin Stock Solution, Trypsin Standard and
trinitrobenzenesulfonic acid (TNBSA) Working Solution were prepared as per protocol
instructions. One hundred microliters of Succinylated Casein Solution were added to one
set of microplate wells and 100μl of assay buffer to a duplicate set of wells, to serve as
blanks. Fifty microliters of each unknown rectal fluids or standard sample were added to
both Succinylated Casein wells and the corresponding blank wells. The plate was then
incubated for 20 minutes at room temperature. Fifty microliters of TNBSA Working
solution were added to each well and the plate incubated for 20 minutes. Absorbance in
the wells was measured at 450nm, using a BioTek® Synergy HT plate reader running
Gen5 software. The change in absorbance was obtained by subtracting the blank from
the corresponding well. A standard curve (ΔA450 against protease standard concentration)
was then plotted and used to assess relative protease activity of the unknown rectal fluids.
The optimized microplate periodic acid-Schiff’s reagent (PAS) assay was used to
assess for the presence of carbohydrates in murine rectal fluids. Briefly, 25μl of rectal
fluids were added to a 96-well microplate, followed by 120μl of freshly prepared 0.06%
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periodic acid in 7% acetic acid. The plate was sealed with plastic adhesive tape and
incubated at 37oC for 1.5 hours. The mixture was then cooled to room temperature, 100μl
of Schiff’s reagent added and then mixed thoroughly by pipetting up and down. The plate
was then sealed with adhesive plastic tape, shaken for 5 minutes using a plate shaker and
color allowed to develop at room temperature for 40 minutes. Absorbance was read at
550nm from a BioTek® Synergy HT plate reader running Gen5 software.
Q-GRFT’s binding ability to gp120. Q-GRFT was incubated with rectal fluids and
seminal plasma for either 6 hours (macaque rectal fluids) or 24 hours (murine, human
rectal fluids and seminal plasma) at 37°C prior to performing a binding ELISA assay.
Plates were coated overnight with gp120 diluted in 1X PBS. The plate was then blocked
for 2 hours at room temperature using 3% BSA in 1X PBS-T. Incubated sample fluids
were added at concentrations starting at 250-300 ng/ml with 2X or 3X dilutions and
incubated for 1-2 hours. The primary antibody (rabbit anti-Q-GRFT), followed by
secondary antibody (goat anti-rabbit) were then added. To develop the reaction,
3,3’,5,5’-Tetramethylbenzidine (TMB) solution was added followed by 1N Sulphuric
acid to stop the reaction. Absorbance was read at 450 nm using a BioTek® Synergy HT
plate reader running Gen5 software. Nonlinear regression (GraphPad Prism) was used to
determine the half maximal effective concentration (EC50) of Q-GRFT binding.
Statistical analysis. Statistical analyses were performed using GraphPad Prism V7.
Numerical data are presented as mean + standard deviation (SD) or mean + standard error
of mean (SEM). Experiments and assays were performed in triplicate. Statistical
differences between sets of data were evaluated using ANOVA. P-values of < 0.05 were
considered significant.

RESULTS
Physical and chemical properties of murine and human rectal fluids
Given the peptide nature of Griffithsin (165) and the variant Q-GRFT, we sought
to characterize and identify the physical and chemical properties of rectal fluids that may
impact the lectin’s stability and activity in this environment. Murine rectal fluids, n=12
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(Table 2.1) had an appearance that ranged from clear and colorless (-) to slightly turbid
(+), with a pH of 7. Carbohydrates were detected in these fluids, and the protein
concentration ranged from 10.60 + 0.00 μg/mL to 431.93 + 0.00 μg/mL, with a group
mean of 121.88 + 3.54 μg/mL. Protease activity ranged from 2.76E-05 + 3.29E-05 μg/
mL trypsin to 3.47 + 0.00 μg/ mL trypsin, with a group mean of 2.19E-01 + 3.65E-02 μg/
mL trypsin . Human rectal fluids, n=6 (Table 2.2) ranged from clear and colorless (-) to
slightly yellow and mildly turbid (++) in appearance. This is likely related to the levels of
fecal-derived substances in the fluids (245). The pH range was 7 to 8, and was consistent
with ranges that have been demonstrated from reported human colonic studies (249).
Protein concentration was 730.00 μg/mL to 1211.89 μg/mL, with a mean of 917.71
μg/mL, and protease activity 0.198 μg/mL trypsin to 1.069 μg/mL trypsin, with a group
mean of 0.38 μg/mL trypsin. Altogether, these results demonstrate that there is a variation
in composition, enzymatic activity and physical make up of murine and human rectal
fluids. The variation in protease activity is likely in part due to microbiota composition
alterations and differences between individuals (250).
Table 2. 1 Physicochemical properties of murine rectal fluids.
Sample
ID
RL001
RL002
RL003
RL004
RL005
RL006
RL007
RL008
RL009
RL010
RL011

carbohydrates
Appearance
+
-

RL012

-

pH
7
7
7
7
7
7
7
7
7
7
7
7

+
+
+
+
+
+
+
+
+
+
+
+

Protein
Concentration
μg/mL
20.27 + 1.65
55.93 + 7.07
380.60 + 10.37
76.27 + 1.18
431.93 + 0.00
109.93 + 0.00
86.93 + 3.06
78.93 + 9.66
94.93 + 0.00
10.60 + 0.00
87.60 + 0.00

Protease activity
μg/mL Trypsin
7.32E-04 + 5.24E-04
3.23E-05 + 7.07E-08
258.38 + 9.23
2.76E-05 + 3.29E-05
4.92E-02 + 0.00
3.47 + 0.00
1.4E-04 + 6.94E-05
5.18E-01 + 4.90E-02
5.68E-04 + 1.40E-03
5.20E-04 + 2.63E-04
4.96E-01 + 0.11

28.60 + 9.43

6.19E-04 + 3.03E-04

Appearance scored as (-) for clear and colorless, (+) for slightly turbid, (++) for slightly
yellow and mildly turbid and (+++) for intense yellow and deeply turbid. PH was
determined using MColorpHastTM test strips. Carbohydrates, protein concentration and
protease activity were determined by optimized microplate periodic acid-Schiff’s reagent
assay, bicinchoninic acid assay and casein colorimetric assay respectively.
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Table 2.2 Physicochemical properties of human rectal fluids.
Sample ID
RL1
RL2
RL3
RL4
RL5
RL6

Appearance
++
++

pH
8
7
7
7
7
7

Protein Concentration
μg/mL
802.50
899.38
899.38
963.13
730.00
1211.88

Protease activity
μg/mL Trypsin
0.237
1.069
0.214
0.198
0.203
0.338

Appearance scored as (-) for clear and colorless, (+) for slightly turbid, (++) for slightly
yellow and mildly turbid and (+++) for intense yellow and deeply turbid. PH was
determined using MColorpHastTM test strips. Protein concentration and protease activity
were determined by bicinchoninic acid assay and casein colorimetric assay respectively.

Stability of Q-GRFT in mouse, macaque and human rectal fluids, and seminal plasma
To establish any inactivating activity of the lectin in rectal fluids, Q-GRFT was
incubated with rectal fluids, starting with an initial concentration of 250 ng/mL, with
two-fold dilutions, at 37°C. The lectin’s binding activity to gp120 was then determined
following incubation. GRFT strongly binds to the HIV envelope glycoprotein 120,
inhibiting transitions necessary for cell entry (165). Therefore, we used the ability to bind
gp120 in an ELISA assay as a surrogate of GRFT stability following incubation with
rectal fluids and seminal plasma. Following incubation for 24 hours with mice rectal
fluids (FIG 2.1A), Q-GRFT’s binding activity to gp120 was not affected. Upon
incubation with macaque rectal fluids (FIG 2.1B) at 37°C for 6 hours, binding activity to
gp120 was not affected. Similarly, incubation of Q-GRFT with human rectal fluids (FIG
2.1C) at 37°C for 24 hours did not impact the lectin’s binding activity to gp120. Because
of the development of Q-GRFT as a potential rectal microbicide for prevention of HIV
infection and transmission during condomless anal intercourse, we determined the
lectin’s binding inhibition in human seminal fluids. In keeping with findings from rectal
fluids, incubation in human seminal plasma (FIG 2.1D) for 24 hours at 37°C did not
impair gp120 binding.
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Figure 2. 1 Stability of Q-GRFT in rectal fluids and seminal plasma. Q-GRFT maintains
its binding to gp120 following incubation with (A) mice rectal fluids, (B) macaque rectal
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fluids, (C) human rectal fluids and (D) human seminal plasma. Q-GRFT was incubated at
37°C for 24 hours in mice-, human rectal fluids, and seminal plasma, and for 6 hours in
macaque rectal fluids. Representative data from one sample (mice and macaque rectal
fluids, and human seminal plasma), and 6 specimens (human seminal plasma) is shown.
For all experiments, Q-GRFT was incubated with PBS, as a control. For both fluids and
PBS, the initial Q-GRFT concentration of 250 ng/ml was used, with two-fold dilutions
performed up to 11 -12 times.

DISCUSSION
The anatomical and physiological properties of the biological environment in
which microbicides will work is critical to their applicability (251). In this study, we
have demonstrated that rectal fluids consist of varying concentrations of carbohydrates,
protein, and proteolytic enzymes, with a fairly stable pH range. Seminal fluids have
previously been shown to demonstrate proteolytic enzymatic activity (252, 253). The
demonstrated enzymatic activity has the potential to degrade or inactivate any peptide
molecules or microbicides administered in the rectal environment. The composition,
chemical and physical properties of a microbicide will influence its efficacy and activity
on mucosal surfaces (254). In addition, an effective microbicide PrEP modality should
withstand any inactivating activity in the rectal environment. Oral administration of
GRFT in Sprague Dawley rats was demonstrated to result in detection of active drug in
fecal extracts that potently neutralized HIV-Env PsV (196). This supports topical local
application given the lectin’s ability to withstand degradative properties of the
gastrointestinal tract. Local mucosal administration ensures the availability of sufficient
and adequate drug product levels in tissues following application. Regardless of the
demonstrated proteolytic potential, we have found that Q-GRFT, a protein molecule,
maintained the ability to bind to gp120 following incubation with rectal fluids and
seminal plasma (Table 2.1, Table 2.2 & Fig 2.1). Interestingly, Fabrice et al., found that
the activity of the molecule 5P12-RANTES, a potential HIV microbicide was affected by
the diversity of human rectal fluid composition, and that fluids from the same individual
collected at different times displayed varying degradative impact on 5P12-RANTES
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activity (245). However, they postulate that even at the most aggressive protease activity
identified, 5P12-RANTES will likely remain stable, with adequate anti-HIV activity.
Rectal microbiota, especially the predominance of Prevotellaceae likely predisposes and
contributes to HIV acquisition (255). Indeed, studies in non-human primates have
demonstrated that microbial differences resulted in differences in SHIV susceptibility
with susceptible animals associated with higher inflammatory activity and lower
Firmicutes and Bacteroides and higher Prevotellaceace spp. (256). The diverse gut
microbiota also contributes to, and shapes the enzymatic response in this environment
(257). Human gut microbial differences have been shown to vary at difference sampling
times within and between individuals over time (258, 259). Inter-subject differences in
microbiome diversity are greater than intra-subject variations (258). Compared to hostderived proteolytic enzymes, the majority of protease activity in the rectal environment is
of microbiota-origin (250).
Studies with cervicovaginal fluids have demonstrated that a wide range of factors
within this compartment mediate antimicrobial protection and work in concert to protect
target cells from infection with HIV. Specifically, beta-defensin 2, macrophage
inflammatory protein-3 alpha (MIP 3α), and HIV-specific IgG antibodies in this
compartment are associated with protection from virus infection (251, 260). In lieu of
this, it is critical that microbicides do not attenuate or diminish local protective properties
of the epithelial mucosa in which they act (251). GRFT has previously been shown to
exhibit stability in cervicovaginal fluids, which are comprised of an acidic pH, various
enzymes, vaginal microflora and macromolecules like mucins (206). Similarly, here, we
have demonstrated that in the rectal environment, despite a varying microbiome
composition, pH and enzymatic activity (245, 249), Q-GRFT is stable and maintains the
ability to bind gp120. Furthermore, the duration of incubation of Q-GRFT with the fluids
did not disrupt gp120 binding.
The impact of semen on HIV-1 transmission in the vaginal environment has been
extensively studied (261-264), and the effects in the rectum are similar to those observed
in this compartment (251). Semen alters the acidic vaginal pH to neutral, fostering an
environment prone to yeast infections and vaginosis. Semen in the reproductive tract
39

induces an influx of activated inflammatory cells and increases the population of
leucocytes in the vaginal tract, making them vulnerable to infection with infectious virus
in seminal fluids (261-263). Localized irritation and inflammation induced by semen
results in further recruitment and activation of more HIV-1 target cells, enhancing virus
infection and transmission. The likelihood of survival of cell-free and cell-associated
virus is increased by the seminal pH neutralization effect and secretion of semen-derived
enhancer of infection (263). Additionally, the electrostatic interaction between
spermatozoa and HIV-1 virions promotes virus infection (263). Mucosal movement of
HIV virions is increased following vaginal pH neutralization by semen, facilitating rapid
viral access to epithelium (265, 266). Contrastingly, studies have also identified antiviral
properties of semen. Seminal plasma contains a potent inhibitor that impedes HIV-1
attachment to DC-SIGN (263). Furthermore, in the vaginal environment, HIV is
inactivated by radicals generated by oxidation of SP polyamines by diamine oxidase
(263). Additionally, cationic polypeptides in seminal plasma contribute to this antiviral
effect (263). Interestingly, Buckheit et al., found that diverse semen samples obtained
from different donors displayed both inhibitory and enhancement properties of HIV
infection (251). In both the vagina and rectum, semen acts as a physical barrier to virus
movement towards epithelial target cells (267). However, once trauma or breach of the
barrier occurs, inflammatory cytokines promote transmission of infection through the
epithelium (251). In our study, incubation of Q-GRFT with seminal fluids did not impede
the lectin’s binding to gp120. Similarly, Harman et al. (268), demonstrated that L’644, a
fusion inhibitor peptide was stable and maintained antiviral activity following incubation
in semen and cervicovaginal fluids for 72 hours. It is therefore likely that Q-GRFT will
maintain anti-HIV-1 activity in the rectal environment in presence of semen.
One limitation of our study is that we did not confirm detection of Q-GRFT
following incubation in rectal fluids and seminal plasma using alternative methods like
western blot. However, given the high potency of GRFT in binding gp120, our results are
strongly suggestive of stability in this assay.
In summary, results from these experiments suggest that despite the diversity in
composition and complexity in the rectal environment, Q-GRFT remains stable and binds
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to gp120. It is likely that the lectin will maintain anti-HIV-1 activity in this biological
compartment.
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CHAPTER 3: IMPACT OF Q-GRFT ON THE GROWTH OF GUT AND RECTAL
MICROBIOME, AND MYCOBIOME COMPONENTS

INTRODUCTION
The vaginal and rectal microbiome has been implicated in the modulation and
efficacy of microbicide activity (269). Local physiologic responses including the
immunologic response, inflammation and epithelial barrier integrity induced by different
microbiota (270), may impact the action of different microbicides. Bacterial vaginosis
(BV) is a condition in which the acidophilic and aerobic vaginal microbiome,
predominantly comprising of Lactobacillus is replaced by anaerobic species,
predominantly Gardnerella (269). BV is associated with an increased risk and
susceptibility to HIV infection among women (271). Studies have identified that women
without BV and subsequently at a lower risk of HIV infection, had Lactobacillus species
as the predominant vaginal microbiota, whereas those with BV and at high risk of virus
infection display large proportions of Gardnerella and Prevotella, among other anerobic
species (272-274). Vaginal dysbiosis reduced the efficacy of a 1% tenofovor gel in
preventing HIV acquisition in women as pre-exposure prophylaxis (269). Gardenerella
vaginalis in BV likely metabolizes locally applied tenofovir, preventing uptake into
mucosal epithelial cells (269). Interestingly, condom use is associated with inflammatory
changes and demonstrates functional changes in vaginal bacterial metabolic pathways
(275). In men, condomless receptive anal intercourse (CRAI) has been associated with a
distinct rectal microbiota, enriched in Prevotellaceae family when compared to males
who have never practiced receptive anal intercourse (276). When compared to anal
intercourse- naïve men, MSM engaging in CRAI displayed elevated Th17 immune cells,
higher proliferation of CD8+ T cells, proinflammatory cytokines secretion and signatures
associated with epithelial injury and repair (276). In previous HIV clinical trials, the
failure of vaginal microbicides to prevent HIV transmission has been suggested to be as a
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result of a shift of the local bacterial community with a loss of natural anti-viral
protection (277). Indeed, healthy women who were vaginally exposed to either of gel
products hydroxyethylcellulose, 6% cellulose sulfate and 4% nonoxynol-9 demonstrated
a shift in the microbial community towards that dominant in strict anaerobes, and
depleted of Lactobacillus species (277). Interestingly, rectal application of Q-GRFT gel
in non-human primates did not result in significant changes to local proteome levels
during the period of lectin use, but demonstrated an increased abundance of beneficial
Ruminococcaceae and Christensenellaceae taxa (203). Currently, no published data is
available detailing the impact of microbicides on vaginal and rectal fungal communities.
Lectins are protein molecules that possess carbohydrate moieties and interact with
other cell wall and membrane components via these structures (1). Griffithsin has been
widely studied for its activity against the human immunodeficiency virus (HIV) and other
viruses (10, 11, 278). Conversely, as a microbicide, Q-GRFT topical use is likely to
impact the stability of resident microbiota. Here we report findings about the impact of
Q-GRFT on representative gut bacterial and fungal microbiota. We identify and report a
novel and the first known antifungal activity of this lectin and postulate a mechanism of
action of growth inhibition. Despite no detectable impact on bacterial microbiota, our
findings support further exploration and development of this lectin as an antifungal agent
given the observed growth inhibitory impact on Candida species in vitro.
MATERIALS AND METHODS
Griffithsin-M78Q expression and product formulation. The API used in the
experiments was recombinantly expressed in the Nicotiana benthamiana plant-based
system, as described previously (279). Because the original plant-produced recombinant
Griffithsin protein is prone to oxidation at methionine-79, a single amino acid
substitution replacing met-78 residue with glutamine (Q) in the non-binding domain has
been performed, generating a stable variant, Q-GRFT. The M78Q variant is more stable
to oxidation than the parent molecule and retains the potency and other characteristics of
the parent protein. The API was dissolved in PBS solution, pH 7.4 at 10+2 mg/mL, and
diluted as needed for use in these experiments.
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Antiviral activity assays. Anti-HIV activity was assessed in vitro using a viral
neutralization assay performed with HOS CD4+ CCR5+ (NIH AIDS Reagent Program
#3318) cells. HOS cells were cultured in DMEM supplemented with 10% FBS (VWR
#97068-085), 1% penicillin/ streptomycin (VWR#97063-708), and 1 μg/mL of
puromycin (VWR#97064-280). Using an opaque tissue culture treated white 96-well
plate, 50 μL of media was added to each well. This was followed by 50 μL of Q-GRFT
diluted 3X from a top concentration of 20 ng/mL in the top wells down the plate. HIV
PsV QH069 was diluted 1:4 in medium and 50 μL per well of diluted virus added to
every sample and positive control well. The 1:4 dilution had been predetermined to yield
enough luminescence (by TCID50 assay). The virus and Q-GRFT were incubated for 1
hour at 37°C. HOS cells were harvested from a flask and diluted to 1 x 105 cells/mL in
culture medium. One hundred microliters of well mixed cells (10,000 cells total per well)
were added to every well. The plate was then incubated for 3 days at 37°C. To read the
plate, 100 μL of medium were removed from each well and 100 μL of Britelite luciferase
assay reagent (Perkin Elmer #6066761) added to every well. Luminescence was
measured on a Synergy HT BioTek® plate reader. To establish the percent neutralization
for every well, the following formula was used:
Percent neutralization =

RLU sample−RLU virus control
RLU virus control

∗ 100.

Data was analyzed using non-linear regression and the IC50 calculated.
Bacterial growth inhibition assays. Gut and rectal microbiome and mycobiome
components were incubated in broth medium in presence of varying concentrations of QGRFT for 24 to 72 hours to determine the lectin’s growth inhibitory effects. The
representative bacterial components tested were purchased from the American Type
Culture Collection (ATCC) and are of human origin. Microbiome components:
Escherichia coli K12 was incubated in Miller’s Luria broth (LB broth), while
Lactobacillus acidophilus and Lactobacillus casei were incubated in De Man, Rogosa
and Sharpe (MRS) broth. Bacteroides fragilis (Nontoxigenic Bacteroides fragilis 9343
and Enterotoxigenic Bacteroides fragilis 086) was incubated in Brain Heart Infusion
media supplemented with clindamycin (BHI-Clindamycin). Clostridium difficile ATCC®
51695 and Bifidobacterium longum longum ATCC® 15707 were incubated in Brain Heart
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Infusion-supplemented (BHIS) media and MRS/ L-cysteine –enriched media,
respectively. Bacterial growth measured as OD 600nm, was monitored using a Synergy
HT BioTek® plate reader.
MIC and cytotoxicity determination for Q-GRFT against Chlamydia and Neisseria
gonorrhea. For determination of the lectin’s growth inhibitory Chlamydia trachomatis
inhibitory effect, 100 μL of McCoy cells (density 5x104 cells/well) were plated in a 96well plate in Eagle’s minimum essential media (EMEM) with 10% Fetal Bovine Serum
(FBS) and glutamine for 24 hours. Chlamydia trachomatis ATCC VR348B was then
added and centrifuged to promote infection. Doxycycline or Q-GRFT was added to the
supernatant in triplicate. Cells were then fixed and stained with iodine in absolute
methanol and glycerol. The wells were then observed for presence of inclusion bodies.
To establish Q-GRFT cytotoxicity to McCoy cells, the McCoy cell density was
determined upon Q-GRFT incubation. To establish inhibitory activity against Neisseria
gonorrhoea, Q-GRFT was added to agar medium inoculated with the pathogen and
MIC50 determined.
Candida growth inhibition assays. To determine fungal inhibition, 1.0×105 cells/mL of
Candida albicans ATCC® 32032, Candida glabrata CDC316, Candida krusei CDC397,
Candida parapsilosis CDC337, Candida auris CDC383, Candida auris CDC384,
Candida auris CDC385, Candida auris CDC386, Candida auris CDC388 and Candida
auris CDC389 were incubated with varying concentrations of Q-GRFT at 37°C in
Sabourand Dextrose culture media. Fungal growth was determined periodically up to 72
hours using either a Bio-Rad TC10TM Automated cell counter, Singapore or an ECHO
Rebel hybrid microscope (RBLTEW31), San Diego, USA. All Candida isolates tested
were of human origin.
Fluorescence microscopy. Candida albicans cells were incubated with Fluoresceinlabelled 7.8 µM Q-GRFT overnight, followed by DAPI staining. The cells were then
fixed in 37% formaldehyde, mounted on glass slides, and visualized using an Axio
Scope.A1 microscope, Carl Zeiss MicroImaging GmbH.
Fluorescence binding intensity. C. albicans cells were incubated with Fluoresceinlabelled 7.8 µM Q-GRFT overnight, washed in PBS, and fluorescence intensity at
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excitation/ emission wavelength 480/ 520 nm determined using a BioTekTM Synergy HT
plate reader.
Detection of hydrogen peroxide and ROS. The staining procedure using 3,3’diaminobenzidine (DAB) (280) was employed to detect hydrogen peroxide in Candida
albicans cells following incubation with Q-GRFT. Briefly, fungal cells (1.0×105
cells/mL) were incubated for 2 hours on microslides with either 7.8 µM Q-GRFT, PBS
(negative control) or 300 mM hydrogen peroxide (positive control) in the presence of 0.5
mg/mL DAB. Formation of hydrogen peroxide within cells, as a brown pellet, was
evaluated microscopically. A count to determine the percentage of brown-stained cells
following Q-GRFT treatment in comparison with the controls was performed from at
least 3 independent experiments in triplicate.
The direct fluorescence method using H2DCF-DA (281) was used to assess
induction of ROS in Candida albicans cells following incubation with Q-GRFT. Briefly,
Candida albicans was grown overnight from stock solution, to achieve growth in the
exponential phase, followed by inoculate into a fresh Peptone Dextrose medium. Cells
were then incubated with Q-GRFT (7.8 µM or 0.78 µM) overnight. Cultures were
harvested and cell numbers optimized and kept constant for all treatment groups.
Harvested cells were then centrifuged at 5000-6000g for 10 minutes followed by washing
the pellet twice in PBS. Cells were then incubated for 30 minutes with H2DCF-DA (10
µM) in PBS in the dark followed by centrifugation. The pellet was washed (2 times) and
resuspended in 200µl PBS in a fluorescence/ black 96-well plate. Fluorescence intensity
was determined with excitation and emission wavelengths at 504 nm and 524 nm,
respectively, using a Synergy HT BioTek® plate reader.
Q-GRFT ability to bind to gp120 and cell wall components. Q-GFT’s ability to bind to
gp120 and Candida albicans cell wall components was determined using an ELISA
assay. Briefly, a 96-well MaxiSorp NUNC plate was coated overnight with0.1 mL per
well of either gp120, chitin, α-mannan or β-glucan. The plate was then blocked for 2
hours using 3% BSA in 1X PBS-T, 0.3 mL per well. Q-GRFT was then added at a
concentration of 250 ng/mL with 2-fold dilutions performed down the plate. The plate
was incubated for 1-2 hours at room temperature. A primary antibody, rabbit anti-GRFT,
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0.1 mL per well, diluted 1:10,000 in 1X PBS was added and the plate incubated for 1
hour. A secondary antibody, goat anti-rabbit, Southern Biotech 4030-05, diluted at
1:25,000 in 1X PBS, 0.1 mL per well added followed by incubation for 1 hour. TMB
solution, 0.1 mL per well was the added for 4 minutes and the reaction stopped with 0.1
mL per well of 1N Sulphuric acid. Absorbance was read at 450 nm using the Synergy HT
BioTek® plate reader.
Viability assays. To determine the impact of Q-GRFT on Candida albicans viability, the
trypan blue exclusion test of cell viability (282), was used. Briefly, Candida albicans was
incubated with Q-GRFT (7.8 µM) at 37°C overnight followed by staining with 0.4%
trypan blue (1 part trypan blue and 1 part cell suspension). The mixture was allowed to
incubate at room temperature for ~3 minutes followed by cell evaluation by optical
microscopy.
C. albicans viability analysis was also carried out using flow cytometry with BD
HorizonTM Fixable Viability Stain 780 (FVS780). Following overnight growth with either
Q-GRFT or PBS control, cells were added to complete RPMI medium (supplemented
with 1M HEPES, penicillin/ streptomycin, fetal bovine serum and 2-Mercaptoethanol),
filtered and centrifuged for 5 minutes at 1600 rpm. One to two million cells were then
added to appropriate flow cytometry tubes, followed by washing with FACS buffer (BD
Biosciences, San Diego California) for 5 min at 1600 rpm. Cells were then blocked with
2 µL of CD16/32 antibody (BioLegend, San Diego, California) for 10 minutes at 4°C,
followed by staining with 1 µL of viability dye, and incubation at 4 °C for 30 minutes.
Cells were then fixed, washed, re-suspended in 300 µL of FACS buffer, and analyzed
using a BD device (BD LSR FortessaTM, USA), following manufacturer’s instructions.
Data was analyzed using Flowjo software (Tree Star, Inc, Ashland, Oregon).
MIC determination. The MIC50s and MIC90s were determined by the broth dilution
method as described by the European Committee on Antimicrobial Susceptibility Testing
(EUCAST) (283).
Scanning electron microscopy. C. albicans cells were grown overnight in the presence of
either PBS or 7.8 µM Q-GRFT, in Sabourand Dextrose media at 37°C. The media was
then rinsed off and cells fixed for 24 hours at 4°C with SEM Fixative (2.5%
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glutaraldehyde, 2.5% formaldehyde, 0.1M sodium cacodylate, pH 7.4). Cells were then
rinsed and serially dehydrated in ethanol. They were then critically dried using
hexamethyldisilazane (HMDS). Cells were then coated with gold/ palladium in a
Cressington 108auto/SE sputter coater followed by examination using the Apreo 2
electron microscope.
Candida albicans RNA extraction and Sequencing. A total of 4.0×107 yeast cells were
used for RNA extraction using the Qiagen RNeasy® Midi Kit, following manufacturer’s
instructions. DNase treatment was performed using the RNase-Free DNase set purchased
from Qiagen®. RNA quantification was carried out spectrophotometrically at 260 nm and
280 nm using a NanoDrop 1000 spectrophotometer (ThermoScientificTM, USA). For
RNA sequencing, pairwise comparisons were made between treated groups [7.8 µM QGRFT (1QG), 0.78 µM (2QG) and 7.8 µM Lec(-)Q-GRFT (3QG)] with vehicle control
(4VC). Sequencing was performed as follows:
1. Library Preparation. Libraries were prepared using the Illumina Stranded mRNA
Prep, Ligation (Illumina Cat# 20040532), IDT for Illumina RNA UD Indexes Set B,
Ligation (Illumina Cat# 20040554). A. Purify and Fragment mRNA. mRNAs were
purified from 200 ng of total RNA samples with oligo(dT) magnetic RNA Purification
Beads and denatured for 5 minutes at 65°C. Then the supernatant was discarded, and the
beads were washed with bead wash buffer. Captured polyadenylated RNAs were eluted
using Elution buffer at 80°C for 2 min. mRNAs were further purified in a second bead
clean-up, then fragmented and primed during elution by adding 19 µl of Fragmentation
Mix to the beads and incubating for 8 minutes at 94°C. After fragmentation, 17ul of
supernatant was removed from the beads and proceeded immediately to synthesize first
strand cDNA. B. Synthesize First Strand cDNA: Following the protocol, 8 µl of First
Strand Synthesis Act D Mix and Reverse Transcriptase were added to each sample and
heated on a thermocycler using preprogrammed conditions, to produce first strand cDNA
from the hexamer-primed RNA fragments. C. Synthesize Second Strand cDNA: Second
Strand Marking Mix was added, mixed well, and incubated at 16°C for one hour. Bluntended, double-stranded cDNA fragments were then purified using Agencourt AMPure
XP Beads at 1.8X. 17.5 µl of elute was collected and stored at -20°C. D. Adenylate 3’
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Ends: Purified samples were mixed with 12.5 µl A-Tailing Mix then incubated on the
preprogrammed thermal cycler. An adenine (A) nucleotide was added to the 3ʹ ends of
the blunt fragments. E. Ligate Anchors: Ligation Mix and RNA index anchors were
added and incubated in a pre-heated thermocycler at 30°C for 10 minutes. Stop Ligation
Buffer was immediately added to each sample and mixed well. F. Clean Up Fragments:
The ligated fragments were purified using Agencourt AMPure XP Beads at 0.8X. 20 µl
of the elute was collected and used for library amplification. G. Amplify Library: 12
cycles of PCR reactions were performed to selectively amplify the anchor-ligated DNA
fragments and to add indexes and primer sequences for cluster generation. Sample and
Barcode Information: Samples were barcoded with IDT for Illumina DNA/RNA UD
Indexes as listed in Table 3.1. H. Clean Up Library: Amplified libraries were purified
using Agencourt AMPure XP Beads at 1.0X. 15 µl of eluted libraries were collected and
stored at -20°C. I. Validate Library: The concentration of libraries was measured by
Qubit dsDNA HS Assay Kit (Invitrogen Q32851). Libraries were diluted and normalized
to the optimal range for Agilent Bioanalyzer analysis using the DNA High Sensitivity Kit
(Agilent Technologies, Cat# 5067-4626). J. Normalize and Pool Libraries: The same
amount of libraries were pooled based on the molar concentration from Bioanalyzer.
2. Library Denaturing and Diluting for MiSeq Nano 300: Pooled library was run on
MiSeq to test quantity and quality, using the MiSeq Reagent Nano Kit V2 300 cycles
(Illumina, Cat. No. MS-103-1001). Library and PhiX control (Illumina, Cat. No. FC-1103001) were denatured and diluted using the standard normalization method following
manufacturer's directions, to a final concentration of 12.5 pM. 300 µl of library and 300
ul of PhiX were combined and sequenced on Illumina MiSeq.
3. Library re-pool: Based on MiSeq results, equal amounts of libraries were re-pooled for
NextSeq run.
4. Library Denaturing and Diluting for Nextseq 500: Library and PhiX were denatured
and diluted using the standard normalization method following manufacturer's directions.
5. Sequencing Run: Sequencing was performed on the University of Louisville Brown
Cancer Center Genomics Core Illumina NextSeq 500 using the NextSeq 500/550 75
cycle High Output Kit v2.5 (20024906). The total volume of library was 1.3 ml at 1.8
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pM, with 1% PhiX spike in. Two runs were made for the analysis described in this
manuscript.

Table 3.1. Sample and Barcode Information
Sample_ID

1QG2_Candida
1QG3_Candida

17_Index_ID
UDP0121
UDP0122
UDP0123

Index 1
15_Index_ID
AGAGAACCTA UDP0121
GATATTGTGT UDP0122
CGTACAGGAA UDP0123

Index 2
GGTTATGCTA
ACCACACGGT
TAGGTTCTCT

2QG1_Candida
2QG2_Candida

UDP0124
UDP0125

CTGCGTTACC UDP0124
AGGCCGTGGA UDP0125

TATGGCTCGA
CTCGTGCGTT

2QG3_Candida
3QG1_Candida
3QG2_Candida

UDP0126
UDP0127
UDP0128

AGGAGGTATC UDP0126
GCTGACGTTG UDP0127
CTAATAACCG UDP0128

CCAGTTGGCA
TGTTCGCATT
AACCGCATCG

3QG3_Candida

UDP0129

TCTAGGCGCG

UDP0129

CGAAGGTTAA

4VC1_Candida
4VC2_Candida
4VC3_Candida

UDP0130
UDP0131
UDP0132

ATAGCCAAGA UDP0130
TTCGGTGTGA UDP0131
ATGTAACGTT UDP0132

AGTGCCACTG
GAACAAGTAT
ACGATTGCTG

1QG1_Candida

Bioinformatics data analysis was performed using the pipeline shown in FIG 3.1 below.

Figure 3. 1 Bioinformatics analysis workflow diagram.
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Statistical analysis. Statistical analyses were performed using GraphPad Prism V7.
Numerical data are presented as means + standard deviation (SD) or mean + standard
error of mean (SEM). The number of repetitions and replicates of each assay and
experiments are reported individually in the descriptions of each of the findings.
Statistical differences between sets of data were evaluated using ANOVA and t-test,
where indicated. P< 0.05 values were considered significant.
RESULTS
Effect of Q-GRFT on HIV replication
Given that GRFT has been shown previously to inhibit HIV replication (206), we
determined whether Q-GRFT, a variant of GRFT (unpublished data), retained anti-HIV
activity by establishing the lectin’s impact on HIV-1 PsV replication. Unlike the mutant
lectin-binding site deficient Q-GRFT [Q-GRFT lec neg ], wild type (WT) Q-GRFT
inhibited HIV-1 PsV QH069 replication (FIG 3.2). The IC50 for lec (-) Q-GRFT was
~27.5 ng/mL while WT Q-GRFT had an IC50 of 0.305 ng/mL (95% CI 0.2027 to 0.4380
ng/mL). These results suggest that Q-GRFT prevents HIV-1 PsV replication in vitro.

Figure 3. 2 Q-GRFT inhibits HIV PsV QH069 replication. Q-GRFT neutralization
activity against HIV PsV was determined using HOS cell assay for anti-HIV PsV activity
and luciferase activity. The graph shows percent virus neutralization (mean + SEM) for
Q-GRFT compared Q-GRFT lec neg deficient in sugar-binding activity, for HIV PsVQH09

51

at varying concentrations of the lectin. The calculated IC50 of WT Q-GRFT is 0.305
ng/mL. Triplicate assays were performed, and representative data is presented.

Effect of Q-GRFT on the growth of rectal microbiome (bacterial) components
Whilst exploring the impact on proteome and microbiome when GRFT was
applied topically as a rectal gel in non-human primates, Girard et. al. found that the lectin
induced small, but significant increases in relative abundances of Ruminococcaceae
NK4A214 and Christensenellaceae R-7, but the effect was not sustained at 7 days post
application (203). No other significant effects were observed in Rhesus macaque rectal
microbiota after application of the gel. Against this background, we investigated the
effect of Q-GRFT on the growth of representative bacteria found in the human gut:
Aerobes -Lactobacillus acidophilus and Lactobacillus casei; facultative anaerobe
Escherichia coli K12; and anaerobes- Bifidobacterium longum longum ATCC® 15707,
Clostridium difficile ATCC® 51695-F2, Enterotoxigenic Bacteroides fragilis and
Nontoxigenic Bacteroides fragilis (FIG 3.3). The selected bacterial components were
incubated in presence of varying concentrations of Q-GRFT broth media, and growth
established by determining optical density (OD) measurements over time on a plate
reader. Q-GRFT had no detectable impact on the growth of any of the bacterial species
tested. These data demonstrated that Q-GRFT likely does not inhibit the growth of
bacterial microbiome.
We then tested Q-GRFT’s growth inhibitory activity against select causative
pathogens for sexually transmitted infections, Chlamydia trachomatis and Neisseria
gonorrhea. There was no detectable impact of Q-GRFT on the in vitro growth of
Chlamydia trachomatis and Neisseria gonorrhea (Table 3.2).
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Figure 3. 3 The effect of Q-GRFT on the growth of rectal microbiome (bacterial)
components.
(A) Lactobacillus acidophilus (B) Lactobacillus casei (C) Escherichia coli K12 (D)
Bifidobacterium longum longum ATCC® 15707 (E) Clostridium difficile ATCC® 51695F2 (F) Enterotoxigenic Bacteroides fragilis and (G) Nontoxigenic Bacteroides fragilis.
Microbiome components were incubated with either varying concentrations of Q-GRFT,
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PBS vehicle or control antibiotics in broth media and growth monitored periodically up
to 24 hours. Data represents results mean + SD from 3 independent experiments.
Table 3.2. MIC50 results for Q-GRFT against Chlamydia trachomatis and Neisseria
gonorrhea.
Compound

Chlamydia trachomatis

Neisseria gonorrhea

Q-GRFT (μg/ml)

>50

>50

Doxycycline (μg/ml)

0.03

-

Penicillin (μg/ml)
0.03
McCoy cells were plated in a 96-well plate and infected with Chlamydia trachomatis.
Cells were then treated with either Q-GRFT or doxycycline, fixed, stained with iodine,
and observed for inclusion bodies to establish MIC50. Q-GRFT was also added to agar
medium inoculated with Neisseria gonorrhea to determine inhibitory activity against the
pathogen.

Effect of Q-GRFT on the growth of Candida albicans
Since yeast and fungi are universally present in gut microbial communities (284),
we next investigated the impact of Q-GRFT on the growth of Candida albicans ATCC
32032, as a representative of the gut fungal community. Yeast counts were determined
using a Bio-Rad TC10TM Automated cell counter, Singapore, or an ECHO Rebel hybrid
microscope (RBLTEW31), San Diego, USA. Following incubation with Candida
albicans for 24, 48 and 72 hours (FIG 3.4A), Q-GRFT significantly inhibited fungal
growth; P<0.0001 at all concentrations tested (7.80 µM, 0.78 µM and 0.078 µM). We
next sought to confirm Q-GRFT’s growth inhibitory activity by incubating C. albicans
with the Q-GRFT variant, Q-GRFT lec neg , devoid of its glycan binding ability. Incubation
of C. albicans with various concentrations of Q-GRFT lec neg for up to 72 hours did not
demonstrate any inhibitory impact on growth (FIG 3.4B), suggesting a role of Q-GRFT’s
binding on fungal inhibitory activity.

54

Figure 3. 4 Effect of Q-GRFT on the growth of Candida albicans. (A) Candida albicans
ATCC 32032 at a concentration of 1.0x105 cells/mL was incubated with varying
concentrations of Q-GRFT and fluconazole control at 37°C in Sabourand Dextrose
culture medium and growth monitored at 24, 48, and 72 hours. (B) C. albicans (1.0x104
cells/mL) was incubated with varying concentrations of Q-GRFT lec neg (7.80 M, 0.78 M),
with fluconazole (3.3 mM) and PBS as controls, at 37°C in Sabourand Dextrose culture
medium. Growth was monitored at 24, 48, and 72 hours. Fungal counts were performed
using either a Bio-Rad TC10TM Automated cell counter, Singapore, or an ECHO Rebel
hybrid microscope (RBLTEW31), San Diego, USA. Both experiments were performed in
triplicate. Representative data (Mean + SD) from at least 3 independent experiments is
shown, with comparisons made using one -way ANOVA.
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Q-GRFT’s growth inhibitory activity is dependent on the lectin’s binding to Candida
albicans
Since Q-GRFT inhibited the growth of C. albicans, we sought to determine if this
activity was dependent on Q-GRFT binding. C. albicans (1.0 × 105 cells/ mL) was
cultured overnight with either Fluorescein-labeled Q-GRFT, unlabeled Q-GRFT or the
Fluorescein-labeled Q-GRFT lec neg. Cells were then centrifuged, washed, and
fluorescence intensity of the pellet determined. C. albicans incubated with FluoresceinQ-GRFT displayed the highest fluorescence intensity compared to the non-labeled QGRFT (P<0.0001) and Fluorescein- Q-GRFT lec neg (P<0.0001) (FIG 3.5A). To confirm
lectin binding, C. albicans was cultured overnight with either Fluorescein-Q-GRFT, QGRFT or Fluorescein- Q-GRFT lec neg, and the cells visualized using fluorescence
microscopy. Green fluorescence was observed around yeast cells incubated with
Fluorescein-Q-GRFT, confirming Q-GRFT’s binding to C. albicans (FIG 3.5B). No
fluorescence was observed following incubation with Fluorescein-Q-GRFT lec neg (data
not shown).
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Figure 3. 5 Q-GRFT binds to Candida albicans. (A) Fluorescence intensity of Candida
albicans cultured with either Fluorescein-Q-GRFT, Q-GRFT or Q-GRFT lec neg, at lectin
concentrations of 7.8 µM. (B) Fluorescence microscopy following culture of Candida
albicans with Fluorescein-Q-GRFT. Green fluorescence demonstrates localization to C.
albicans cells. DAPI demonstrates DNA staining. Scale bars are 3 µm. Experiments were
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performed in triplicate and repeated at least 3 times. The results shown are Mean + SD
(A) and representative images of the microscopy studies (B).

Q-GRFT binds to Candida albicans cell wall component α-mannan but not chitin or
β-glucan
We next investigated the C. albicans cell wall components to which Q-GRFT
binds. Since the lectin bound to C. albicans, we hypothesized that Q-GRFT likely binds
to either chitin, glucans or mannans, which are predominant core components of the
fungal cell wall (285, 286). In addition, chitin is a polymer of N-acetyl-D-glucosamine
(287), while mannan is an N-glycosylated polysaccharide with oligomannose side chains
and branch chain mannose residues (288). Furthermore, β-glucans are composed of
linkage glucose units (285). These structures, hence, provide likely binding targets for
lectins, including Q-GRFT (6). Using ELISA binding assays (FIG 3.6A), we determined
the ability of Q-GRFT to bind to plate-immobilized antigens α-mannan, β-glucan and
chitin. Q-GRFT bound to α-mannan with EC50 23.47 ng/mL (95% CI 17.63 to 35.25
ng/mL). Q-GRFT did not bind to chitin or β-glucan. Because Q-GRFT binds to gp120,
we next sought to determine if the lectin’s binding to the glycoprotein is inhibited in the
presence of free and unbound cell wall components α-mannan, chitin or β-glucan in a
competition assay. Additionally, as antigens attach to the solid interface in the ELISA
assay, they are likely to denature and/ or undergo conformational changes that may affect
their interaction with other biomolecules (289). Therefore, Q-GRFT was incubated with
either free α-mannan, chitin or β-glucan, prior to determining its binding to gp120. QGRFT’s binding to gp120 was inhibited in the presence of high concentrations of αmannan (FIG 3.6B), but not chitin (FIG 3.6C) or β-glucan (FIG 3.6D). Results for EC50
and CI values for the free-antigen binding assays are shown in Table 3.3 below. One
limitation of the α -mannan binding assay was that we did not demonstrate maximal
binding as we did not obtain the plateau readings upon Q-GRFT incubation. However,
altogether, results from these binding studies are strongly suggestive that that Q-GRFT
binds to α-mannan, but not chitin or β-glucan in the C. albicans cell wall.
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Figure 3. 6 Q-GRFT binds to C. albicans cell wall. (A) Q-GRFT binds to C. albicans
cell wall component α-mannan but not chitin or β-glucan. An ELISA binding assay was
performed, with the plate coated with 100 µL of either α-mannan (20 µg/mL), chitin (2.0
mg/mL) or β-glucan (40 µg/mL). Q-GRFT’s binding to these components was then
determined. (B) Unlike the low concentration (0.005 µg/mL), higher concentrations of αmannan (0.5 µg/mL and 0.05 µg/mL) inhibited Q-GRFT’s binding to gp120, in a
competition ELISA assay. Q-GRFT was incubated with free (unbound) α-mannan and its
ability to bind gp120 determined. When incubated with free (unbound) chitin (C) and βglucan (D) Q-GRFT’s binding to gp120 was not inhibited in a competition ELISA assay.
ELISA plates were coated with gp120 for assays in (B)-(D) and absorbance determined
upon Q-GRFT binding. Experiments were performed in triplicate and repeated at least 3
times. Representative data from the experiments is shown. One-way ANOVA was used
for all statistical comparisons.
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Table 3.3. Competition ELISA assay values (EC50 and 95% CI) for Q-GRFT binding to
α-mannan, chitin and β-glucan.

Q-GRFT incubation

EC50 (ng/ mL)

95% CI (ng/ mL)

79.35

69.19 to 97.85

-

-

-

-

Q-GRFT in PBS

72.46

55.17 to 115.10

Q-GRFT + chitin 0.096 µg/ mL

7.30

6.73 to 7.92

Q-GRFT + chitin 9.60 µg/ mL

5.79

4.85 to 6.98

Q-GRFT + chitin 960 µg/ mL

6.18

5.45 to 7.04

Q-GRFT in PBS

6.02

5.23 to 7.00

Q-GRFT + β-glucan 0.005 µg/

7.77

5.90 to 10.58

Q-GRFT + β-glucan 0.05 µg/ mL

7.92

6.51 to 9.90

Q-GRFT + β-glucan 0.5 µg/ mL

6.01

5.37 to 6.77

Q-GRFT in PBS

5.32

4.73 to 6.00

Q-GRFT + α-mannan 0.005 µg/
mL
Q-GRFT + α-mannan 0.05 µg/
mL
Q-GRFT + α-mannan 0. 5 µg/ mL

mL

Q-GRFT was incubated with either free α-mannan, chitin, or β-glucan in solution, and the
lectin’s binding to a 96-well plate-coated gp120 determined. The table summarizes QGRFT EC50 and 95% CI values following incubation with the respective α-mannan,
chitin, or β-glucan concentrations.

Effect of Q-GRFT on Candida albicans’ cell structure, integrity and oxidative status
Treatment of C. albicans with helianthus annus (Helja) lectin has been shown to
alter membrane permeability and induce intracellular formation of oxidative species
(280). Therefore, we hypothesized that Q-GRFT lectin may act similarly, altering fungal
cell wall permeability and inducing expression of intracellular reactive oxidative species
(ROS), with subsequent cellular injury and/ or damage, leading to leading to cell death.
To demonstrate the impact on cell wall integrity, C. albicans was incubated with 7.8 µM
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Q-GRFT overnight at 37°C, followed by Trypan Blue staining, with the dye uptake
demonstrating breached cell wall/ membrane integrity, and penetration into dead/ nonviable cells. Compared to the PBS control, Q-GRFT treatment resulted in significant
intracellular blue color staining, indicative of non-viable cells with impaired cell wall
integrity, P<0.0001 (FIG 3.7A). To further confirm disruption of cell wall and membrane
integrity, we next performed live/ dead cell viability staining of 7.8 µM Q-GRFT- and
PBS control- treated C. albicans cells and measurements determined at flow cytometry
(FIG 3.7B and 3.7C). These cells were incubated at 37°C overnight under the respective
treatment conditions. FIG 3.7B is a representative image of the gating strategy for both
Q-GRFT and PBS-treatments. Fixable Viability Stain 780+ cells were considered as dead
cells with disrupted membrane integrity. Q-GRFT treatment resulted in a significantly
higher proportion of dead cells, compared to PBS control treatment, P<0.0001 (FIG
3.7C).
To investigate the induction of ROS by Q-GRFT, C. albicans cells were
incubated overnight with 7.8 µM Q-GRFT followed by incubation with 3, 3diaminobenzidine (DAB) for 2 hours. In the presence of peroxides, DAB is oxidized to
an insoluble brown precipitate that is visualized within cells using optical microscopy.
Compared to the PBS vehicle treated control, a significantly large proportion of Candida
albicans cells incubated with Q-GRFT developed a brown intracellular precipitate.
Quantification of this effect revealed that the presence of peroxides was significantly
higher (P<0.0017) following Q-GRFT treatment than with PBS control (FIG 3.7D). To
confirm the presence of ROS, we used the H2DCF-DA assay technique to profile the
oxidative status of Q-GRFT- treated and PBS vehicle-treated control cells. This assay is
dependent on cellular esterase ability to cleave acetate groups on H2DCF-DA, releasing
an intermediate H2DCF product which reacts with ROS forming fluorescent 2’,7’dichlorofluorescein (DCF) (281). Compared with PBS vehicle-treated control cells, QGRFT treatment was associated with higher fluorescence activity (P<0.002, P<0.006 for
7.8 µM and 0.78 µM respectively) following H2DCF assay (FIG 3.7E). Centrifugation of
cells during preparation for H2DCF assay may induce ROS accounting for the low-level
induction observed in the negative control (PBS vehicle-treated) cells (281). It is likely
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that different Q-GRFT concentrations elicit various levels of cellular stress, accounting
for the differences in ROS formation for both 7.8 µM and 0.78 µM Q-GRFT treatments.
To further evaluate any structural changes to C. albicans following treatment with
Q-GRFT, high resolution scanning electron microscopy (SEM) was performed for both
Q-GRFT- treated and -PBS vehicle- treated control cells (FIG 3.8). Yeast cells were
treated with either 7.8 µM Q-GRFT or PBS vehicle and incubated overnight at 37°C prior
to imaging. The vehicle- treated control cells demonstrated a normal budding pattern,
were predominantly spherical to oval in shape (FIG 3.8A), with polar buds and bud scars
(FIG 3.8B) and smooth edges and surfaces (FIG 3.8C). Q-GRFT treated cells were
spherical to circular (FIG 3.8D, 3.8E), rough in appearance, demonstrated desiccated and
wrinkled surfaces with uniform indentations (FIG 3.8E, 3.8F), and with a loss of polar
budding (FIG 3.8F).

Figure 3. 7 Effect of Q-GRFT on C. albicans' cell integrity and oxidative status. (A)
Yeast cells were incubated in the absence or presence of Q-GRFT (7.8 µM) overnight at
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37°C, followed by staining with Trypan Blue to detect non-viable cells. Data is
representative of results from at least 3 experiments with 3 biological replicates, Mean +
SD, P<.0001. (B) C. albicans (1.0 x 105 cells/ mL) was incubated overnight with either
Q-GRFT 7.8 µM or PBS control and cell viability determined using flow cytometry.
Dead cells were identified following staining with 1 µL Fixable Viability Stain 780 and
were those that demonstrated up take of the dye. Representative gating strategy for both
Q-GRFT treated, and PBS control-treated cells is presented. (C) Quantification of the
percentage of dead cells obtained from flow cytometry measurements for Q-GRFTtreated and PBS-treated C. albicans in (B). Results show Mean + SD, P<0.0001.
Experiments were performed three times and representative data is shown. (D) Candida
albicans cells were incubated with Q-GRFT (7.8 µM) or PBS overnight followed by
incubation in the presence of 0.5 mg/mL DAB for 2 hours to detect hydrogen peroxide.
Quantification of the proportion (percentage) of DAB staining cells following either QGRFT or PBS treatment for the experiments is shown, Mean + SD, P=.0017. (E)
Candida albicans was incubated overnight with Q-GRFT (7.8 and 0.78 µM) or medium
only at 37°C. Cells were harvested and 3.2 x 106 cells per treatment used for direct
fluorescence using the H2DCF-DA assay to determine Reactive Oxygen Species (ROS)
levels in the cells. Experiments were performed in triplicate and representative data is
shown, Mean + SD, Q-GRFT 7.8 µM P=0.0015 and Q-GRFT 0.78 µM P=0.0068.
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Figure 3. 8 C. albicans surface phenotype following treatment with Q-GRFT. C.
albicans was grown overnight in Sabourand medium in presence of either PBS (A-C) or
7.8 µM Q-GRFT (D-E) at 37°C. Cells were then observed by SEM. (A) Budding
morphology of C. albicans. Note the spherical to oval appearance of cells. Magnification
x7500. (B) Cells with smooth surface, polar budding and bud scars (arrows).
Magnification x10000. (C) Note the smooth cell surface and absence of any ‘non-polar’
bud scars. Magnification x12500. (D) Cells with spherical to circular shape with rough
surface. Magnification x7500. (E) Note the rough surface, uniform indentations with a
desiccated and wrinkled appearance. Magnification x10000. (F) Note the loss of polar
budding, more circular appearance, and cells with multiple bud scars (arrows).
Magnification x17500.

Impact of Q-GRFT on the growth of non-Candida albicans species
Given the recent increase in Candida spp. resistance to antifungal drugs (290), we
next investigated the impact of Q-GRFT on the growth of human pathogenic nonCandida albicans species including the multidrug resistant (MDR) Candida auris. Most
of the C. auris strains isolated from patients and identified in the United States belong to
clades originating from South America and South Asia (291). We therefore tested QGRFT’s growth inhibitory activity on representative isolates from these and other clades
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including C. auris CDC388 and C. auris CDC389 -South Asia clade; C. auris CDC385
and C. auris CDC386 -South America clade; and C. auris CDC383 and C. auris CDC384
-Africa clade. The other non-Candida albicans species tested included Candida glabrata
CDC316, Candida krusei CDC397 and Candida parapsilosis CDC337. Q-GRFT was
incubated with Candida glabrata, Candida krusei and Candida parapsilosis at 37°C and
growth monitored periodically using an automated cell counter, at 24, 48 and 72 hours.
Compared to the medium control, Q-GRFT significantly inhibited the growth of all the
species tested, with the greatest effect demonstrated with the 7.80 µM lectin
concentration, P<0.0001 for all species and concentrations tested (FIG 3.9A, 3.9B, 3.9C).
When incubated with Candida auris, Q-GRFT significantly inhibited the growth of
strains Candida auris CDC388 and Candida auris CDC389, P<0.0001, for the lectin
concentrations 0.78 µM and 7.8 µM tested (FIG 3.9D, 3.9E). There was no observable
impact on the growth of strains Candida auris CDC383 (FIG 3.9F), Candida auris
CDC384 (FIG 3.9G), Candida auris CDC385 (FIG 3.9H) and Candida auris CDC386
(FIG 3.9I).
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Figure 3. 9 Impact of Q-GRFT on growth of non-C. albicans species. (A) Candida
glabrata CDC316 (B) Candida krusei CDC397 (C) Candida parapsilosis CDC337 and
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multi-drug resistant Candida auris strains (D) Candida auris CDC389 (E) Candida auris
CDC389 (F) Candida auris CDC383 (G) Candida auris CDC384 (H) Candida auris
CDC385 and (I) Candida auris CDC386 at a concentration of 1.0x105 cell/mL were
incubated with different concentrations of Q-GRFT and fluconazole control at 37°C in
Sabourand Dextrose culture media and growth monitored up to 72 hours. Fungal counts
were performed using either a Bio-Rad TC10TM Automated cell counter, Singapore, or an
ECHO Rebel hybrid microscope (RBLTEW31), San Diego, USA. Data represents mean
+ SD from 3 independent experiments and was analyzed using one-way ANOVA.

Minimum inhibitory concentrations of Q-GRFT for Candida spp.
Starting with a maximum concentration of 95 µg/mL, MICs were determined for
Q-GRFT’s activity against different Candida isolates and are summarized in Table 3.4.
The MIC50s of Q-GRFT for C. albicans, C. glabrata, C. parapsilosis, C. krusei, C. auris
CDC388 and C. auris CDC389 were 6, 95, 24, 95, 48 and 95 µg/mL, respectively, while
MIC90s for C. albicans, C. parapsilosis and C. auris CDC389 were 95 µg/mL for all
isolates, respectively.

Table 3.4. MIC50s and MIC90s of Q-GRFT against different Candida species.
Candida isolate

MIC50 (µg/mL)

MIC90 (µg/mL)

ATCC32020

6

95

Candida glabrata CDC316

95

-

CDC337

24

95

Candida krusei CDC397

95

-

Candida auris CDC388

48

95

Candida auris CDC389

95

-

Candida albicans

Candida parapsilosis

RNA expression profile of C. albicans following treatment with Q-GRFT
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To better understand the impact of Q-GRFT on C. albicans growth and
metabolism, we sought to determine the differential RNA expression profile upon lectin
treatment. C. albicans was treated overnight with either 7.8 µM Q-GRFT (1QG), 0.78
µM Q-GRFT (2QG) or the binding-site deficient lectin 7.8 µM Q-GRFT lec neg (3QG),
and comparisons made with the untreated control (VC), following RNA isolation and
sequencing. The principal component analysis (PCA) results showed that the
experimental groups clearly had good separation based on treatment status (FIG 3.10A).
Differential expression analysis was performed for the different treatments using
DESeq2. When compared to VC, venn diagram analysis identified 1134, 83 and 493
differentially expressed genes (DEGs) that were only unique to 1QG, 2QG and 3QG,
respectively (FIG 3.10B). In addition, 587, 55 and 268 genes were uniquely up-regulated
DEGs, while 567, 43 and 254 were uniquely down-regulated DEGs for 1QG, 2QG and
3QG, respectively (FIG 3.11A, 3.11B). Cluster analysis of the DEGs for all groups
demonstrated significant differences upon treatment (FIG 3.10C, 3.11C). Further analysis
of differential expressed genes in the 1QG treatment group demonstrated significant
abundant elevations of genes involved in carbohydrate metabolism (GAL10), nitric oxide
metabolism (YHB1), filamentous growth (FGR41), and DNA and protein synthesis,
among other genes (adjusted p value<0.05). Decreased genes included those involved in
RNA synthesis (RNR1), filamentation (RBR1) and phosphate ion transport (PHO84),
among others (adjusted p value<0.05) (FIG 3.10D). Kyoto Encyclopedia Analysis of
Genes and Genomes (KEGG) pathway analysis indicated that upregulated DEGs
following 1QG treatment were highly associated with metabolic pathways, ribosome,
metabolites biosynthesis, cell cycle and DNA repair, and genes in response to oxidative
stress (like SOD3), among others (Data not shown). The top 20 down-regulated DEGs for
1QG vs VC treatment are shown in Table 3.5. Low dose treatment (2QG) demonstrated
elevation of genes required to maintain mitochondrial respiration during stressful periods
(AOX1, AOX2, MRF1), glutamate metabolism (GAD1) and cell adhesion and virulence
(PGA22), among others. Conversely, genes responsible for meiotic division (MCD1,
CCN1), iron metabolism (HMX1) and filamentous growth and hyphae formation during
cell stress (SHA3, GIN4), among others were significantly decreased (FIG 3.10D).
KEGG pathway analysis indicated that following 2GQ treatment, upregulated DEGs
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were highly associated with glycolysis/ gluconeogenesis, carbon metabolism,
biosynthesis of secondary metabolites, cell cycle and DNA replication and repair, among
others. The top 20 down-regulated DEGs for 2QG vs VC treatment are shown in Table
3.6. Treatment with QGRFT lec neg resulted in decreased expression of genes involved in
iron metabolism (FRE7, FRE30), copper homeostasis (CTR1), biofilm formation and
RNA synthesis (RNR1) (FIG 3.10E). Upon treatment with Q-GRFT lec neg, KEGG
pathway analysis revealed upregulation of metabolic pathways, cell cycle, meiosis and
homologous recombination. Interestingly, genes (GPX2, SOD3) produced in response to
oxidative stress were among those downregulated with Q-GRFT lec neg treatment. The top
20 down-regulated DEGs for 3QG vs VC treatment are shown in Table 3.7. The
PANTHER Classification System (292) was used to identify enriched Gene Ontology
biological processes for each set of differentially expressed genes. Results revealed that
Q-GRFT treatment (1QG) significantly enriched biological processes involved in DNA
damage repair, DNA replication, sterol and steroid biosynthesis and disaccharide
metabolism (FIG 3.10E). Similarly, 2QG treatment enriched processes involved in DNA
and RNA metabolism, carbohydrate metabolism including glucose, galactose and
pyruvate and amino acid catabolism (FIG 3.12A). Q-GRFT lec neg treatment enriched
processes involved in DNA formation and elongation, cell adhesion and biofilm
formation (FIG 3.12B).
Given these findings, we next sought to determine if the differences in RNA
expression were initiated earlier in C. albicans treatment and would be preserved when
compared to the overnight treatment. C. albicans was cultured overnight, and then
incubated with either Q-GRFT, Q-GRFT lec neg, medium only or with PBS. Samples were
incubated at 37°C for 4 hours, followed by RNA sequencing (FIG 13). Compared with
medium, PBS and Q-GRFT lec neg, Q-GRFT upregulated the expression of 113, 2 and 61
genes, respectively. Additionally, 38, 84, and 6 genes were down regulated following QGRFT treatment, when compared with medium, PBS and Q-GRFT lec neg treatments,
respectively (Table 3.8). Genes altered following Q-GRFT treatment were responsible for
cell cycle regulation, stress response, cell repair and various other metabolic processes
(Table 3.9).
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Figure 3. 4 C. albicans RNA expression profile following treatment with Q-GRFT. C.
albicans at a concentration of 1.0x105 cells/mL was incubated overnight at 37°C in SDA
medium with either 7.8 µM (1QG), 0.78 µM (2QG), 7.8 µM Q-GRFT lec neg (3QG) or
control medium (VC). RNA was isolated and sequencing performed to determine
expression under the different treatment conditions. Experiments were performed in
triplicate. (A) Principal Component Analysis (PCA) plot performed on normalized read
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counts for all samples. Similar colors represent cells that were subjected to a similar
treatment. (B) Venn diagram showing shared differentially expressed genes for all DEGs.
The intersection of the three circles represents overlapping DEGs among the three
treatments. (C) Cluster analysis of DEGs for genes showing a differential expression
|Log2FC| > 2 in the comparison following different treatments. Red color represents
upregulation; green color represents downregulation. (D) Volcano plot to examine the
log2 fold change of DEGs at 1QG treatment, for significance level p<0.05 and adjusted p
value (q<0.05). Log2 fold change on the x-axis is plotted against -log10(p-value) on the
y-axis. (E) Enriched GO functions of DEGs. Top 20 enriched biological processes with
the adjusted p-values (FDR) for the 1QG vs VC treatment group.

Table 3.5. The top 20 down-regulated DEGs for 7.8 µM Q-GRFT treated C. albicans
(1QG) vs non-treated control (VC) cells.
Gene name/ Description
RNR1, ribonucleotide-diphosphate reductase subunit
hypothetical protein CAALFM_C102370CA
PHO84, phosphate transporter
RBR1, Repressed by RIM101 protein 1
CAALFM_C107490CA, DNA-directed DNA polymerase alpha subunit
CDC46, MCM DNA helicase complex subunit
CTF18, Ctf18p
POL1, DNA-directed DNA polymerase alpha catalytic subunit
DUT1, bifunctional dITP/dUTP diphosphatase
TRY6, Transcriptional regulator of yeast form adherence 6
YBL053, Topoisomerase 1-associated factor 1
TOS4, Tos4p
hypothetical protein CAALFM_C201420CA
SHA3, putative serine/threonine protein kinase
CDC54, MCM DNA helicase complex subunit
PGA45, Predicted GPI-anchored protein 45
HCM1, Hcm1p
SMC3, cohesin subunit
hypothetical protein CAALFM_C501070CA
CSM3, Chromosome segregation in meiosis protein 3
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Log2FC
-2.145
-2.255
-1.907
-2.065
-1.516
-1.668
-1.7
-1.655
-1.481
-1.852
-1.382
-1.308
-1.432
-1.055
-1.321
-1.505
-1.598
-1.79
-1.306
-1.108

P-value
3.14E-62
2.07E-61
2.76E-40
7.04E-38
2.01E-35
2.85E-35
4.92E-33
1.02E-32
5.12E-32
6.81E-31
9.75E-31
8.96E-30
9.69E-30
2.79E-29
3.78E-29
1.91E-28
1.22E-27
1.59E-26
8.46E-26
4.48E-25

Adjusted P-value
1.95E-58
6.44E-58
5.72E-37
8.76E-35
1.93E-32
2.22E-32
2.55E-30
4.87E-30
2.27E-29
2.82E-28
3.79E-28
3.28E-27
3.35E-27
9.15E-27
1.18E-26
5.41E-26
3.17E-25
3.96E-24
2.02E-23
9.61E-23

Table 3.6. The top 20 down-regulated DEGs for 0.78 µM Q-GRFT treated C. albicans
(2QG) vs non-treated control (VC) cells.
Gene name/ Description
Log2FC
hypothetical protein CAALFM_C201630WA
-0.941
MCD1, kleisin alpha
-1.165
hypothetical protein CAALFM_C102370CA
-0.907
CCN1, Ccn1p
-0.931
hypothetical protein CAALFM_C602090CA
-0.759
SHA3, putative serine/threonine protein kinase
-0.542
HMX1, Hmx1p
-0.984
PUT4, Put4p
-0.868
hypothetical protein CAALFM_C100090WA
-0.85
GIN4, protein kinase
-0.652
FRE7, Fre7p
-0.514
TNA1, Tna1p
-1.013
VID21, Vid21p
-0.804
RPP0, ribosomal protein P0
-0.751
CAS5, Cas5p
-0.386
hypothetical protein CAALFM_C503430WA
-0.698
RNR1, ribonucleotide-diphosphate reductase subunit-0.629
MNT2, alpha-1
-0.379
SMC3, cohesin subunit
-0.798
AAT22, Aat22p
-0.608
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P-value
6.53E-15
6.93E-15
7.20E-12
8.74E-11
5.17E-10
7.51E-09
8.32E-09
6.19E-08
8.92E-08
1.32E-07
1.48E-07
3.23E-07
4.63E-07
5.68E-07
5.77E-07
6.09E-07
9.43E-07
1.38E-06
1.44E-06
1.73E-06

Adjusted P-value
1.08E-11
1.08E-11
7.46E-09
5.44E-08
2.48E-07
2.46E-06
2.59E-06
1.43E-05
1.91E-05
2.64E-05
2.88E-05
5.43E-05
7.03E-05
8.16E-05
8.16E-05
8.42E-05
0
0
0
0

Table 3.7. The top 20 down-regulated DEGs for 7.8 µM Q-GRFTlec neg treated C.
albicans (3QG) vs non-treated control (VC) cells.
Gene name/ Description

Log2FC

P-value

Adjusted P-value

FRE7, Fre7p
hypothetical protein CAALFM_C501070CA
FRE30, Fre30p
RNR1, ribonucleotide-diphosphate reductase subunit
PGA45, Predicted GPI-anchored protein 45
CTR1, high-affinity Cu transporter
TRY6, Transcriptional regulator of yeast form adherence 6
PHO84, phosphate transporter
MET3, sulfate adenylyltransferase
SOD3, Superoxide dismutase
DNA-directed DNA polymerase alpha subunit
CDC46, MCM DNA helicase complex subunit
GDA1, guanosine diphosphatase
putative ATPase
GIT1, Glycerophosphoinositol permease 1
GPX2, Glutathione peroxidase
PRI2, DNA primase subunit
SAM2, methionine adenosyltransferase
DPB2, DNA polymerase epsilon noncatalytic subunit
CDC54, MCM DNA helicase complex subunit

-1.389
-1.562
-1.312
-1.518
-1.595
-1.034
-1.791
-1.605
-1.549
-1.228
-1.138
-1.252
-1.099
-0.908
-1.922
-1.028
-1.385
-0.887
-0.818
-0.946

4.53E-44
4.14E-36
2.61E-33
3.65E-32
9.83E-32
1.15E-29
4.31E-29
4.83E-29
1.10E-27
6.88E-23
4.81E-21
9.57E-21
1.58E-20
2.06E-18
4.06E-18
4.78E-18
2.21E-16
2.97E-16
7.37E-16
7.91E-16

2.82E-40
1.29E-32
5.42E-30
5.67E-29
1.22E-28
1.19E-26
3.76E-26
3.76E-26
7.59E-25
4.28E-20
2.49E-18
4.58E-18
7.02E-18
8.54E-16
1.58E-15
1.75E-15
7.63E-14
9.73E-14
2.23E-13
2.24E-13

FIG 3.11 C. albicans RNA expression profile following treatment with Q-GRFT. C.
albicans at a concentration of 1.0x105 cells/mL was incubated overnight at 37°C in SDA
medium with either 7.8 µM (1QG), 0.78 µM (2QG), 7.8 µM Q-GRFT lec neg (3QG) or
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control medium (VC). RNA was isolated and sequencing performed to determine
expression under the different treatment conditions. Experiments were performed in
triplicate. Venn diagrams showing shared differentially expressed genes for upregulated
DEGs (A) and downregulated DEGs (B). The intersections of the three respective circles
represent overlapping DEGs among the three treatments. (C) Cluster analysis for genes
showing a differential expression |Log2FC| > 2 in the comparison demonstrating the zscore normalized expression (DESeq2 normalized counts). Volcano plots to examine the
log2 fold change of DEGs at 2QG vs VC (D) and 3QG vs VC (E) treatments, for
significance level p<0.05 and adjusted p value (q<0.05). Log2 fold change on the x-axis
is plotted against -log10(p-value) on the y-axis.
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Figure 3. 5 Top 20 enriched GO functions/ biological processes of DEGs with the
adjusted P-values (FDR): (A) 2QG vs VC and (B) 3QG vs VC treatment groups.
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Figure 3.13 Experimental plan to determine early RNA expression following C. albicans
treatment at different conditions. C. albicans was grown overnight, followed by
incubation with either Q-GRFT, Q-GRFT Lec Neg, medium only, and PBS for 4 hours at
37C. RNA was then extracted, and sequencing performed.

Table 3.8. Comparison of differentially expressed genes following C. albicans growth at
different conditions.
Contrast

DEGs (ALL)

Up regulated

Down regulated

Q-GRFT v Medium

151

113

38

Q-GRFT v PBS

86

2

84

Q-GRFT v Q-GRFTLec

67

61

6

Neg
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Table 3.9. Q-GRFT specific differentially expressed genes following C. albicans
treatment for 4 hours at 37°C.
Gene

Function

Up regulated
FAV3

Α-1,6-mannase; cell wall biogenesis/ degradation

CYK3

Cytokinesis protein 3

ACE2

Cell wall transcription factor

PEX13

Peroxin-13; fatty acid metabolic activity

HOF1

G1/S specific cyclin

1QGT

Cyclin dependent kinase

Down regulated
DPS1

Aspartyl-tRNA synthetase, ATP binding, RNA binding

AAT1

Aspartate transaminase, pyridoxal phosphate binding,
cellular amino acid metabolism

PHR2

pH-responsive protein 2(apical cell growth and
morphogenesis)

AOX2

Alternate oxidase, oxidoreductase, electron transport
respiratory chain

SOD4

Cell surface superoxide dismutase

HHT21

Histone h3.1; DNA repair, transcription regulation

Some of the genes up regulated and down regulated, and specific to C. albicans treatment
with Q-GRFT for 4 hours at 37°C.
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DISCUSSION
Our findings reveal that Q-GRFT inhibits HIV-1 PsV replication and the growth
of C. albicans, with no demonstrable impact on gut bacterial microbiome, and pathogenic
Neisseria gonorrheae and Chlamydia trachomatis. In preventing HIV-1 infection, GRFT
inhibits giant cell formation between HIV-infected T cells and non-infected CD4+ target
T cells. GRFT also inhibits HIV transmission by blocking CD4+ T cell destruction and
viral replication through the DC-SIGN mediated pathway (293). GRFT is highly potent
against HIV-1 with activity being demonstrated at sub nanomolar concentrations (293).
Our results confirm that Q-GRFT inhibits HIV-1 PsV replication (EC50 0.305 ng/mL), in
keeping with what other groups and ours have found with GRFT. Therefore, following
modification of the parent lectin, Q-GRFT maintains a potent HIV-1 antiviral effect by
inhibiting viral replication.
The gut microbiome plays a role in maintaining health with dysbiosis implicated
in promoting inflammation and disease (294, 295). Because Q-GRFT is currently being
developed as a topical rectal microbicide (246), the protein nature and structure of the
lectin makes interaction with gut and rectal microbiome components inevitable. In a
previous study (203), rectal macaque treatment with the lectin did not result in any
detrimental changes in the resident bacterial microbiome at post-challenge when
compared with the baseline population. Moreover, some gastrointestinal and vaginal
microbiota components like Lactobacillus species putatively produce lectin proteins that
modulate their interactions in the local environment. These lectins may bind pathogens
and host cells, disrupting the pathogen-human epithelial binding interaction. Lactobacilli
lectins may bind to Staphylococcus aureus and Group B Streptococci, hindering the
epithelial attachment (296, 297). Biofilm formation by Salmonella Typhimurium and
uropathogenic Escherichia coli is significantly impaired by the putative lectins, inhibiting
infection by these microorganisms (297, 298). In our study, we incubated representative
gut bacteria with Q-GRFT for up to 24 -48 hours in vitro to establish any impact on the
growth of these microbiome components. In keeping with results from Girard et al, (203)
we did not detect any growth inhibitory effects for the microbiota components tested.
These findings are also similar to reports from the recently approved dapivirine vaginal
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ring, that demonstrated no impact of its use on local cervicovaginal immunity and
microbiome community (275).
Yeast and fungi are components of the gut mycobiome. Dysbiosis and overgrowth
of fungal species results in a shift in the diversity and richness in group members, with
subsequent inflammation (299, 300). Candida spp. infections pose a major health concern
in both immunocompromised patients and immunocompetent individuals (301). Lectins
have been investigated for their role as antifungal agents, given the need to develop new
antifungal agents and the increasing burden of disease posed by fungi and yeast
infections. Helianthus annuus lectin derived from sunflower decreased C. albicans
survival by impairing the cell wall integrity, induced hydrogen peroxide formation and
inhibited the yeast to filamentous morphological transition responsible for virulence. The
lectin also impairs fungal cell adherence to surfaces and interferes with biofilm
development with a resultant reduced coverage area (280). By binding to glucose,
mannose and N-acetylglucosamine in the fungal cell wall, other lectins exhibit antifungal
activity, with various degrees of growth inhibition. Lectin TEL (from Talisa esculenta
fruit) inhibited Saccharomyces cerevisiae, Fusarium moniliforme and Colletotrichum
lindemuthianum growth while AML (from soursop Annona muricata), which binds
glucose and mannose, inhibited F. solani, F. oxysporum and Colletotrichum musae
growth. These lectins inhibit fungal spore germination and mycelium growth. They also
altered the synthesis of chitin, altering cell wall deposition and formation (302). The
lectins DvioL, DRL ConBr are extracts from Dioclea violacea, D. rostrata and
Canavalia brasilienis legumes respectively. These extracts bind glucose and mannose
and have demonstrated antifungal activity against yeasts isolated from vaginal secretions,
including C. guilliermondi, C. shehatae, C. membranafaciens and K. apiculata (302305). Putatively produced lectins from Lactobacillus spps have been shown to bind to C.
albicans and inhibit biofilm formation (297). We determined the impact of Q-GRFT on
the growth of C. albicans, as a representative of the mycobiome in the gut and colon. We
found that Q-GRFT bound to α-mannan in the fungal cell wall and inhibited the growth
of C. albicans. We also show that the binding and inhibition is via the lectin binding
receptor, since the mutant lectin binding site-deficient Q-GRFT variant neither bound to
C. albicans, nor inhibited fungal growth. Our data suggests that the lectin impaired cell
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wall integrity by increasing permeability and likely induced the formation of ROS within
the cell.
Q-GRFT exposure to C. albicans likely results in an osmotic imbalance, as
evidenced by the shriveled appearance and collapsing cells with surface indentations.
Lectin-treated cells also demonstrate an increase in budding with multiple bud scars and a
loss of the normal polar budding orientation. This is indicative that Q-GRFT-induced
changes affect normal cell division. The loss of polar budding and multiple bud scars is
an attempt by C. albicans to divide multiple times to escape stress-induced conditions
(306). Interestingly, Tos4 gene regulates the G1/S cell cycle phase and promoting cell
division (307). Q-GRFT treatment was associated with down-regulation of Tos4.
Additionally, in response to oxidative stress, C. albicans expresses antioxidant genes to
neutralize and escape stress, including superoxide dismutase (SOD), glutathione
peroxidase (GPX2), thioredoxin (TRX) and thioredoxin reductase (TRR) (308). Q-GRFT
treatment was associated with up-regulation of SOD while cells treated with the nonbinding mutant lectin exhibited downregulation of GPX2 and TRR1. Because we have
used in vitro assays to demonstrate growth inhibition, there is a likelihood for cells
incubated with mutant Q-GRFT to undergo stressful growth conditions given volume and
space limitations with this assay. When cells grow uninhibited in media, they will reach a
critical mass when they start to compete for nutrients within the restricted space. This has
the potential to induce metabolic responses within cells to escape these stressful
conditions. However, given the clear differential expression of genes following Q-GRFT
treatment in comparison to the mutant treated cells, it is evident that the lectin does
impact multiple metabolic pathways within C. albicans after treatment. In fact, mutant QGRFT treated C. albicans was associated with increase trehalose metabolism, a hallmark
for general stress response (309). Cell cycle arrest, disaccharide metabolism, biofilm
formation and DNA strand elongation were among the upregulated pathways following
mutant Q-GRFT treatment. Similarly, QG treatment demonstrated upregulated stress
response pathways including monosaccharides, glucose, galactose and amino acid
metabolism, biofilm formation and DNA replication, among others.
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Further experiments that will need to be performed to confirm the mechanism of
cell killing are time course determinations that will localize the particular duration at
which cell death is initiated or occurs. Additionally, antioxidant experiments upon QGRFT treatment will highlight the exact role of the lectin on ROS formation and
elucidate its role in cell killing.
Here, we have established that Q-GRFT demonstrates potent inhibitory activity
against non-Candida albicans species of clinical importance, Candida glabrata, Candida
krusei and Candida parapsilosis. Interestingly, C. krusei has been described to harbor
innate resistance against fluconazole (310, 311), while azole resistance is increasingly
being documented for C. glabrata and C. parapsilosis. In addition, our study established
that Q-GRFT demonstrates growth inhibition of Candida auris CDC388 and Candida
auris CDC389, strains belonging to the South Asia clade, one of those that are dominant
in the United States (291). However, growth in strains Candida auris CDC383, Candida
auris CDC384, Candida auris CDC385 and Candida auris CDC386 was not impacted
following incubation with Q-GRFT. C. auris exhibits multi drug resistance, and panresistant strains have recently been identified (312-316). N- and O-linked mannans with
α-1,2-, α-1,3-, α-1,6- and β-1,2-linked mannose sugar residues make up the structure of
mannoproteins in the Candida cell wall (317). Because we have identified α-mannan as a
binding ligand for Q-GRFT, it is likely that the highly diverse composition of mannan
structures and mannosyl residues in different Candida species (318) contributes to the
differential response to cell treatment and variations in MICs observed in our study.
Mannan in C. albicans is comprised of branching N-linked polysaccharide units and
short-chain O-linked mannan oligosaccharides. Additionally, the N-linked mannan is
made up of a long chain of α-1,6-linked mannose backbone that bridges with
oligomannose side chains, predominantly consisting of α-1,2-, α-1,3-, and β-1,2-linked
mannose residues with sparse phosphate groups (317-319). The mannan in C. glabrata is
comprised of small branches with minimal α-mannan content and one or two β-1,2linked mannose residues (317, 318, 320). The long chain of α-1,2-linked mannose
subunits with one or two α-1,6-linked mannose residues, and a few short side chains of
α-1,2-linked mannose residues constitute the mannan in C. krusei (318, 321, 322). While
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C. parapsilosis mannan consists of both of α-1,2-, α-1,3-linked mannose residues that are
found in C. albicans, it does not comprise of 1-O-α-phosphorylated units (323). In
addition, contrasting the other pathogenic Candida species, C. auris mannan is
predominant in β-1,2-linked mannose residues (324). These mannan differences in
composition and structure are likely to underscore the variations in the growth activity
observed when different Candida species were incubated with Q-GRFT. Overall, these
findings suggest that Q-GRFT’s anti-Candida activity may be beneficial as an additional
strategy or alternative to the current antifungal treatment, given that growth inhibitory
activity was observed in these different strains, despite the structural differences in their
cell wall composition, as well as the documented innate resistance to common antifungal
agents.
Mucosal transmission of HIV and viral shedding in genital secretions is increased
in co-infection with STIs, including Neisseria gonorrhea and Chlamydia trachomatis
(325, 326). Importantly, both these pathogens express mannosylated glycoproteins in
their outer membranes (327, 328) that can act as ligands for lectins (329). The Neisseria
gonorrhea cell wall envelope is rich in β-linked N-acetyl-D-glucosamine (D-GlcNAc)
and β-D-galactosyl (β-D-Gal) that promote interaction with wheat germ agglutinin and
ricin lectins. The other structural polysaccharide components α-N-acetyl-Dgalactosamine (α-D-GalNAc) and β-D-Gal linked to GalNAc and/ or GlcNAc promote
interaction with soybean agglutinin, peanut agglutinin and Dolichos biflorus lectins
(330). Chlamydia trachomatis possesses terminal mannose structures on the surface and
in elementary bodies (EBs). These structures interact with and bind the lectin from
Galanthus nivalis (GNA), with a resultant GNA-dependent inhibition in the number of
intracellular inclusions (EBs). The GNA lectin prevented Chlamydia trachomatis
infection of McCoy cells (331). In our study, we did not demonstrate any inhibitory effect
of Q-GRFT on Neisseria gonorrhea and Chlamydia trachomatis. However, unlike the
GNA lectin (331), Q-GRFT was neither toxic nor inhibitory to the growth of McCoy
cells. Our findings do not demonstrate any inhibitory impact of Q-GRFT to the growth of
Neisseria gonorrhea and Chlamydia trachomatis.
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In conclusion, we show that Q-GRFT is a potent antiviral against HIV-1 PsV and
demonstrate the lectin’s first report denoting antifungal activity, with growth inhibition of
both C. albicans and non-C. albicans species, including some strains of the multi drug
resistant C. auris. The lectin does not impact the growth of resident gut bacterial
microbiome components. We identify that Q-GRFT binds to α-mannan via the lectinbinding receptor, with a resultant induction of reactive oxidative species that damage
cellular structures, leading to death. These findings underscore the need to further explore
the lectin’s utility in in vivo infections, and future development of Q-GRFT as an
antifungal agent.
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CHAPTER 4: EFFICACY AND IMMUNOLOGICAL CONSEQUENCE OF Q-GRFT
IN VAGINAL CANDIDIASIS

INTRODUCTION
Vulvovaginal candidiasis (VVC) is an ongoing global challenge, and is
predominantly caused by the common fungal pathogen, Candida albicans (332).
Approximately 75% of women will develop at least one episode of vulvovaginal
candidiasis during their lifetime (333). About 138 million women globally are affected
by recurrent vulvovaginal candidiasis (RVVC) annually, with the numbers expected to
increase to 158 million each year, by 2030 (334). Candida organisms are commensals in
the vagina, with overgrowth resulting in vaginal and vulval inflammation contributing to
the pathological hallmarks of infection (335). Factors that predispose women to
candidiasis include use of oral contraceptives, hormone replacement therapy, pregnancy
and antibiotic use (336, 337). Recurrent vaginal candida infections are associated with
mental discomfort (218), in addition to the physical symptoms that include pruritus,
burning pain, profuse leucorrhea, redness and interrupted and restless sleep as a result of
vulval and vaginal mucosal irritation (338, 339).
The major drugs currently used for the treatment of vaginal candidiasis include
azoles, echinocandins, and polyenes. Unfortunately, there are increasing reports of
resistance by fungal pathogens to these antifungals (340-342). The resistance is attributed
to the static function of many antifungals, in addition to microbial recalcitrance upon
repeated drug exposure (343, 344). In addition, long-term drug use, prophylactic
administration, and exposure to antifungals through agriculture and contaminated food
consumption contribute to the growing trend of drug resistance (345-347). In addition,
intrinsic natural resistance to antifungal therapy has been demonstrated in some
pathogenic fungal species including azole-resistant Aspergillus species (348),
fluconazole-resistant C. krusei (349) and C. glabrata (350), and echinocandin- resistant
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Cryptococcus neoformans. This demonstrates the urgent need to develop more antifungal
agents and strategies relevant to the eradication of these infections. The vaginal mucosa is
the first line of defense against Candida through maintaining an acidic mucosal pH that is
not optimal for Candida and providing anatomical and physiological barriers to infection
(351, 352). Candida overgrowth triggers an epithelial cell-mediated cytokine response,
with a resultant recruitment of immune cells like neutrophils, dendritic cells, and T cells
(351, 353, 354). Symptomatic infection demonstrates elevated cellular infiltration with
PMNs and variable fungal presence, whereas protection from VVC has been associated
with limited or absent inflammatory responses in the vagina (355). A balance between
Th2/ Th1 cytokines has been suggested as the determinant in susceptibility to and
pathogenesis of vulvovaginal candidiasis and RVVC (356, 357). Th2 cytokines are
associated with susceptibility to pathogenic infection, with Th1 cytokines conferring
protection. In dermal and oral candidiasis, Th17- induced IL-17 and IL-22 have been
identified as key mediators, conferring immunity against C. albicans infection (358, 359).
Acting in concert, these cytokines recruit neutrophils into epithelial tissues, induce the
production of antimicrobial peptides in mucosa, and up-regulate pro-inflammatory
cytokines (360-362), promoting antifungal immunity. Notwithstanding, IL-17’s role in
mediating immune responses in vaginal candidiasis is still controversial (363, 364).
Interestingly, recently, Il-17 has also been associated with a rapid protection of vaginal
epithelial cells in early candidiasis infection (353).
Numerous endogenous and plant-derived lectins have previously demonstrated in
vitro antifungal activity (302, 365). Griffithsin (GRFT) is a lectin originally derived from
red alga Griffithsia sp. GRFT has demonstrated broad-spectrum antiviral properties and
activity (10, 11, 278). Native GRFT is prone to oxidation (366), and the Palmer group
developed an engineered form, Griffithsin-M78Q (Q-GRFT), with improved stability,
and similar antiviral activity to GRFT. Using in vitro studies, we have demonstrated a
novel antifungal activity of Q-GRFT, with potent growth inhibition of Candida species
including C. albicans, C. parapsilosis, C. krusei, C. glabrata and against strains of the
pan-resistant C. auris (13). To our knowledge, no study has reported efficacy of Q-GRFT
in vaginal candidiasis in vivo models. Here, we investigated the efficacy of Q-GRFT in
vaginal candidiasis using prophylactic and therapeutic murine models. We describe the
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impact of topical Q-GRFT administration on vaginal fungal burden and the
immunological consequence of C. albicans infection in the context of topical Q-GRFT
therapy.

MATERIALS AND METHODS
Mice
Female CBA/J mice (Jackson Laboratories) were maintained under specific
pathogen-free conditions in the Center for Translational Research vivarium, at the
University of Louisville, Louisville, Kentucky.
Candida albicans and vaginal inoculation
The C. albicans ATCC 32020 strain was grown on Sabourand dextrose agar
plates overnight at 30 °C prior to use, and cell preparation done with slight modifications
to the animal model development protocol by Conti et al. (367). Briefly, 10 milliliters of
Sabourand dextrose media were inoculated with 1 colony of C. albicans from the agar
plate and incubated at 30 °C with shaking for 18 hours. Cells were then sub-cultured
1:100 dilution overnight, followed by preparation of 1.0 × 108 cells/mL blastospores from
the stationary phase, that were suspended in sterile PBS. Cells were kept on ice until
when vaginal inoculation was performed in mice. Twenty microliters of the C. albicans
preparation were dispensed into each mouse’s vagina using a P50 positive displacement
pipettor.
Estradiol Treatment, Lavage, and Fungal Burden
Estradiol at a concentration of 0.5 mg/mL was dissolved in sesame oil. Mice were
then injected subcutaneously with 100 µL of the hormonal preparation in the lower
abdomen 3 days prior to C. albicans challenge, and then once weekly for the duration of
the experiment. To perform the lavage, 100 µL of sterile PBS were dispensed into the
mouse vagina and aspirated back and forth several times, and then transferred to labelled
Eppendorf tubes on ice. The lavage was then diluted 1:100, and 50 µL of the diluted fluid
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plated on Sabourand agar. Colli rollers were used to spread the lavage. The plates were
incubated at 30 °C for 24-48 hours, and colonies counted to establish the fungal burden.
Vaginal treatment
Forty microliters (40 µL) of a 1% Q-GRFT gel formulated in Carbopol (400 ng),
40 µL of Carbopol placebo gel, 100 µL of nystatin solution at a concentration of 20
mg/mL (Mayne Pharma, Greenville, NC, USA) and 100 µL of sterile 1X PBS were
instilled per vaginum in mice from the different animal groups, using appropriate
pipettors.
Hematoxylin and Eosin, Periodic acid Schiff staining
For Hematoxylin and Eosin (H & E) staining, sections were deparaffinized and
placed in xylene. Sections were then hydrated in alcohol and water baths and stained in
hematoxylin for 3 minutes. They were then washed in running water for 5 minutes,
differentiated in 1% acid alcohol for 5 minutes, washing in running tap water, dipped in
alkaline solution (ammonia water) and washed again. They were subsequently stained in
1% Eosin Y for 10 minutes, washed in tap water for 3 minutes, dehydrated in increasing
concentrations of alcohols and then cleared in xylene. Sections were then mounted and
observed under a microscope.
For periodic acid Schiff (PAS) staining, sections were dewaxed followed by
incubated in 0.5% periodic acid for 5 minutes, washed in running tap water for 3 minutes
and then immersed in Schiff’s reagent for 15 minutes. Sections were then washed in tap
water for 5 minutes, counterstained with hematoxylin for 2 minutes, washed in running
tap water for 3 minutes, dehydrated in ethanol and cleared in xylene for 5 minutes.
Sections were then mounted with Entellan® and a cover slip applied. The sections were
then viewed under a microscope.
Flow Cytometry and Luminex analysis
Cellular phenotypic analysis was carried out using flow cytometry with the
following antibodies: CD45 and CD11b (BD Biosciences, San Diego California), and
F480 (BioLegend, San Diego, California), Ly6G and viability dye (BD Horizon). Vaginal
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lavage specimens were added to complete RPMI medium (supplemented with 1M
HEPES, penicillin/ streptomycin, fetal bovine serum and 2-Mercaptoethanol), filtered and
centrifuged for 5 minutes at 1600 rpm. One million cells were then added to appropriate
flow cytometry tubes, followed by washing with FACS buffer (BD Biosciences, San
Diego California) for 5 min at 1600 rpm. Cells were then blocked with 2 µL of CD16/32
antibody (BioLegend, San Diego, California) for 10 minutes. An antibody mix was
prepared for the surface staining primary antibodies, added to the mixture followed by
incubation at 4 °C for 30 minutes. Cells were washed, re-suspended in 300 µL of FACS
buffer, and analyzed using a BD device (BD LSR FortessaTM, USA), following
manufacturer’s instructions. Data was analyzed using Flowjo software (Tree Star, Inc,
Ashland, Oregon).
Vaginal lavage supernatants were analyzed for cytokines by a mouse Cytokine/
Chemokine Th17 Magnetic Bead Panel (EMD Millipore, St. Charles, MO). The panel
was subsequently analyzed with a Milliplex MAP Kit on a MagPix with Luminex xMAP
technology, following the manufacturer’s directions.
Statistical Analysis
Where appropriate, tests used to determine significance between experiments are
outlined in the figure legends of each figure. Data are representative of 2-4 independent
experiments for each time points. One way ANOVA was performed using GraphPad
Prism7.05 (GraphPad Software, Inc, La Jolla, California) to determine statistical
difference. A P value <0.05 was considered significant.
Ethics Statement
This study was approved by and carried out in accordance with recommendations
of the University of Louisville Institutional Animal Care and Use Committee (IACUC),
under IACUC ID 19453.
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RESULTS
Q-GRFT reduced the fungal burden in a Preventative model of murine vaginal
candidiasis
To evaluate the efficacy of Q-GRFT in a preventative/ prophylactic murine
model, we established an experimental model for vaginal infection (FIG 4.1A), based on
that described by Conti et. al (367). Female CBA/J mice were injected subcutaneously
with estradiol, followed by twice daily vaginal instillation of a Carbopol gel formulation
similar to a product that we previously demonstrated had HSV-2 inhibitory activity (368).
The Carbopol gel formulation delivered 400µg Q-GRFT per dose twice daily for 5 days.
We challenged the animals with C. albicans on day 3. Vaginal lavage was performed on
24 hours following administration of the final Q-GRFT treatment. We determined the
efficacy of Q-GRFT in the prevention of vaginal candidiasis by establishing the fungal
burden in vaginal lavage fluids after vaginal pre-treatment, fungal inoculation, and
follow-up treatment with Q-GRFT. Fungal burden was evaluated by plating lavage fluids
on Sabourand agar plates that were incubated for 48 hours at 30°C, followed by counting
of colonies. Our results demonstrated that Q-GRFT treatment resulted in a significantly
lower fungal burden when compared with the infected untreated controls (P=0.0417)
(FIG 4.1B). Similarly, treatment with the positive control nystatin, a polyene antifungal
agent, resulted in a significantly lower fungal burden (P=0.0016), while there was no
inhibition demonstrated with PBS (P=0.4849) and placebo (P=0.5963) when compared
with the infected controls. Additionally, uninfected animals did not demonstrate any
fungal growth (P=0.0016).
Upon infection and epithelial penetration, tissue resident-macrophages are among
the initial immune cells that encounter Candida, and phagocytose the fungal cells to
achieve clearance (369). Furthermore, pro-inflammatory cytokines released by
macrophages and epithelial cells recruit neutrophils and inflammatory monocytes to
eradicate Candida infection (369, 370). Therefore, using flow cytometry, we sought to
determine if pre-treatment with Q-GRFT influenced the expression of vaginal innate
immune cells [neutrophils (CD45+,Ly6G+,CD11b+) (FIG 4.1C top) and mononuclear
phagocytes (CD45+,CD11+,F4/80+) (FIG 4.1C bottom) in a vaginal infection murine
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model. Compared to infected controls, there was no difference in the population of
neutrophils following pre-treatment with either Q-GRFT (P>0.9999), placebo
(P>0.9999), or PBS (P>0.6510) (FIG 4.1D). In addition, treatment with nystatin resulted
in significantly higher populations of neutrophils (P=0.0011), while uninfected animals
had lower neutrophils (P=0.0483), in comparison with infected controls. Similarly, there
was no difference in mononuclear phagocyte populations following treatment with QGRFT (P=0.9461), placebo (P=0.9155), and PBS (P=0.6263), in comparison with the
infected controls. Nystatin resulted in higher monocyte populations (P=0.0380), while
uninfected animals demonstrated significantly lower monocytes (P=0.0368) than infected
animals. These results demonstrate that while Q-GRFT significantly inhibits Candida
growth in a preventative murine model, unlike nystatin treatment, the protective effect
does not occur in the context of inflammatory immune responses.
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Figure 4. 2 Q-GRFT significantly inhibits vaginal fungal infection in a prophylaxis
model of murine candidiasis. (A) Experimental scheme. CBA/J mice (N= 10 per group)
were estradiol-treated at Day -3, followed by twice daily instillation of either Q-GRFT
gel, nystatin solution, PBS, or Carbopol placebo gel per vaginum for the next 5 days. At
Day 0, mice were inoculated with 20 µL of C. albicans blastospores at a cell
concentration of 1.0 X 108 CFU/mL, per vaginum. A vaginal lavage was performed 24
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hours after the final dose administration. (B) Vaginal fungal burden (CFU/mL) following
treatment, for mice in (A). Each dot represents one mouse, N=10 mice per group.
Experiments were performed and repeated at least 2 times, and representative data of
Mean + SEM is shown. (C) Flow cytometry gating strategy for neutrophils, and
mononuclear phagocytes in the vaginal lavage. Neutrophils were identified as
CD45+Ly6G+CD11b+, while monocytes were CD45+CD11+F4/80+ cells. (D) Neutrophil
and (E) mononuclear phagocyte cell populations in the vaginal lavage following the
respective treatments. N=10 animals per group, and each dot represents a population of
cells from a single mouse. Measurements are representative of cell populations from
experiments performed at least 2 times. Mean + SEM data is presented. For all
experiments, one-way ANOVA was used for statistical analyses, and P<0.05 was
considered significant.

Q-GRFT Enhanced Clearance of Vaginal Candidiasis In a Therapeutic Murine Model
To study the role of Q-GRFT in the treatment of candidiasis, a murine therapeutic
experimental model was developed, (FIG 4.2A), based on that described by Conti et. al
(367). Mice were injected subcutaneously with estradiol, followed by inoculation with C.
albicans vaginally 3 days later. Vaginal lavage was performed on day 4 following fungal
challenge, to determine baseline fungal burden. Twice daily vaginal instillation of 400µg
Q-GRFT was started on day 5 and continued for a total of 7 days. A vaginal lavage was
performed 24 hours after the final dose to determine fungal burden by colony counts on
Sabourand agar plates, and immune response to treatment using flow cytometry and
Luminex ELISA assay. Pre-treatment fungal burden (FIG 4.2B) confirmed that all mice
had established vaginal infection prior to initiating treatment, with no significant
differences in fungal burden in any of the infected groups prior to initiation of treatment.
Compared to placebo, treatment with topical vaginal Q-GRFT gel resulted in a significant
inhibition of C. albicans burden (P=0.0379), similar to that seen with the control nystatin
(P=0.0003), at the end of the dosing period (FIG 4.2C). FIG 4.2D depicts the
representative fungal growth on Sabourand agar plates following incubation for 48 hours,
at 30°C for the infected controls (left) and Q-GRFT treated animals (right). These results
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indicated that Q-GRFT was an effective treatment for vaginal candidiasis in a murine
model.

Figure 4. 3 Efficacy of Q-GRFT in a murine model of vaginal candidiasis. (A)
Experimental scheme. CBA/J mice were estradiol-treated, followed by vaginal
inoculation with 20 µL of C. albicans blastospores at a cell concentration of 1.0 X 108
CFU/mL 3 days later. Treatment with either Q-GRFT, nystatin, placebo, or PBS by
vaginal instillation was started on Day 5 following inoculation and continued twice daily
for a total of 7 days, respectively. Vaginal lavage was performed at Day 4 and Day 12 to
establish pre-treatment and post-treatment fungal burden, respectively. (B) Day 4 (pre93

treatment) Vaginal fungal burden (CFU/mL), and (C) Day 12 (post-treatment) burden.
Each dot represents one mouse, N=20 mice per group. Experiments were performed at
least 2-3 times and representative data from 2 experiments, Mean + SEM is shown. Oneway ANOVA was used for statistical analyses and P<0.05 was considered significant. (D)
Representative photographs of C. albicans culture colonies for vaginal lavage fluids
collected from untreated infected controls (Left) and Q-GRFT treated mice (Right).

Treatment With Q-GRFT Does Not Induce Overt Changes in Innate Immune Cell
Phenotypes in Vaginal Candidiasis
Upon epithelial penetration, tissue resident-macrophages are among the initial
immune cells that encounter Candida and will phagocytose the fungal cells to achieve
clearance (369). Additionally, pro-inflammatory cytokines released by macrophages and
epithelial cells, will recruit neutrophils and inflammatory monocytes to eradicate
Candida infection (369, 370). Therefore, we next sought to determine if treatment with
Q-GRFT influenced the expression of vaginal innate immune cells, neutrophils
(CD45+,Ly6G+,CD11b+), (FIG 4.3A), and mononuclear phagocytes
(CD45+,CD11b+,F4/80+), (FIG 4.3B), in candidiasis using flow cytometry. Compared to
infected controls, Q-GRFT did not induce any significant changes in populations of both
neutrophils, P=0.7279 , and mononuclear phagocytes, P=0.1960. Similarly, neutrophils
populations were not significantly different between infected controls and nystatin treated
mice, P=0.1771, while monocytes were elevated following treatment, P=0.0055.
Compared with the infected untreated controls, uninfected mice demonstrated
significantly lower neutrophils (P=0.0039), but not mononuclear phagocytes, P=0.0873.
Both placebo and PBS did not result in any changes in neutrophil (P=0.3626, P=0.111),
and monocyte (P=0.2464, P=0.9939) populations, respectively. These results
demonstrate that Q-GRFT does not induce overt changes in neutrophil and mononuclear
phagocytic populations following vaginal infection with C. albicans.
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Q-GRFT is Associated With Expression of Lower Amounts of Cytokines IFNɤ and IL10, but not IL-22 and IL-23
The Th1/ Th17 immune interplay contributes to fungal immunity and tolerance in
the vaginal mucosa (355-357), with elevated levels of related cytokines associated with
pathogen clearance. IL-22 contributes to polymorphonuclear neutrophilic response and
alarmin production, and low levels of the cytokine have been associated with chronic and
recurrent mucosal fungal infection (355). Interestingly, some clinical observations have
not demonstrated deficiencies of Th17 cytokines in blood or vaginal fluids of patients
with RVVC (371, 372). Working in concert with transforming growth factor (TGF-β),
IL-6 promotes the differentiation of naïve CD4+ T cells to Th17 phenotype (373). Murine
tolerance to VVC has been associated with IL-10 (355, 374), while clearance is increased
with secretion of Th1 associated cytokine, interferon gamma (IFNɤ) (353, 375, 376). In
addition, local IL-23 is protective in VVC, with low levels likely to correlate with
increased susceptibility to C. albicans infection (377). We therefore sought to establish
the expression profile of vaginal cytokines in lavage fluids following Q-GRFT treatment
in VVC. Cytokines were assayed using the Luminex xMAP, a multiplex ELISA assay
method. Compared to the infected untreated controls, Q-GRFT was associated with lower
expression of IFNɤ (P<0.0001) (FIG 4.3C), and IL-10 (P=0.0365) (FIG 4.3F).
Additionally, there was no significant difference in the expression of cytokines IL-22
(P>0.9999) (FIG 4.3D) and IL-23 (P=0.1955) (FIG 4.3E), following Q-GRFT treatment.
These findings were in keeping with what was observed following nystatin treatment that
demonstrated lower IFNɤ (P<0.0001), and IL-10 (P=0.0457), but not IL-22 (P>0.999)
and IL-23 (P=0.4924). However, unlike in both untreated infected animals and PBS
controls, Il-22 and IL-23 following Q-GRFT and nystatin treatments demonstrated a
trend towards lower cytokine levels. In comparison with the infected untreated controls,
both placebo and PBS treatments did not demonstrate any differences in expression of
either IFNɤ (P=0.6012, P=0.1303), IL-22 (P=0.2470, P>0.9999), IL-23 (P=0.0895,
P=0.2656), or IL-10 (P=0.1336, P=0.9508), respectively. Uninfected controls
demonstrated lower IFNɤ (P<0.0001), IL-22 (P=0.0261), IL-23 (P=0.0103), and IL-10
(P=0.0032). These results suggest that the lower IFNɤ and IL-10 cytokines expressed
following Q-GRFT treatment are likely related to a lower fungal burden, compared to the
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infected untreated controls. It is also likely that IL-22 and IL-23 decline over a longer
period following vaginal fungal clearance, given the trend towards lower cytokine levels
observed in this study.
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Figure 4. 4 Q-GRFT treatment is associated with lower levels of vaginal inflammation in
candidiasis.
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(A) Neutrophil and (B) mononuclear phagocyte cell populations in the vaginal lavage
following infection and respective treatments. N=20 animals per group, and each dot
represents a population of cells from a single mouse. Measurements are representative of
cell populations from experiments performed at least 2 times. Mean + SEM data is
presented. (C), (D), (E), and (F) are cytokine levels in vaginal washes of CBA/J mice
collected after 7 days of twice daily topical treatment with either Q-GRFT, nystatin, PBS,
or placebo. Mice were inoculated with 20 µL (1.0 x 108 cfu/mL) of C. albicans
blastophores, and cytokines measured using the Luminex xMAP multiplex ELISA assay.
(C) IFNɤ. (D) IL-22. (E) IL-23 and (F) IL-10. Each dot represents cytokine
measurements from a single animal, and analyses were performed in duplicate.
Measurements are representative of results from at least 2 independent experiments.
Mean + SEM data is presented. ANOVA was used for statistical analysis, with P<0.05
considered significant.

Histology of Vaginal Tissue Following Treatment With Q-GRFT Demonstrates Paucity
of Infection
To further investigate the effect of Q-GRFT on vaginal candidiasis, we evaluated
the impact of topical administration on the histology of infected tissues at the end of the
drug treatment period. Microscopic analysis revealed that infected untreated animals
displayed significant vaginal luminal congestion with high fungal growth/ burden (FIG
4.4A, 4.4B and 4.4C), unlike Q-GRFT-treated animals that displayed lower congestion
(FIG 4.4D, 4.4E and 4.4F). Consistent with our microbiological observations, H&E and
PAS staining demonstrated that Q-GRFT was an effective treatment against treated
vaginal candidiasis.
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Figure 4. 5 Histological evaluation of vaginal candidiasis following treatment with QGRFT.
CBA/J mice were infected with C. albicans vaginally. 5 days later, topical treatment was
initiated with Q-GRFT gel (vaginally) twice daily for 7 days. Post-treatment (Day 12)
tissue histology is presented. (A) Representative H&E staining of mice vaginal tissue in
the infected, untreated group. (B) and (C) PAS staining of infected, untreated mice. Note
the high vaginal luminal congestion with fungal growth/ burden. (D) Representative H&E
staining of vagina tissues from Q-GRFT treated mice. (E) and (F), PAS staining of
vaginal tissue from Q-GRFT-treated mice. Note: (*) represents fungal hyphae and black
arrows depict neutrophils in the vagina.

DISCUSSION
Our study demonstrated that Q-GRFT significantly inhibited vaginal infection in a
prophylactic model and enhanced fungal clearance in a therapeutic murine model of
candidiasis. Cytokines expressed in the vagina following C. albicans infection induce
large populations of neutrophils in the epithelium, underscoring their mucosal immune
cell activation and recruitment function (353). Elevated levels of cytokines are likely
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required to initiate and maintain mucosal protection and homeostasis following C.
albicans vaginal infection (353, 378). Additionally, Zhang et al. showed that epithelial
treatment with nystatin, further enhanced the initial immune process generated early in
infection, resulting in fungal clearance (353). In our preventive model, we have
demonstrated that pre-treatment with Q-GRFT prevented infection establishment, but did
not affect neutrophil and monocyte populations, in comparison with infected control
animals. In the therapeutic model, unlike the infected controls, treatment with Q-GRFT
was effective in fungal clearance and was associated with expression of lower quantities
of cytokines IFNɤ and IL-10, but not IL-22 and IL-23, with a predominance of non-viable
C. albicans cells. These results are similar to observations in the nystatin treatment
animals.
Human live vaginal challenge studies have demonstrated that protection from
candidiasis is associated with asymptomatic colonization with Candida, and the absence
of any inflammatory response. Additionally, a heavy inflammatory response with cellular
predominance of PMNs is observed in symptomatic disease (364). Furthermore, a
positive correlation has been observed between PMN infiltration and vaginal fungal
burden in a subset of individuals (335). Comparably, in murine studies, a heavy vaginal
infiltration with PMNs has been observed in subsets of inoculated animals, despite no
impact on the fungal burden (379, 380). Given the failure in characterizing disease
severity in murine models based on clinical signs and symptoms of vaginitis, the rigid
criteria based on high and low PMN responses ably predicts symptomatic and
asymptomatic conditions in mice with VVC (379, 381). In fact, in vitro PMN migration
assays have demonstrated that vaginal lavage fluids from high PMN (symptomatic) mice
have higher chemotactic activity, when compared to those from low PMN
(asymptomatic) animals (379).
Cytokines and chemokines secretion by epithelial cells is only minimally changed
upon treatment with Griffithsin (382). Additionally, we have demonstrated that daily
topical epithelial treatment with Q-GRFT results in drug accumulation in tissues (chapter
5). Furthermore, multiple topical Q-GRFT application in macaques was associated with a
small, and likely insignificant increase in frequencies of rectal mucosal CD4+ cells (204).
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Therefore, in the preventive model, daily treatment with Q-GRFT likely resulted in drug
accumulation in vaginal mucosal tissues, with a resultant direct inhibitory effect against
C. albicans infection establishment. Griffithsin’s inability to trigger an overt
inflammatory response likely accounts for the lack of difference in the populations of
neutrophils and monocytes triggered upon infection, in comparison with control animals.
Infection with C. albicans likely triggered cytokines early in infection in the
therapeutic model, leading to attraction and activation of innate immune cells among all
mice inoculated with fungal blastospores. Treatment with Q-GRFT and the control
nystatin resulted in fungal clearance, albeit with detectable low fungal burden upon
completion of the dosing period. This low fungal burden may subsequently contribute to
the ensuing recruitment of immune cells into the vagina, likely maintaining the antigenic
trigger for cytokine production. Given that there was no difference in the levels of IL-22
and IL-23 in both Q-GRFT and nystatin treated animals, it is plausible that the rate of
cytokines decline lags the rate of fungal clearance. Moreover, Oesterreicher et al. have
demonstrated that cytokine dysregulation may often persist, even after fungal pathogen
clearance when different antimycotics are used (383).
Pro-inflammatory cytokines are highly expressed in vaginal infection to enhance
the clearance of Candida infection. In humans, Candida-specific TH cells secrete IL-17
and IFNɤ, with the TH1-induced interferons aiding in the activation of fungicidal
activities of macrophages and neutrophils (384-386). In addition, working cooperatively,
Th17- produced IL-17 and IL-22 cytokines facilitate mucosal protection against Candida
infection by inducing neutrophil recruitment and activation, epithelial cell activation and
release of β-defensins (370, 387, 388). Additionally, IL-23 demonstrates a protective role
during the early phase of candidiasis by expanding Th17 effector cells and regulating IL22 production (389, 390). Interestingly, in humans, protection from vaginal candidiasis
appears to be independent of TH17 cell responses, despite their role in other mucosal
tissues antifungal immunity (370, 371, 391). In murine models, neutrophil recruitment in
response to chemotactic S100 alarmins produced by vaginal epithelial cells has been
demonstrated to be independent of IL-17 (392). TH2 signaling has demonstrated mixed
results with regards to immunity to fungal infection (370). Wild type mice deficient of
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IL-4 or IL-10 have been reported to demonstrate increased resistance to candidiasis
(393). Contrastingly, studies have demonstrated IL-4’s critical function in the
development of protective responses to Candida infection (394). Moreover, Mencacci et
al. have reported that in IL-12 deficient mice, IL-10 is required for the development of
potent TH1 immunity to candidiasis (395). In these mice, exogenous IL-10 attenuated IL4 production and enhanced resistance to infection through inhibition of the CTLA-4/B7-2
costimulatory pathway. They further postulate that a positive regulatory loop exists
between IL-12 and IL-10, which hinders innate antifungal immunity, but is essential for
optimal co-stimulation of IL-12-dependent CD4+Th1 cells. IL-10, an anti-inflammatory
cytokine, inhibits TH1 cells, NK cells and macrophages activity, hindering pathogen
elimination and contributing to tissue damage in presence of infection (396). Cytokines
and chemokines are constitutively produced by vaginal epithelial cells in variable
amounts (397). However, there is an increase in their production during infection with C.
albicans, with a predominance of proinflammatory cytokines (397). In response to
infection, production of TH1 cytokines IL-12 and IFNɤ, and TH2 cytokines TGFβ and IL10, was increased (397). In our study, Q-GRFT treatment was associated with lower
vaginal cytokines IFNɤ and IL-10, when compared to the infected control animals.
Additionally, there was no demonstrable difference in cytokines IL-22 and IL-23 for all
infected mice, regardless of treatment status. Cytokines IL-22 and IL-23, secreted in
response to the initial vaginal infection, are still elevated upon completion of the 7 days
treatment, despite the resultant low fungal burden. It is likely that the observed trend
towards lower levels of these cytokines is related to the delayed period of decline
following treatment. Indeed, De Luca et al. observed that IL-22 was still detectably
elevated 7 days after infection in gut mucosal tissue (390). Given that IL-23 stimulates
IL-22 production (390), this may likely also explain the persistently elevated levels of
both cytokines in all infected mice experimental groups at the end of the treatment
period.
So far, there is no demonstrated toxicity, T-cell activation, or immunological
stimulation of GRFT or Q-GRFT in in vitro and in vivo studies (203, 382, 398). We have
previously suggested in in vitro studies that Q-GRFT binds to α-mannan in C. albicans’
cell wall, impairs membrane barrier integrity and likely induces reactive oxygen species
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formation, with resultant damage to intracellular organelles (13). Here, we have
demonstrated that Q-GRFT significantly inhibited infection in a preventive model, and
enhanced candidiasis clearance in murine therapeutic studies, with associated lower proinflammatory and anti-inflammatory cytokines. Altogether, these data demonstrate that
delivery of Q-GRFT to the vagina significantly inhibited C. albicans infection, leading to
a lower fungal burden, that in turn triggered a lower expression of inflammatory
cytokines. Q-GRFT has shown promise in preventing viral sexually transmitted
infections, including HSV-2 and HIV-1 (219, 220, 368, 399). Our data demonstrate
additional potential for utility of Q-GRFT vaginal dosage forms in both preventing and
treating candidiasis, and further support incorporation of Q-GRFT in multipurpose STI
prevention modalities.
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CHAPTER 5: DEVELOPMENT OF Q-GRFT AS AN INTRANASAL SPRAY FOR
BROAD-SPECTRUM CORONAVIRUSES PROPHYLAXIS

INTRODUCTION
Over the past 2 decades, three coronaviruses of the Betacoronavirus genus have
emerged as serious human pathogens. The ongoing COVID-19 pandemic has caused over
200 million infections globally and over 614,000 deaths to-date in the United States.
The virus that causes COVID-19, SARS-CoV-2, replicates efficiently in the upper
respiratory tract – the nasopharynx and oropharynx – as well as in lungs and
gastrointestinal tissue (400). High viral replication in the nasopharynx in the early stages
of infection, prior to symptom onset, accounts for the high transmissibility of SARSCoV-2. While ocular transmission has been reported (228, 229, 401, 402), respiratory
aerosols and droplets are the most frequent sources of human transmission events (403,
404). Consequently, the development of an intranasal spray that inhibits replication of
virus in the upper respiratory tract is an effective strategy to curb virus spread and will
provide synergy to vaccine approaches and biomedical interventions, such as personal
protective equipment (PPE) and measures like social-distancing and frequent hand
washing, in eliminating the pandemic.
The PREVENT-CoV (PRe-Exposure prevention of Viral ENTry of
CoronaViruses) study seeks to demonstrate feasibility for application of an intranasal
drug delivery approach as a technology to prevent the establishment of upper respiratory
infection. This study will be the first-in-human application of Q-GRFT as an intranasal
product. Q-GRFT is an oxidation-resistant variant of Griffithsin (GRFT), a lectin initially
extracted from red sea algae (279). GRFT and the variant Q-GRFT, are expressed and
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produced by recombinant methods in Nicotiana benthamiana plants (279). The GRFT
homodimer remains remarkably stable in the environment due to its thermal melting
temperature over 78°C, and resists digestion by human and bacterial proteases (405, 406),
and has negligible in vitro and in vivo host toxicity (407). The broad-spectrum antiviral
lectin GRFT binds oligomannose glycans that represent a significant fraction of the Nlinked glycan molecules present on the heavily glycosylated coronavirus S protein (408).
GRFT strongly inhibits viral entry by binding to a broad array of coronaviruses, including
SARS-CoV (409); MERS-CoV (410, 411); and SARS-CoV-2 (176, 412). GRFT also
targets high-mannose glycan structures present on many pathogenic enveloped viruses
including human immunodeficiency viruses (HIV) types 1 and 2, herpes simplex virus
type 2 (HSV-2), hepatitis C virus (HCV), Japanese encephalitis virus (JEV), porcine
epidemic diarrhea virus (PEDV), while exhibiting a remarkable safety profile (10, 189,
405, 413-418).
Our overarching goal is to develop Q-GRFT, the active pharmaceutical ingredient
(API), as a non-vaccine broad-spectrum COVID-19 pre- and post-exposure prophylactic
in the form of a daily administered nasal spray product. The long-term durability of
antibody response to vaccines is not yet well established, and booster doses will be
required to maintain effective immunity to SARS-CoV-2 (419, 420). Vaccine hesitancy
continues to hinder public vaccination rates (421). Additional tools for prevention are
needed to effectively impact the current pandemic. Moreover, certain vulnerable groups,
such as organ transplant recipients, may not develop adequate immune responses after
vaccination. To this end, an intranasal spray product like Q-GRFT would provide a
much-needed strategy for infection prevention, especially in light of the constant
evolution of SARS-CoV-2, which will inevitably prolong the pandemic. While other
studies have proposed developing intranasal products for utility against SARS-CoV-2
(422-424), our program is the first to evaluate intranasal administration of the Q-GRFT
lectin and will establish nasal pharmacokinetic (PK) characteristics for this drug
candidate when administered via this route. Inflammatory responses including cytokine
storms are associated with poor outcomes in COVID-19 (425). Q-GRFT’s inability to
trigger significant mucosal and systemic inflammation makes it an ideal candidate as an
alternative strategy against coronaviruses (382). Additionally, as coronaviruses mutate to
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avoid immune detection, it is unlikely that they will lose the glycan shield and sugars to
which Q-GRFT binds. This is because loss of envelope glycans results in attenuated cell
infectivity, which is detrimental to virus survival (213, 214). Furthermore, while other
strategies like neutralizing antibodies target specific epitopes in the virus structure, QGRFT interacts with a wider array of ligands in the virus envelope, facilitating its broadspectrum antiviral activity (176, 214). Interestingly, GRFT has demonstrated a
significantly higher potency (about 11-fold higher) than remdesivir in inhibiting live
SARS-COV-2 infection (IC50 63 nmol/L vs EC50 0.77 µmol/L) (176, 426).
The rationale for the development of a Q-GRFT intranasal spray is based upon
several criteria. Prophylactic intranasal spray products are designed to deliver
medications locally in nasal cavities or systemically. Local drug delivery, the primary
focus of our product, likely prevents or at least significantly reduces the acquisition of
respiratory infections with a high concentration of product in the respiratory cavity. Local
drug delivery is also a logical choice of product delivery for viral respiratory infections
including SARS-CoV-2, whose initial point of entry/ infection in the body occurs
predominantly via the nasal cavity. This delivery site avoids hepatic first-pass
metabolism of the product (427). Even though Q-GRFT may be subjected to local
enzymatic activity in the nasal environment, studies elsewhere have demonstrated the
lectin’s ability to withstand and avoid degradation in the presence of protease activity
(206). Additionally, it is a convenient, easy-to-use approach, and is widely accepted as a
method of drug administration for a variety of disease processes (428, 429), even as
chronic therapy.
The role of lectins in nasal preparations is increasingly being explored due to their
unique properties. Upon binding to cell surface receptors, lectins may remain on the
surface or may be internalized by receptor-mediated endocytosis. The dual properties
enable lectins to act as a direct drug delivery mechanism or play a role in active cellmediated drug uptake (430). The major drawback of this delivery approach is the
possibility of premature drug inactivation or early shedding by mucous drainage (431).
Other impediments to overcome with intranasal drug delivery include the continuous
outward ciliary movement on the epithelial apical surface that clears trapped substances,
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as well as nasal proteases and pH considerations that may impact drug stability (431).
Several studies have shown that lectins trigger low ciliary clearance and scant mucosal
irritation (168, 432). The lectin wheat germ agglutinin (WGA) has been used as part of a
lectin-modified nanoparticles intranasal delivery approach: WGA binds to N-acetyl-Dglucosamine and sialic acid moieties that are abundant in the nasal cavity and olfactory
mucosa. Due to its potent mucosal binding, WGA conjugation with mucoadhesive
polymers resulted in increased drug delivery to the target site (433).
The intranasal delivery approach has previously been explored for efficacy
against respiratory infections with mixed results, necessitating the need for the continued
development of preventative modalities in this area. Preclinical evaluation of a nasal
spray containing carrageenan showed that the sulfated polysaccharide derived from red
seaweeds (Rhodophyceae) maintained antiviral effectiveness against human rhinoviruses
and human coronavirus OC43 in in vitro assays (434). Intranasal sprays with interferons
were also shown to protect human volunteers from infection with coronavirus, influenza,
and rhinoviruses (435). In a randomized, double-blind, placebo-controlled exploratory
study evaluating the antiviral efficacy and safety of an Iota-carrageenan containing nasal
spray, patients infected with any respiratory virus and intranasally treated with the
polysaccharide recovered 1.9 days faster from common cold symptoms compared to
placebo-treated individuals, (P=0.046). In addition, when Iota-carrageenan was
administered within 48 hours of development of the common cold symptoms, the
polysaccharide was associated with lower viral replication (P=0.009), and expression of
pro-inflammatory markers (436). Given that immunocompromised individuals may not
mount a sufficient immune response to completely eliminate infections (437, 438), this
may hinder the utility of a carrageenan product in disease prevention. However, the study
was not designed to investigate carrageenan’s preventative effects in healthy individuals.
Intranasal antibody prophylaxis also showed great promise against viral respiratory tract
infections in animals along with clinical efficacy in human studies (439-441).
Altogether, these background data and studies strongly support the development
of a Q-GRFT intranasal spray to prevent the establishment of SARS-CoV-2 infection.
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This strategy will synergize with prevention approaches that include the use of vaccines
and physical interventions like PPE.
Here, we present preclinical results from engineered human epithelia, ex-vivo and
cadaver studies. The studies provide evidence of Q-GRFT detection in epithelial tissues
and confirmed the ability to quantify Q-GRFT in nasal, nasopharyngeal, and
oropharyngeal fluids. We also outline the clinical protocol for the planned PREVENTCoV Phase 1a clinical study that will evaluate the safety, tolerability, and
pharmacokinetics of intranasal administration of Q-GRFT in healthy male and female
volunteers. Secondary endpoints for the study will include user perceptions, acceptability,
and the impact of product use on participants’ olfactory sensation, and quality of life. The
data generated from this study will support further development of Q-GRFT in future
clinical studies, as a nasally administered drug candidate against coronavirus infection.

MATERIALS AND METHODS
Approval to conduct this Phase 1a study has been granted by the University of Louisville
Institutional Review Board, under IRB# 21.0704, and the trial will be carried out in
compliance with Good Clinical Practices conduct. The study has also received
authorization for the intranasal use of Q-GRFT under Investigational New Drug
Application (IND) #151381.
MatTek epithelial tissue treatment and Q-GRFT concentration determination
Apical corneal and airway epithelial tissues in MatTekTM (MatTek Corporation,
Ashland, MA, U.S.A.) tissue were treated with either 67 µg/mL, 6.7 µg/mL, or 0.67
µg/mL Q-GRFT, and drug concentrations determined in tissue wash fluids, per the
manufacturer’s instructions. Upon arrival, the 6-well plates were prepared by the addition
of tissue-specific maintenance media. The tissue cap containing epithelial tissue was
placed in the prepared well plate and incubated overnight at 37°C, 5% CO2. Excess
accumulated mucus was then carefully removed by aspiration, followed by gentle rinsing
of the apical surface twice with 400 µL assay media. Basolateral media was then
removed and replaced with 1mL fresh assay media, as appropriate for each tissue type.
One hundred fifty microliters of various concentrations of Q-GRFT were added to the
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apical tissue surface followed by incubation for 1 hour at 37°C, 5% CO2. Apical contents
were aspirated, tissue washed once with 400 µL assay buffer, and plates incubated for 24
hours at 37°C, 5% CO2. Samples were collected from the apical surface by washing with
400 µL assay buffer and stored at -80°C, until concentration determination. The same
preparation procedure was followed every twenty-four hours to obtain samples at 48
hours, 72 hours, 96 hours, and 120 hours. After collecting the last sample, tissues were
lysed with 1 mL of Trizol and stored at -80°C. Q-GRFT concentrations in the collected
specimens were determined by ELISA.
Human fresh tissue Q-GRFT concentration determination
To evaluate whether intranasally administered Q-GRFT would be detected in the
nasal cavity, a fresh-tissue study was performed using a recently donated human cadaver.
Two squirts (100 µL per squirt) of fluorescein-labeled Q-GRFT nasal spray solution
were instilled into each nasal cavity using a multidose nasal spray actuator. Nasal,
nasopharyngeal, and oropharyngeal cavities were swabbed every 15 minutes under
endoscopic guidance. Swab contents were eluted with PBS, and Q-GRFT concentrations
determined by either ELISA or fluorescence determination. For both ELISA and
fluorescence determinations, standard Q-GRFT concentrations were prepared and serially
diluted, prior to generation of a standard curve using optical density (OD) and
fluorescence measurements. A BioTek Synergy HT plate reader (Vermont, U.S.A.)
running Gen5 software was used. Specimen concentrations were determined by making
comparisons with the standard curves generated, respectively.
Luminex cytokines
Cytokine concentrations were determined following collection of tissue wash
fluids from the MatTek tissues mentioned above. Prior to analysis, protein concentrations
were determined using a bicinchoninic acid (BCA) protein assay (PierceTM BCA Protein
Assay Kit, Thermo Scientific, Rockford, IL, USA), according to manufacturer’s protocol.
Concentrations were normalized for all samples prior to loading on a Human Cytokine/
Chemokine Magnetic Bead Panel (EMD Millipore Corporation, Billerica, MA, U.S.A.).
The panel was analyzed with a Milliplex MAP Kit on a MagPix with Luminex xMAP
technology (Luminex, Northbrook, IL, USA).
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Statistical analysis
Where appropriate, tests used to determine significance between experiments are
outlined in the figure legends of each figure. Data are representative of 2-3 independent
experiments for each time points. One way ANOVA was performed using GraphPad
Prism7.05 (GraphPad Software, Inc, La Jolla, California) to determine statistical
difference. A P value <0.05 was considered significant

PRE-CLINICAL EXPERIMENTAL STUDY RESULTS
Q-GRFT Accumulates and is Detected in ex vivo Epithelial Tissues Upon Treatment
We evaluated the ability to detect and quantify Q-GRFT in the airway and corneal
epithelia following topical application in MatTekTM EpiAirway and EpiCornea tissues.
Epithelial tissues were treated with either 67 µg/mL, 6.7 µg/mL, or 0.67 µg/mL Q-GRFT
for one hour daily, followed by washing, and a 24-hour incubation period. The tissues
were then washed and Q-GRFT in the epithelial wash fluids was quantified by ELISA.
This was repeated daily for 5 days (120 hours). In EpiAirway epithelia, there was a
significant dose-cumulative effect that was observed with 67 µg/mL Q-GRFT, with the
drug levels initially accumulating up to 96 hours following treatment, then subsequently
declining at the 120-hour period (FIG 5.1). Table 5.1 shows the P-values for the different
Q-GRFT concentrations when drug levels in treated EpiAirway tissues were compared
with cells only controls. Similarly, epithelial drug accumulation was observed with 67
µg/mL Q-GRFT in EpiCornea tissue up to 96 hours, with a decline in concentration at
120 hours, when treated tissues were compared with untreated controls (FIG 5.1). Table
5.2 shows P-values for comparisons made between Q-GRFT treated EpiCornea tissues
and cells only controls. Loss of epithelial cell viability after 96 hours likely accounted for
the reduction in Q-GRFT concentrations observed at 120 hours.
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Figure 5. 1 Q-GRFT accumulation by dose in epithelial tissues following treatment.
MatTekTM EpiAirway (left) and EpiCornea (right) epithelial tissues were treated with
either 67 µg/mL, 6.7 µg/mL, or 0.67 µg/mL Q-GRFT, incubated for 1 hour at 37°C, 5%
CO2, washed, then incubated for 24 hours, washed and Q-GRFT levels determined in the
tissue wash fluids by ELISA. Treatment and Q-GRFT determination was repeated once
daily for up to 120 hours. Experiments were performed at least two times, in triplicate.
Mean + SEM values are presented. Statistical analysis was performed by one way
ANOVA. P<0.05 was determined as significant.

Table 5.1 P-values for EpiAirway tissues treatment with Q-GRFT.

Q-GRFT
treatments
67 µg/mL
6.7 µg/mL
0.67 µg/mL

24 hours

48 hours

P- value
72 hours

0.0231
0.8969
0.9946

<0.0001
0.9190
0.9889

<0.0001
0.2381
0.9885
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96 hours

120
hours

<0.0001
0.9594
0.9994

<0.0001
0.7022
0.9935

Table 5.2 P-values for EpiAirway tissues treatment with Q-GRFT.

Q-GRFT
treatments
67 µg/mL
6.7 µg/mL
0.67 µg/mL

24 hours

48 hours

P- value
72 hours

0.0002
0.9298
0.9990

<0.0001
0.0579
0.9997

<0.0001
0.6413
0.9998

96 hours

120
hours

<0.0001
>0.9999
>0.9999

0.0006
0.9988
>0.9999

Q-GRFT Does Not Affect the Basal expression of Inflammatory cytokines in Epithelial
Tissues Following Treatment
We next sought to establish if treatment of epithelia with Q-GRFT induced
secretion of any inflammatory cytokines. Using the apical wash fluids collected from the
tissues at the end of the dosing period, we determined the inflammatory cytokines
expression profile. Cytokines were assayed using the Luminex xMAP multiplex ELISA
assay method. When compared with untreated cells-only controls, there was no
detectable difference in the expression of either pro-inflammatory or anti-inflammatory
cytokines by both EpiAirway (FIG 5.2) and EpiCornea tissues (FIG 5.3). These results
demonstrated that in vitro, Q-GRFT does not significantly affect basal expression of
epithelial cytokines.
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Cytokine/ chemokine concentration (pg/ mL)
Figure 5. 2 Q-GRFT does affect basal expression of inflammatory cytokines in airway
epithelium. MatTekTM EpiAirway tissues were treated with either 67 µg/mL, 6.7 µg/mL,
or 0.67 µg/mL Q-GRFT, incubated for 1 hour at 37°C, 5% CO2, washed, then incubated
for 24 hours, washed, and incubated for 24 hours. This treatment was repeated once daily
for up to 120 hours. Wash fluids at 120 hours were used to measure cytokines, using
Luminex xMAP multiplex ELISA assay. Experiments were performed in triplicate, N=6
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samples per treatment group, and Mean + SD values are presented. Statistical analysis

Cytokine/ chemokine concentration (pg/ mL)

was performed by one way ANOVA. P<0.05 was determined as significant.

Figure 5. 3 Q-GRFT does not affect basal expression of inflammatory cytokines in
cornea epithelium. MatTekTM EpiCornea tissues were treated with either 67 µg/mL, 6.7
µg/mL, or 0.67 µg/mL Q-GRFT, incubated for 1 hour at 37°C, 5% CO2, washed, then
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incubated for 24 hours, washed again, and incubated for 24 hours. This treatment was
repeated once daily for up to 120 hours. Wash fluids at 120 hours were used to measure
cytokines, using Luminex xMAP multiplex ELISA assay. Experiments were performed
in triplicate, N=6 samples per treatment group, and Mean + SD values are presented.
Statistical analysis was performed by ANOVA. P<0.05 was determined as significant.

Q-GRFT is Detected and Quantifiable in The Human Nasal Cavity, Nasopharynx, and
Oropharynx
To develop and validate assays for the detection of Q-GRFT in the planned
clinical trial, we performed a fresh tissue study with topical application of Q-GRFT spray
in the nasal cavity. Here, two sprays (100 µL per spray) of fluorescein-labelled Q-GRFT
were instilled in the nasal cavity of a human cadaver (body donated within 24 hours of
death), followed by observation for drug dispersion and specimen collection under
endoscopic guidance by the study rhinologist (FIG 5.4). Specimens were collected from
the right nasal cavity (NCR), left nasal cavity (NCL), right nasopharynx (NPR), left
nasopharynx (NPL), right oropharynx (ROP), and left oropharynx (LOP) every 15
minutes, with efforts made to sample different sites at each collection time. Care was
taken to avoid the swab coming into contact with the cavity walls during sampling. Nasal
samples were taken from the middle nasal turbinate. The nasal cavity epithelium was
pink with normal anatomical findings (FIG 5.4A). Q-GRFT was uniformly distributed
along all nasal cavity walls and the oropharynx (FIG 5.4B and FIG 5.4C).
The specimens collected were eluted in PBS prior to quantification by ELISA and
fluorescein determination (FIG 5.5). Swabs collected from the different sites
demonstrated variations in weight (FIG 5.5A). Quantification of Q-GRFT concentrations
by both fluorescence activity and ELISA demonstrated variations in drug levels sampled
from different anatomical sites. However, there was observable similarity in the drug
concentrations measured by both methods from specimens obtained from the same site
(FIG 5.5B and FIG 5.5C). Hence, these findings demonstrate that ELISA and
fluorescence assay are reliable methods for quantifying Q-GRFT concentrations. We will
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utilize the ELISA assay to quantify drug concentrations for specimens collected in the
planned clinical study.

Figure 5. 4 Q-GRFT is detectable in the human nasal cavity, nasopharynx, and
oropharynx.
A fresh tissue study was performed with a donor human cadaver (body donated within 24
hours of death) to assess the dispersion properties, establish, and validate assays to
determine Q-GRFT concentrations in nasal, nasopharyngeal, and oropharyngeal fluids.
Fluorescein-labelled Q-GRFT was instilled in the nasal cavity as an intranasal spray, 2
squirts per nostril, visualization and sampling was done under endoscopic guidance by a
rhinologist. (A) Left nasal cavity (left), left middle turbinate (middle), and oropharynx
prior to Q-GRFT treatment. Note the pink color of the epithelium. (B) Left nasal cavity
(left), left middle turbinate (middle), and oropharynx (right) following intranasal QGRFT administration. The yellow-brown color of the Fluorescein-Q-GRFT depicts drug
dispersion after administration. (C) Swab in the left nasal cavity (left) and right nasal
cavity (right) during sampling of the respective middle turbinates.
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Figure 5. 5 Q-GRFT is quantifiable in the human nasal cavity, nasopharynx, and
oropharynx. A fresh tissue study was performed with a donor human cadaver (recently
died within 24 hours) to assess the drug levels and validate ELISA and fluorescence
assays for collected nasal, nasopharyngeal, and oropharyngeal fluids. Fluoresceinlabelled Q-GRFT was instilled in the nasal cavity as an intranasal spray, 2 squirts (100
µL per squirt) per nostril, visualization, and sampling was done under endoscopic
guidance. (A) Weight of samples collected from different anatomical sites. (B) Q-GRFT
concentrations from fluids collected from the respective anatomic sites, as determined by
fluorescence intensity method. (C) Q-GRFT concentrations from fluids collected from
the respective anatomic sites, as determined by the ELISA assay method. Measurements
were done in triplicate and repeated at least 2-3 times. Representative data, Mean + SD is
shown. Data was analyzed using one-way ANOVA. (NPR-right nasopharynx; NPL-left
nasopharynx; NCR-right nasal cavity; NCL-left nasal cavity; ROP-right oropharynx and
LOP-left oropharynx).

PHASE 1A CLINICAL STUDY PROTOCOL DESIGN
Study Objectives
The primary objective of this first-in-human intranasal exposure study is to evaluate
the safety, tolerability, and pharmacokinetics (PK) of Q-GRFT intranasal spray
administered as a single dose in a Phase 1a trial. Secondary objectives include the
assessment of user perceptions and acceptability, and the impact of product use on
participants’ olfactory sensation, and quality of life.
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Clinical Study Design
This will be a randomized, double-blind, single-site trial. In this Phase 1a study
(FIG 5.6), 18 participants will be randomly assigned 2:1 to either Study Arm 1 or 2 to
receive either a single dose of study product or placebo under direct observation (Table
5.3). Due to the 2:1 randomization, stratification will be balanced to safeguard for
extreme allocation distribution (such as all females being assigned to the placebo arm).
Although a ‘healthy population’ will be enrolled, biological sex (male, female) and race
(white and other) will be considered as stratification factors. In the placebo arm, 3 males
and 3 females will be enrolled; this will comprise 4 whites (split between male and
female) and 2 others (split between male and female); enrollment for the treatment arm
will be double the distribution in the placebo arm. Replacements will be planned to
substitute for dropouts due to reasons unrelated to the treatment. Three age and sexmatched participants will be held in reserve for participants that drop out after drug
exposure prior to completing a full follow-up for safety. Participants in Arm 1 will
receive a single dose of Q-GRFT study product delivered intranasally as two sprays (200
µL per nostril), for a total dose of 3.0 mg. Participants in Arm 2 will receive a single dose
of placebo product, delivered intranasally as two sprays per nostril. This intranasal
product will contain the same ingredients as the study product minus the active Q-GRFT
component. Following administration of the intranasal product in both arms, PK
sampling will be performed at different time points (1 hour, 6 hours, 24 hours, and 3 days
post-dose administration), followed by a safety review after 24 hours, 3 days, and 2-3
weeks later with a phone call. If this clinical dose is determined safe and acceptable, the
study will advance to Phase 1b to assess future dose loading questions or de-escalation
adjustments.
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Figure 5. 6 Phase 1a study design.

Table 5.3. Phase 1a Study Arms
Arm

N

Method of

Study Product

Dosing

Randomized,

Q-GRFT

Single-dose,

Double-blind

Intranasal

one time

Assignment
1

12

spray
(7.5 mg/ mL)
2

6

Randomized,

Placebo

Single

Double-blind

Intranasal

administration

spray
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Study Participants/ Population
The study population will consist of healthy male or female individuals who will
satisfy the following inclusion criteria.

Inclusion Criteria
Participants will be aged 18-60 years at screening; have a negative SARS-CoV-2
test using the rapid antigen test at screening; be able and willing to provide written
informed consent; be able to provide adequate information for locator purposes; be
available to return for all study visits, barring unforeseen circumstances; and agree not to
participate in other research studies involving drugs and/or medical devices during the
study period. In addition, female participants should not be pregnant at the baseline or
enrollment visit or breastfeeding during the study and must be: either post-menopausal or
using (or willing to use) an acceptable form of contraception (e.g., abstinence, barrier
method, IUD, hormonal contraception, surgical sterilization, or vasectomization of male
partner); male participants in heterosexual relationships should be willing to use barrier
methods during intercourse, and/ or have their partners using any of the acceptable forms
of contraception listed above. Participants should have no plans to receive any vaccines
while on the study or be able to safely defer vaccinations until completion of study
participation. Furthermore, they must agree to not use intranasally-applied medication for
the duration of the study.
Exclusion Criteria
Participants will be excluded if they meet these criteria or have any of the
conditions: ongoing moderate to severe allergic rhinitis or asthma, history of chronic
obstructive pulmonary disease (COPD), or chronic rhinitis with ongoing sinusitis.
Additionally, participants will not be enrolled if they report any of the following at the
screening visit: ongoing common cold or flu-like symptoms for 48 hours prior to the
screening, including sore throat, blocked nose, runny nose, cough, or sneezing;
participants known to experience moderate or severe or higher seasonal allergies, such as
hay fever, (symptoms in excess of mild, intermittent nasal rhinorrhea, sneezing, or
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itchy/watery eyes); participants who report non-therapeutic injection drug use in the 6
months prior to screening, including those who report recreational snorted drug use;
participants who report prescription medication/ concomitant therapy use other than for
contraception and antibiotics. Prohibited medications include systemic steroids, intranasal
medicines, among others. Participants who actively smoke at the time of screening; those
with a known allergy to methylparaben, propylparaben, or any ingredients of the
formulated drug product; individuals who take systemic immunomodulatory medications
(Thalidomide, Lenalidomide, Pomalidomide, Imiquimod, etc.), anticoagulants, or other
drugs assessed by the site Investigator as invalidating within the 4 weeks prior to the
enrollment; those with a history of alcohol/ substance abuse within 6 months of study
enrollment; subjects with a history of any vaccination within the 2 weeks prior to
enrollment; participants enrolled in another research study involving drugs or medical
devices within the 4 weeks prior to PREVENT-CoV enrollment; and those who have
plans to relocate away from the study site area during the period of study participation.
Furthermore, participants with any of the following laboratory abnormalities at
Screening will not be enrolled: white blood cell count < 2,000 cells/mm3 or > 15,000
cells/mm3; hemoglobin <12 g/dL for men and <11 g/dL for women; calculated creatinine
clearance >1.1 x upper limit of normal (ULN); alanine transaminase (ALT) and/or
aspartate aminotransferase (AST) > 1.1 × the site laboratory ULN; total bilirubin > 1.1 x
ULN; and ≥ +1 glucose or +2 protein on urinalysis (UA). Additionally, participants may
not be enrolled if they report any other condition or prior therapy that, in the opinion of
the investigator, would preclude informed consent, make study participation unsafe,
make the individual unsuitable for the study, or unable to comply with the study
requirements. Such conditions may include but are not limited to, a current or recent
history (within last 6 months) of severe, progressive, or uncontrolled substance abuse,
renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological,
cerebral disease, or severe nasal septum deviation, or other conditions that may cause
nasal obstruction like nasal polyps or prior nasal/ sinus surgery.
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Study Product
The intranasal spray product used in the cadaver study, and which will be utilized
in the Phase 1a study contains Q-GRFT (7.5 mg/mL) as the active pharmaceutical
ingredient (10 mg/mL Q-GRFT stock solution in phosphate-buffered saline, pH 7.4),
water-soluble preservatives (parabens), a viscosity modifying agent (lambda carrageenan
polymer), stabilizing agent, acidifying agent, and solvents (PBS and purified water). The
placebo intranasal spray will be identical to the active product formulation minus the
API.

Study Procedures
Participants Recruitment, Screening, and Retention
Male and female participants will be recruited from a variety of sources, using
key strategies that will include: clinician-patient referrals; use of existing “study
registries” that contain the names and phone numbers of individuals who have given
informed consent to be reached for future studies for which they may be eligible;
participant referrals (participants may refer their friends or partners who meet eligibility
criteria); and passive self-referral by interested individuals who see a study poster or
brochure. Both male and female participants will be recruited, and strategies will be
undertaken to ensure equitable opportunity to enroll from members of both biological sex
to the extent possible. Additionally, minorities that are representatives of the diversity of
Jefferson County, Louisville, KY will be sought. Enrollment will be performed at the
University of Louisville, Louisville, KY.
Volunteers will be prescreened to determine eligibility. Approximately 40
volunteers will be screened to enroll 18 participants meeting the eligibility criteria. Study
staff will meet as needed to discuss the ongoing recruitment status, targets, and strategies.
Staff will follow up with all persons who express an interest in the study to ensure that
screening appointments are scheduled in a timely manner.
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Once enrolled, the study site will make every effort to retain participants for the
duration of follow-up in order to minimize loss-to-follow-up bias. This will be done
through exhaustive explanation of the study visit schedule and procedural requirements
during the informed consent process both in-person and using a pre-recorded information
video, and re-emphasis at each study visit; thorough explanation of the importance of all
dosing and sampling phases to the overall success of the study; use of appropriate and
timely visit reminder mechanisms (via email and/or telephone); and immediate and
multifaceted follow-up on missed visits.
Informed Consent, Clinic Visits, and Assessment
All participants will provide written informed consent prior to participation in the study.
Participants will have a right to withdraw from the study at any time for any reason.
Participants will be prescreened using online questionnaires and telephone
interviews, and selected volunteers will be invited for the screening visit at the next
available appointment. At Visit 0, written informed consent will be obtained, along with
locator information, demographics, and medical history. A brief physical examination
including a visual inspection of the nose and throat and an assessment of olfaction will be
conducted. A baseline quality-of-life questionnaire (Short Form-12 item; SF-12) will also
be administered. Eligible participants will have blood, urine, nasal, and throat specimens
collected, and a rapid COVID-19 test performed. Baseline specimens (plasma samples,
nasal, nasopharyngeal, and oropharyngeal fluids) will also be collected using a swab for
baseline PD and cytokines evaluation.
Visit 1 (enrollment and single-dose exposure) will occur 3-4 days following
screening at Visit 0. Here, eligibility will be confirmed, and a complete clinical
assessment performed. Plasma samples will be obtained for storage for future research,
and repeat blood tests performed if indicated, for follow up of any prior abnormal blood
tests. Participants will then receive either the single-dose Q-GRFT DP intranasal spray or
placebo, two sprays into each nostril, as per the randomization assignment. PK sample
collection will then occur at 1 hour and 6 hours post-dosing.
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Visit 2 will occur 24 hours post-dosing and will include clinical evaluation and
PK sampling. Nasal, nasopharyngeal, and oropharyngeal fluids will be collected. Blood
will be collected for cytokine evaluation and plasma storage for future research. Olfaction
will be assessed using the Brief Smell Identification Test (BSIT) and an acceptability
questionnaire will be completed.
Visit 3 will be the final safety evaluation and PK sampling visit and will occur 2
days after visit 2. Here, participants will complete a product acceptability questionnaire,
the SF-12, and undergo a symptom-directed physical exam, including a nose and throat
inspection. Olfaction will also be assessed. Blood will be collected for full hemogram and
storage. In addition, nasal, nasopharyngeal, and oropharyngeal fluids will be collected,
and the product acceptability questionnaire administered.
A final Phase 1a study exit phone call (visit 4) will be made to the participants
within 2-3 weeks after visit 3 to inquire about any adverse events that the participant may
have experienced as a result of product administration. The product acceptability
questionnaire will again be administered in an online format. If this initial dose exposure
is found to be safe and tolerated, the study will proceed to Phase 1b.
Intervention Groups
Eighteen enrolled participants will be randomly assigned 2:1 to receive either
study product or placebo arms. Based on prior studies with similar eligibility
requirements, the site is expected to enroll 6 participants per week. Accrual is anticipated
to take approximately 2-4 weeks.
Drug and Dose selection
Our extensive studies with rectal toxicology in rats and rabbits did not reach a
maximum tolerated dose, even though animals were dosed with a 30 mg/mL gel
formulation that delivered a tissue concentration measured in PK assays at more than
1,000 fold the EC90 of HIV-1 (196). Both mice and Syrian Golden hamsters have been
treated with GRFT intranasally in efficacy studies against SARS-CoV (442) and NiV
(443), respectively. Rhesus macaques have been exposed to nebulized GRFT. No toxicity
has been reported in these studies, and the anticipation extends to the studies described in
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this proposal. Evidence of Q-GRFT distribution to the brain is perhaps the most
significant toxicity risk that we may encounter, which will result in the need for extensive
neurotoxicity assessments in the toxicology studies planned to support Phase 2 clinical
studies.
Based on efficacy observed in the SARS-CoV, NiV, and MERS-CoV models, 7.5
mg/ mL of Q-GRFT (total dose of 3.0 mg) will be administered to participants in Phase
1a. This dose is 1000- fold higher than the effective dose (EC50) that was protective in
tissue exposure experiments (unpublished).
Outcome Measures
The endpoints selected for this study are appropriate measures of prophylactic
preventative effect. A single dose exposure will be used to determine the safety,
acceptability, and PK of a Q-GRFT intranasal spray product in preventing SARS-CoV-2
infection.

Safety and Tolerability
Routine Clinical Laboratory Tests
Routine hematology, blood chemistry, and urinalysis will be performed for
participants, as described in Table 5.4. A complete blood count with differential, blood
chemistry, urinalysis, and pregnancy test (βhCG) for female volunteers will be performed
at the screening visit. Repeat hematology and a comprehensive metabolic panel will be
performed at Visits 3.
Physical Examination and Nasal Endoscopy
A complete physical examination will be performed per Table 5.4. An
abbreviated physical examination, including a nose and throat exam, and routine
examination of the lungs, heart, abdomen, skin, and central nervous system will be
performed. Subsequent nasal endoscopy will be performed by the study rhinologist
during PK sample collection to ensure accuracy and consistency at all time points. The
direct visualization afforded by endoscopy will allow for swabbing the same anatomic
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location at each sampling time point, reducing sampling variability. Additionally, this
will mitigate participant discomfort during the sampling procedure.
Vital Signs
Vital signs (heart rate, blood pressure, temperature, and respiratory rate) will be
measured as specified in Table 5.4 after the subject sits quietly for 5 minutes on all visits
and as clinically indicated.
Body weight and Height
Bodyweight and height will be recorded at the initial health assessment, with
weight measured again at subsequent study clinical visits.
Olfactory Assessment
Evaluation of olfactory function will be performed at the time points specified in
Table 5.4. Sense of smell will be determined using the University of Pennsylvania BSIT,
a validated assessment of olfactory function (444). The BSIT assesses an individual's
ability to detect odors at a suprathreshold level. The test consists of 12 items provided in
a 12-page booklet. On each page, there is a "scratch and sniff" strip embedded with a
microencapsulated odorant along with 4 choice options. The participant smells the strip
and chooses the odor from the four choices listed (445). Scores range from 0-12. The
BSIT has demonstrated good reliability (r=.71) and takes less than 5 minutes to
complete.
Any clinically significant change from baseline on follow-up assessments will be
recorded as an adverse event (AE). If the changes are persistent, a full neurological
evaluation will be performed.
Quality of Life
Quality of Life will be determined by the Short Form (SF)-12, a truncated,
reliable version of the SF-36. The SF-12 uses 12 questions to evaluate eight domains that
provide a general assessment of health-related quality of life from the participant’s
perspective (446). The SF-12 includes subscales to assess mental and physical
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functioning. Subscales are scored according to publisher specifications and standardized
to allow comparison to the general US adult population.
Any clinically significant change from baseline on follow-up assessments will be
recorded as an adverse event (AE). If the changes are persistent, a full neurological
evaluation will be performed.
Product Acceptability Assessment
Product acceptability, feasibility, and tolerability will be evaluated by a
questionnaire as specified in Table 5.4. Questionnaire items are derived from existing,
validated questionnaires with adaptation for the current study (447). Participant
experience and opinion of efficacy, sensory perceptions, spray characteristics,
administration process, applicator design, and use regimen will be assessed. Responses
will help determine product characteristics disliked or considered likely to challenge
future sustained use by participants. Items are rated on 5-point Likert scales. The
proportion of participants reporting product characteristics considered a barrier to use
will be calculated. A Likert scale rating of lower than 3/5 on a given item will be
considered a ‘dislike’ or potential barrier to future product use.

Pharmacokinetics Assessment and Ex Vivo Efficacy
As per Table 5.4, nasal, nasopharyngeal, and oropharyngeal swabs will be
collected at visits 0, 1, 2 and 3, to determine the drug concentration. Inhibition of SARSCoV-2 infectivity will be assessed by plaque reduction neutralization assay (PRNT) and
correlations with Q-GRFT drug levels established.
Tolerability Assessment and Management- Adverse events
Throughout the study, each participant’s condition will be closely monitored.
Signs and symptoms of possible adverse events (AEs) may be reported by the study
participants or observed by staff. They will be elicited from the participants by using
direct or indirect questions like ‘How have you felt since your last visit to the clinic?’ and
‘Have you experienced any changes in your wellbeing since receiving the study product?’
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All AEs, whether reported by the subject, elicited by staff, or observed by the
investigator, will be recorded. The start and end dates, AE-specific severity, relationship
to study drug, and any actions taken to address the AE will also be documented.
Outcomes such as whether AE resulted in death, required or necessitated hospitalization,
any persistent or significant disability/ incapacity, any intervention to prevent these
outcomes, and whether the events and actions taken were reported to the Data and
Medical Monitor, Institutional Review Board (IRB) and study sponsor will be recorded.
Serious adverse events (SAEs) occurring in a study participant or any worsening
of SAEs at any time during the study will be reported within 24 hours to the investigator,
who will then immediately inform the Medical Monitor and IRB. For female participants,
if any pregnancy occurs during the study, the investigator will immediately notify the
Medical Monitor and IRB upon learning of the occurrence.
Tolerability of Q-GRFT in study volunteers will be derived from the frequency of
AEs and study withdrawal due to any reported discomfort during the dosing period. As
per Table 5.4, blood samples will be collected as previously described. If toxicity is
identified following drug administration, the subject will be re-evaluated with a full
physical examination and repeat blood tests performed to confirm toxicity. If the repeat
tests are normal, this will be documented. Additionally, if still abnormal, appropriate
action will be taken, and subsequent blood draws performed serially until resolution is
documented.
Sample and Data Storage
Samples and data collected will be stored at the University of Louisville Clinical
Trials Unit (CTU) and CPM laboratory, Louisville, KY. IRB approval will be sought for
all the study procedures. Consent for samples and data storage will be provided by all
participants. All biospecimens collected during the study will be de-identified, processed,
and analyzed blindly until study completion. Similarly, electronic data will be deidentified, stored on secured servers with encryption, and accessed only by authorized
users. A REDCap online database system hosted at the University of Louisville will be
utilized to store, secure, organize, and analyze data (448). Responses on paper
questionnaires will be entered to REDCap by study personnel. Upon conclusion of the
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study, the de-identified stored specimens and data will be made available for use by other
researchers and investigators upon request to the Principal Investigator.
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Table 5.4. Schedule of Phase 1a Study Visits and Evaluations.
Assessment

Visit 0

Visit 1

Visit 2

Visit 3

Visit 4

Screening

Enrollment, single
dose exposure

Safety
assessment

Final safety review, PK
sampling

(Phone call)

X

X

X

X

X

X

X

X

Informed Consent

X

Inclusion/Exclusion

X

X

Medical History

X

X

Pregnancy (urine βhCG)

X

Concomitant
Medications

X

Demographics

X

Locator Information

X

Randomization

X

Study Dosing

Dose 1

Vital signs

X

X

X

X

Physical Exam

X

X

X

X

Nose and Throat Exam

X

X

X

X

Nasal, Nasopharyngeal,
& Oropharyngeal Swab
collection

X

X

X

X

COVID-19 Rapid
Antigen test

X

Hematology: Complete
blood count (CBC)

X

X

Comprehensive
Metabolic Panel (CMP)

X

X

Urinalysis

X

Plasma sample for
Q-GRFT Detection

X

Plasma sample for
SARS-CoV 2 antibodies
detection

X

Cytokines evaluation

X

AEs

X

X

X

Quality of life
assessment

X

Olfactory function
assessment

X

X

X

X

X

X

Product acceptability
questionnaire
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X

X

X

X

X

Planned Analyses
Data Analyses
All participants who receive the study product will be included in the safety and
efficacy analyses. All intra-and inter-participant outcome measures collected during the
study period will be analyzed by an experienced biostatistician.
Data will be summarized following recommended standard guidelines. Data from
sets of patients that complete each study visit and any reasons for early study termination
will be noted and compared across study arms. Descriptive statistics (median, mean,
standard error, standard deviation, minimum and maximum) will be used to summarize
data for doses received and study visits completed. Similarly, demographic and baseline
characteristics for participants in all groups will be summarized using descriptive
statistics. Biomarker changes between pre- and post-dosing will be analyzed using paired
tests. Descriptive summary statistics will be reported according to observed data, and
missing data will not be imputed. Bayesian and likelihood estimates will be used for
limited analyses where formal inferential statistics will be required for participants with
missing follow-up assessments. A P value <.05 will be considered statistically
significant.
Safety Analyses
Concomitant/ ongoing Medications. Any concomitant medications including
those not related to the study product will be coded according to the World Health
Organization (WHO) Drug dictionary and tabulated by the dosing group.
Adverse Events. Incidence of all treatment-related AEs and treatment-emergent
AEs (TEAEs) will be summarized. A TEAE is an event that first occurs or worsens in
intensity following the administration of a study drug. The Medical Dictionary for
Regulatory Activities (MedDRA) will be used to classify AEs by system organ class and
preferred term. For incidence reporting, when participants report more than one AE that
will have been coded to the same system organ class or preferred term, the participant will
be counted only once for that system organ class or preferred term. Events that occur
between the signing of informed consent and the first study drug administration will be
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recorded. A list of possible AEs including the participant incidence of TEAEs, treatmentrelated AEs, SAEs, deaths, and AEs resulting in study termination, will be constructed. For
the stratification of AEs by severity, the worst severity for each participant during the study
will be presented. Appropriate generalized linear models will be used for comparisons of
significant differences between groups.
In addition, for the safety analysis, the number and frequency of ≥ Grade 2 AEs and
≥ Grade 1 nasal cavity-related AEs will be tabulated for the intranasal administration
method. To determine whether AEs are occurring excessively, the proportion of subjects
that experience an AE will be calculated for a method of administration. A single summary
outcome of this type (yes/no) can be reasonably assumed to follow a Bernoulli distribution.
Table 5.5 and Table 5.6 show, for selected true underlying rates between .01 and .45, the
probability of zero, one or more, and two or more subjects experiencing AEs in a sample
group of participants.

Table 5.5. Analysis of Safety Event Frequency for Arms of Size 12 (Q-GRFT nasal
spray).
Event Rate

P(0 events

P(>=1 events

P(>=2 events

P(>=3 events

(%)

|=12)

|=12)

|=12)

|=12)

1

0.886

0.114

0.006

0.000

5

0.540

0.460

0.118

0.020

10

0.282

0.718

0.341

0.111

15

0.142

0.858

0.557

0.264

25

0.032

0.968

0.842

0.609

35

0.006

0.994

0.958

0.849

45

0.001

0.999

0.992

0.958
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Table 5.6. Analysis of Safety Event Frequency for Arms of Size 6 (placebo spray).
Event Rate P(0

events P(>=1

events P(>=2

events P(>=3

(%)

|=6)

|=6)

|=6)

|=6)

1

0.941

0.059

0.001

0.000

5

0.735

0.265

0.033

0.002

10

0.531

0.469

0.114

0.016

15

0.377

0.623

0.224

0.047

25

0.178

0.822

0.466

0.169

35

0.075

0.925

0.681

0.353

45

0.028

0.972

0.836

0.558

events

The study will be paused for clinical data safety review in the event that four or
more study participants in the treatment arm or two or more participants in the placebo arm
experience an AE ≥ Grade 3. With 18 total subjects, the probability that 3 or more AE ≥
Grade 3 events occur given a true Grade 3 or more AE rate is shown in Table 5.7. Hence,
it is highly unlikely that the study will be paused unless the true AE ≥ Grade 3 event rate
is 10% or more.
Serious Adverse Events. In a similar manner to AEs above, SAEs will be listed
and summarized. The sponsor will be notified of any SAEs within 24 hours of their
discovery.
Clinical Laboratory Results. Blood samples will be measured in a qualified
clinical laboratory. Descriptive statistics will be used for actual values and any changes
from baseline will be tabulated by study visit. Clinical laboratory values outside of the
normal reference ranges post-baseline will be recorded and analyzed using appropriate
binary measures. Any changes from the baseline to worsening severity in the laboratory
values will be recorded and analyzed with appropriate test statistics.
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Vital signs. Data observed at baseline and any change from baseline will be
determined for all measurements at the clinic visits. These data will be summarized with
descriptive statistics and analyzed using an appropriate generalized linear mixed model.
Study Objectives. As mentioned above, patients will be closely monitored for any
adverse events and toxicity, with repeat blood draws until AE resolution. To account for
the inherent correlation, repeated measures statistics will be included in a repeated
measures factor analysis with random effects. For the exploratory objectives, correlations
will be determined between Q-GRFT drug levels obtained at PK sampling with SARSCoV-2 infectivity in vitro and ex vivo. For olfactory sensation and quality of life,
Spearman’s statistics and Student’s t-tests will be used for correlation analysis and
comparisons between groups, respectively.

Table 5.7. Analysis of Safety Event Frequency for both Arms of Size 18.
Event Rate

P(0 events

P(>=1 events

P(>=2 events

P(>=3 events

(%)

|=18)

|=18)

|=18)

|=18)

1

0.835

0.165

0.014

0.001

5

0.397

0.603

0.226

0.058

10

0.150

0.850

0.550

0.266

15

0.054

0.946

0.776

0.520

25

0.006

0.994

0.961

0.865

35

0.000

1.000

0.995

0.976

45

0.000

1.000

1.000

0.997

DISCUSSION
The initial SARS-CoV pandemic was reported in 2002-2003 (409), while MERSCoV outbreaks have continued to-date since the first human case was identified in 2012
(411, 449). Coronaviruses have also been responsible for seasonal noncomplicated upper
and lower respiratory tract infections (450, 451). The ongoing COVID-19 pandemic,
caused by SARS-CoV-2 has resulted in unprecedented worldwide pandemonium. Unlike
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the response to the multiple epidemics and pandemics due to coronaviruses in the past,
only the current COVID-19 pandemic has resulted in rapid and fast-paced development
of effective vaccines to curb infection (452).
Treatments that have received either Emergency Use Authorization or full
approval by the FDA for utility in treatment and/ or prevention include Remdesivir (453);
monoclonal antibodies like sotrovimab, and casirivimab plus imdevimab; and vaccines,
including products marketed by Pfizer-BioNTech, Moderna, and Janssen to date (454);
The search for more effective approaches and treatments is on-going (455, 456). A nonvaccine broad-spectrum prophylactic nasal spray provides an ideal adjunctive strategy to
prevent virus infection and transmission. This is warranted since long-term data about the
durability of antibodies in the elderly and immunocompromised individuals following
vaccination is still under investigation (457). Furthermore, numerous reports have
emerged of vaccinated individuals being re-infected with SARS-CoV-2 (458). The
current spread and transmission of new viral variants complicate the current approved
therapeutic and prevention modalities (459).
Studies have shown that intranasal sprays can decrease the risk of acquisition and
establishment of viral respiratory infections. In rodent models, intranasal spray with low
pH gel and antibody prophylaxis prevented infection with influenza virus (460, 461).
Pilot studies in humans with hypertonic nasal saline irrigation (462) and Rupintrivir nasal
spray (463) have demonstrated efficacy against viral upper respiratory infections
including Rhinovirus colds. Our network of collaborators and other researchers have
shown that GRFT inhibits viral entry of all coronaviruses tested, including SARS-CoV,
MERS-CoV, and SARS-CoV-2 (10, 176, 189). Moreover, delivery of GRFT to the upper
respiratory tract provides significant protection from SARS-CoV (464), MERS-CoV
(unpublished), and paramyxovirus Nipah virus (11) in animal models. This observation is
also supported by our preliminary data showing that pre-exposure treatment with QGRFT protected 3-dimensional human airway tissues from SARS-CoV-2 infection and
reduced viral replication (unpublished). In addition, our in vitro epithelial tissue treatment
studies have demonstrated that topical application of Q-GRFT results in detectable drug
levels in tissue washes, which accumulate with repeat administration.
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Given the urgent need for therapeutic interventions to prevent the spread of the
COVID-19 pandemic, we strongly believe that Q-GRFT API in an intranasal spray will
protect against SARS-CoV-2 infection and transmission. Our hypothesis is further
supported by our preliminary findings in the fresh tissue study, where Q-GRFT
application demonstrated the ability of Q-GRFT to disperse and will likely protect against
SARS-CoV-2 cell entry.
In light of this background and preliminary findings, our PREVENT-CoV Phase
1a study will assess the safety, acceptability, and pharmacokinetics of Q-GRFT intranasal
spray as broad-spectrum prophylactic for coronavirus infections. This study will be the
first proof of concept trial to determine if a Q-GRFT intranasal spray formulation is safe
and acceptable for human use. Clinically relevant endpoints have been carefully selected,
including olfactory function and determination of PK parameters. Q-GRFT intranasal
spray is a topically administered product with a low likelihood of systemic side effects.
Although the expectation is the demonstration of a low risk of toxicity, careful
assessments of safety, including systemic symptomatology, will be undertaken in this
trial with special consideration for issues related to central nervous system toxicity. This
is due to the potential for Q-GRFT exposure via the olfactory epithelium when
administered through the nasal route. The design of this study will allow for the
exploration of these questions while protecting the safety of participants.
For the drug to prevent coronavirus infection, it is critical that the product must be
present in the appropriate anatomical site and at the ideal concentration, throughout the
period of exposure to infection. Consequently, the multicompartmental PK included in
this study will generate important data that, in combination with the SARS-CoV-2
neutralization findings, will help determine if the test product has the appropriate profile
to support further development in Phase 1b and subsequent clinical trials.
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CHAPTER 6: CONCLUSION AND FUTURE DIRECTIONS

SUMMARY OF Q-GRFT INTERACTIONS AND UTILITY IN MUCOSAL
INFECTIONS AND IMPLICATIONS FOR FUTURE RESEARCH
Throughout this work, we have analyzed Q-GRFT interactions in the mucosal
environment and determined the lectin’s impact on related infections using both murine
models and in vitro assays. Our overarching hypothesis was that Q-GRFT was stable in
mucosal epithelia and would likely be an ideal alternative strategy for the prevention and
treatment of infections in this environment. A number of hypotheses were explored. First,
we hypothesized that Q-GRFT was stable in rectal mucosa. To test this hypothesis, we
incubated Q-GRFT with murine, macaque and human rectal fluids, and determined the
lectin’s ability to bind gp120. Additionally, Q-GRFT was incubated with human seminal
fluids prior to determining its binding to gp120. Next, we hypothesized that Q-GRFT
could inhibit the growth of gut and rectal microbiome components. To test this, Q-GRFT
was incubated with bacterial and fungal representative components of gut and rectal
microbiota, and their growth monitored periodically. Based on results demonstrating in
vitro inhibition of C. albicans growth, we next hypothesized that Q-GRFT in a murine
model would be efficacious and eliminate fungal infection in a vaginal candidiasis model.
Finally, given results from previous studies, we hypothesized that an intranasal
formulation of Q-GRFT would be effective as prophylaxis against coronaviruses
infection in the human population. To test this hypothesis, using airway and corneal
epithelia, we determined whether Q-GRFT is detectable following topical tissue
treatment. Next, in a fresh-tissue cadaver study, we administered Q-GRFT as an
intranasal spray to determine the pattern of dispersion, and to establish whether the drug
will be detected upon sampling. Lastly, we designed a protocol for a Phase 1a study, to
establish safety, tolerability, and pharmacokinetics of Q-GRFT intranasal spray following
a single dose administration.
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From the findings of this work, a number of conclusions can be made about potential
implications, and taken altogether, support future development of Q-GRFT as a potential
strategy for the treatment of select mucosal infections.
Q-GRFT was stable and maintained its ability to bind to gp120 following incubation with
murine, macaque and human rectal fluids, and seminal plasma.
Glycoprotein 120 binding studies with Q-GRFT following incubation of the lectin
with murine, macaque, and human rectal fluids, including human seminal fluids
demonstrated that the lectin remains stable, in the rectal environment. Additional studies
that evaluated the composition of rectal fluids demonstrated the presence of protease
enzymes, proteins and carbohydrates in rectal fluids, with a pH range of 7-8. Despite the
degradative enzymes in these fluids, Q-GRFT maintained the ability to bind gp120
following incubation. Interestingly, incubation for both brief and extended durations (6
hours versus 24 hours) demonstrated no significant impact on gp120 binding. One
limitation in our experiments is that we did not confirm the stability of Q-GRFT
following incubation with an alternative method like western blot. Additionally, when
antigens are coated on plates in ELISA assays, there is a likelihood of conformational
changes altering their interaction with other molecules (289). Conformational changes in
gp120 may have impacted Q-GRFT binding in these assays. Nonetheless, the data
suggested that Q-GRFT may remain stable in the rectal environment and supports further
evaluation of its potential as an antimicrobial agent in animal and human studies.
Furthermore, our stability results in rectal fluids are in keeping with earlier studies of
Griffithsin’s stability in cervicovaginal fluids (206).
Q-GRFT inhibits the growth of fungal microbiome component C. albicans, but not
bacterial components.
In broth media, the growth of bacterial microbiome components Lactobacillus
acidophillus, Lactobacillus casei, Escherichia coli, Bifidobactrium longum longum,
Clostridium dificile, Enterotoxigenic Bacteroides fragilis and Nontoxigenic Bacteroides
fragilis was not impacted by incubation with Q-GRFT. Contrastingly, we made a novel
finding, that the growth of fungal component C. albicans was inhibited following
incubation with Q-GRFT. We have established that Q-GRFT likely binds to cell wall α138

mannan, but not chitin or β-glucan in C. albicans. We further demonstrated that Q-GRFT
binding is associated with a breach in cell wall and membrane integrity, and appears to
induce formation of reactive oxidative species, with subsequent cell death. Additionally,
binding induces the expression of genes responsible for the cell’s reaction to stressful
stimuli, including those involved in neutralizing ROS formation and escaping stress.
Furthermore, we have established that Q-GRFT binds to other Candida strains, including
C. glabrata, C. krusei, C. parapsilosis, and the multi-and pan-resistant C. auris. Given
the differences in MIC50s and MIC90s demonstrated, we postulated that variations in the
cell wall composition of α-mannosyl sugars likely contribute to the differential response
observed following incubation of Q-GRFT with different Candida strains. Interestingly,
we also demonstrated significant growth inhibition of isolates in the C. auris South Asia
clade, that is predominant in the United States. These results signify the potential of QGRFT as an alternative strategy against fungal infections.
Q-GRFT is efficacious against vaginal candidiasis in prophylaxis and therapeutic murine
models.
In prophylactic and therapeutic murine models of vaginal candidiasis, we have
demonstrated that Q-GRFT significantly inhibited infection and enhanced C. albicans
clearance, respectively. Additionally, lower quantities of pro-inflammatory cytokines
and innate immune cells were observed following vaginal Q-GRFT treatment, when
comparisons were made with infected, untreated animals. These findings suggest QGRFT is associated with higher fungal clearance, with subsequently lower antigenic
stimulation of cytokines, predisposing to the lower pro-inflammatory response observed
in the lectin treated animals. Moreover, it is likely that the initial vaginal infection
triggers recruitment of the immune cells, that persist even beyond the period of drug
administration. Because we assessed the immune cells response and population 12 days
post-infection, it is possible that changes may occur at even later timepoints. From our
data, Q-GRFT appears not to directly impact changes in the immune response to vaginal
candidiasis. The lack of immune stimulation is in keeping with earlier studies that have
not demonstrated any direct induction of immunity and inflammatory response when Q-
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GRFT was applied either topically or systemically (204, 382). Key to note however, is
that the investigations in these studies were not done in the context of on-going infection.
Q-GRFT is detectable in epithelial tissues upon topical treatment and was quantifiable in
human nasal and pharyngeal mucosal membranes in a fresh-tissue cadaver study, in
preparation for a Phase 1a clinical trial to establish safety, acceptability, and PK of an
intranasal spray.
Given its broad-spectrum antiviral activity, Griffithsin has been demonstrated
binding to coronaviruses. In response to the on-going COVID-19 pandemic, we are
developing an intranasal spray as a pre-exposure prophylaxis against coronaviruses. In in
vitro studies with air way and corneal epithelia, we have demonstrated that Q-GRFT is
detectable and quantifiable following tissue treatment. Additionally, in a fresh human
tissue cadaver study, we determined that upon instillation, Q-GRFT disperses widely in
the nasal cavity, and is detected in nasopharyngeal and oropharyngeal compartments. The
mucosa in these anatomic cavities contains receptors for coronaviruses. Using ELISA and
fluorescence experiments, we have established assays that precisely determine drug
levels in nasal, nasopharyngeal, and oropharyngeal cavities following administration.
Furthermore, the planned Phase 1a study will enable assessment of the safety,
tolerability, and pharmacokinetics of Q-GRFT intranasal spray in a first-in-human nasal
exposure of the drug product, in preparation for future efficacy studies, as prophylaxis
against coronaviruses.
In summary Q-GRFT is stable in the rectal mucosal environment, and maintains
its ability to bind gp120, despite the presence of degradative enzymes in these cavities.
Although no impact has been demonstrated on bacterial microbiome, Q-GRFT inhibits
the growth of fungal microbial component C. albicans as well as other Candida species
of clinical importance. Furthermore, Q-GRFT is efficacious in the treatment of vaginal
candidiasis in a murine model. The lectin’s broad-spectrum antiviral activity extends to
include coronaviruses, and Q-GRFT is detectable in nasal, nasopharyngeal,
oropharyngeal, and ocular epithelial mucosa, tissues that possess receptors with binding
targets for coronaviruses. Intranasal application of a Q-GRFT spray formulation resulted
in detectable and quantifiable drug levels, which were comparably evaluable using both
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ELISA and fluorescence assays. A planned phase 1a clinical study will establish baseline
safety, tolerability and pharmacokinetic characteristics that will be critical in future
development of Q-GRFT as an intranasal prophylaxis against coronaviruses.

DISCUSSION
For rectally administered drugs to achieve maximal efficacy, the product should
be able to withstand any degradative activity in this environment. Interestingly, the rectal
environment is adjudged to be remarkably constant and stable and demonstrates low
enzymatic activity when compared to other regions of the gastrointestinal tract (465). In
addition, in spite of the relatively small surface area of the mucosa in this region, delivery
of drugs via this route results in significant local and systemic levels (466). In fact,
following systemic absorption, drugs delivered rectally partially bypass the liver,
avoiding significant hepatic first-pass effect (466, 467). Our study has suggested that the
lectin Q-GRFT is stable when incubated with rectal fluids. Studies have revealed that
numerous lectins are stable and can withstand aggressive environments like acidic pH,
heat and enzymatic activity, retaining their ability to interact with cell membrane glycans
(468). This has subsequently resulted in studies that have evaluated the utility of lectins
in gastrointestinal and colorectal cancers and other pathologies (469). Dietary wheat germ
agglutinin (WGA) has been investigated as a modality to deliver protein drugs to
gastrointestinal mucosa when orally administered, and the lectin has demonstrated only
minimal degradation by brush border proteases (468). Other lectins that have
demonstrated stability and binding to glycans in mucin despite the degradative
gastrointestinal environment are Viscum album from mistletoe, Urtica dioica agglutinin
from stinging nettle, Tricum vulgaris from wheat germ, Galanthus nivalis from
snowdrop, Canavalia ensiformis from jack bean, Phaseolus vulgaris from kidney bean,
Ulex europaeus from gorse and Lotus tetragonolobus from the asparagus pea (470). The
stability demonstrated by other lectins supports our studies to develop Q-GRFT as a drug
product for utility in the rectal environment. However, since we have demonstrated this
stability in vitro, there is a need to evaluate Q-GRFT’s resistance to degradation in an in
vivo setting. Ideal experiments would include performing an SDS/ PAGE or Western blot
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analysis of Q-GRFT that has been administered rectally in murine, macaque or human
fluids. The findings would confirm existence or absence of any degradative impact on QGRFT in rectal mucosa.
Additionally, we demonstrate no impact on the growth of bacterial components of
the microbiome. In vivo studies in macaques have identified that GRFT does not
demonstrate any significant impact on the bacterial proteome (203). Contrastingly, some
other lectins have demonstrated antibacterial activity, including against some of the
isolates we tested in our study. A lectin extracted from the mushroom Sparassis latifolia
demonstrated antibacterial activity against Escherichia coli, Staphylococcus aureus and
Pseudomonas aeruginosa (471). The chitin-binding potato lectin, Solanum tuberosum has
inhibitory activity against Escherichia coli, Listeria monocytogenes and Salmonella
entiritidis (472). The MCL lectin from mollusks Mytilus californianus is specific for Dgalactose and N-acetyl-D-galactosamine. MCL inhibited the growth of Escherichia coli
and Lactobacillus planatarum (473). It is possible that differences in the binding glycan
targets for Q-GRFT and other lectins account for the diverging impact on bacterial
microbiota and pathogens.
GRFT is the most potent lectin demonstrating anti-HIV-1 activity that has been
studied so far (165). The gp120 spike on the HIV envelope has about 11 high-mannose
oligosaccharides with which GRFT interacts (166). The lectin displays high affinity and
potency interactions at low picomolar concentrations that are essential in its antiviral
inhibitory activity (6). Amino acid aspartate residues in the binding site (Asp 30, Asp 70,
and Asp 112) are crucial for high mannose interactions (6). Indeed, point mutations in
each amino acid partially inhibited gp120 binding, while GRFT variants with mutations
of all aspartate residues were deprived of HIV-1 binding ability (167).
GRFT demonstrates synergistic antiviral activity with tenofovir (reverse
transcriptase inhibitor), enfuvirtide (gp41 fusion peptide inhibitor), and maraviroc (CCR5
antagonist) (208). In CCR5-tropic cell fusion assays, covalent linkages between GRFT
and C37, a gp41-binding peptide resulted in a several-fold increase in the lectin’s
potency, compared to when GRFT was used alone (474). Combinations of GRFT with
various antiretroviral drugs (entry inhibitors, integrase inhibitors, protease inhibitors and
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reverse transcriptase inhibitors) demonstrated synergistic and additive effects, reducing
cell to cell fusion, and high potency against CD4+ T cell destruction (293). GRFT/
antiretroviral drugs combinations also inhibited viral replication in T cells via inhibition
of DC-SIGN-mediated transmission (293). GRFT’s activity has also been explored in
combination with other carbohydrate binding agents. GRFT has demonstrated synergistic
activity against HIV-1, HIV-2, and other lectin-resistant HIV-1 strains when combined
with Hippearstrum hybrid agglutinin, Galanthum nivalis agglutinin, a mannose-specific
mAb 2G12, microvirin, and banana lectin (475). Glycans on HIV-1 gp120 shield
neutralization-sensitive epitopes from antibody recognition (476). The glycan at position
386 of gp120 shields the CD4 binding domain (476). Disruption of mannose molecules
on gp120 by GRFT likely increases antibody-dependent neutralization of HIV-1 virions
(166). GRFT enhanced the interaction between gp120 and 48d mAb, which recognizes a
CD4 binding domain (477). Furthermore, GRFT enhanced the binding of HIV-1 to plates
coated with mAbs b12 and b6 (476). These findings suggest that GRFT triggers the
exposure of CD4-binding sites on gp120, and promote binding enhancements and
neutralization synergy between the lectin and some mAbs (476).
The intact dimeric GRFT is required for effective anti-HIV-1 activity (9).
Monomeric GRFT (mGRFT) created by inserting either 2 or 4 amino acids at the
dimerization interface did not demonstrate adequate anti-HIV-1 activity, despite viral
binding at the carbohydrate-binding sites (9, 166). The HIV-1 envelope displays few
gp120 spikes (7 to 14) per virion (478, 479). It is postulated that this is a viral adaptation
to evade humoral immunity by limiting multivalent interacts with B cell receptors, given
the wide distance between spikes, attenuating the B cell response (480-482), and
preventing binding by antibodies that would enhance neutralization (482). As with many
other antivirals, HIV-1 may evade the inhibitory activity conferred by GRFT. Viral
resistance to GRFT is largely via the loss of envelope glycosylation sites on gp120 (166).
The loss of glycosylation sites at positions 234 and 295 led to resistance to natural GRFT
(477). Furthermore, de-glycosylation at positions 295, 448, N295, and N448 were
associated with attenuated sensitivity to GRFT (483, 484). Loss of glycosylation at
position 230, 234, 241, 289 in the C2 region, and 339, 392, and 448 in the C3-C4 region
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reduced GRFT inhibitory activity (485). Glycan rearrangement in V4 has also been
shown to induce reduced HIV-1 sensitivity to GRFT (485).
Preliminary data and preclinical studies suggest that Q-GRFT will probably be an
effective antiviral from the prevention of HIV-1 infection and transmission in the rectal
epithelium. Q-GRFT has demonstrated efficacy and utility as a single agent for use
against infection and transmission. However, given the rapidly mutating character of
HIV-1, there is need to further explore Q-GRFT utility as part of a combination regimen
for HIV-1 infection prevention in the rectal environment.
We have shown that Q-GRFT binds to C. albicans and suggested that the lectin
induces ROS formation, with a breach in cell wall integrity. Antifungal activity of
currently used drugs has been established. Polyenes penetrate the fungal cell wall and
bind to ergosterol, causing membrane damage (486). Azoles inhibit C14α demethylation
of lanosterol, interfering with ergosterol synthesis, a component of the cell wall (487).
Despite divergent modes of activity, these antifungal drugs alter cellular metabolism and
respiration, and ultimately result in ROS formation (488). Interestingly, ROS is critical in
cell proliferation, hypoxia adaptation and cell fate determination, however, excessive
ROS causes irreversible damage leading to cell death (489). Metabolic changes and
damage that is initiated upon antifungal interaction with cells results in activation of
stress-like responses, that trigger signaling through the RAS/ PKA pathway (488).
Deletions in RAS pathway genes RAS1 or RAS2 enhanced resistance to antifungal
treatment, while deletion of effector kinases TPK1, TPK2 and TPK3 delayed cell killing
(488). It is also suggested that other pathways may be recruited, with the cell
subsequently activating mitochondrial activity and switching from fermentation to
respiration Abrupt induction of mitochondrial activity leads to overproduction of toxic
ROS, in a manner likely dependent on the tricarboxylic acid (TCA) cycle and electron
transport chain pathways (488). Furthermore, antifungal treatment was associated with
cellular accumulation of monosaccharides and disaccharides like glucose, fructose,
mannose, and disaccharide trehalose. Because production of these sugars is expensive to
the cell requiring a lot to energy to achieve, these metabolic changes likely alter
respiration with subsequent ROS overproduction by the dysfunctional mitochondria
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(488). Ultimately, cell death occurs. It is suggested that antifungal stress may closely
mimic and mirror that due to effects like heat, osmotic stress, and alcoholic stress, which
all result in induction of stress-related pathways (488). This is evidenced by the
similarities in over-activated cellular pathways that are triggered, collapse of cellular
ATP levels, and ROS production in both scenarios (488, 490-492). Antifungal treatment
elevates the AMP/ATP ratio through the rapid consumption of ATP in heightened
cellular metabolism (488). In both bacteria and yeast, ROS damages DNA by introducing
double-strand breaks, and other forms of cellular damage like proteins, and membranes
that lead to cell death (488, 493, 494).
Similarly, several lectins have been found to demonstrate antifungal activity with
the induction of ROS formation. The Machaerium acutifolium (MaL) lectin which
inhibits the growth of C. albicans and C. parapsilosis, alters membrane structure and
induces ROS production in Candida parapsilosis (495). MaL, an N-acetyl-Dglucosamine-binding lectin altered plasma membrane proton-pump ATPase activity,
induced the production of ROS following oxidative stress, with resultant DNA damage.
The mannose-binding lectin, Helja, derived from sunflower plant, inhibited the growth of
C. tropicalis and C. albicans. In addition, Helja induced numerous morphological changes
including inhibiting pseudohyphae formation, altered membrane permeability and
resulted in the production of ROS (496). In our study, Q-GRFT treatment resulted in
enhanced cellular metabolism including pathways responsible for glucose metabolism,
disaccharide synthesis, galactose metabolism, as well as trehalose metabolic processes.
This is indicative of cellular response to stress conditions induced following Q-GRFT
treatment. In addition, antioxidant genes like SOD were upregulated, suggestive of fungal
response to oxidative stress and ROS formation. Q-GRFT further upregulated processes
involved in DNA damage repair, double strand breaks, ATP formation, pathways that
suggested DNA injury following lectin treatment. Altogether, these data suggest
induction of stressful conditions upon Q-GRFT treatment, with induction of intracellular
processes that may subsequently trigger cell death via a ROS-dependent pathway.
Experiments specifically evaluating mitochondrial ROS production, including oxidative
phosphorylation following Q-GRFT treatment will aid in identifying the specific role of
this pathway in fungal response to the lectin.
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In murine studies, we have shown that Q-GRFT significantly prevented infection
and enhanced fungal clearance in a therapeutic model. We also demonstrated that QGRFT’s antifungal activity was not associated with an inflammatory response, when
compared to the nystatin-treated control group. The fact that Q-GRFT did not require an
inflammatory response to inhibit infection is likely a positive property for this lectin,
especially among immunocompromised individuals who may not mount adequate
responses. Indeed, in a rat model, nystatin demonstrated protection against C. albicans,
but up-regulated INFɤ-related cellular responses, IL-17 signaling and enhanced vaginal
epithelial cell (VEC) - IgG mediated immunity (353). Contrastingly, clotrimazole
treatment blocks C. albicans-induced epithelial cell lysis and prevents fungal activation
of the epithelial ‘danger response’ without inducing inflammation (497). Clotrimazole
attenuates local inflammation and significantly reduces the vaginal neutrophilic
infiltration associated with candidiasis (497). Indeed, in the absence of fungal infection,
clotrimazole inhibited epithelial TNF-α-induced IL-8 production and NF-κB activity
(498). High resolution scanning electron microscopy experiments will be helpful in
assessing fungal phenotypic changes in murine vaginal candidiasis. In addition, RNA
sequencing studies will aid in identifying if the in vitro gene expression profiles we
demonstrated herein are preserved in in vivo infections.
Our studies propose developing Q-GRFT for the prevention and treatment of
mucosal infections, including HIV-1, vaginal candidiasis, and SARS-CoV-2. It is
anticipated that Q-GRFT use in these infections will likely involve daily dosing for either
short periods or a couple of days for vaginal candidiasis and coronaviruses infection. As a
rectal microbicide, it is likely to be used ‘as needed’ or an ‘on demand’ product.
Subsequently, serial exposures or chronic use may be associated with the risk of eliciting
immunogenicity in the form of anti-drug antibodies (ADAs) (499). These ADAs are
either neutralizing antibodies that dampen the benefit of the biotherapeutic agent
administered, or non-neutralizing antibodies that may also attenuate efficacy by
impacting pharmacokinetics, pharmacodynamics, and drug clearance (500). Interestingly,
studies have reported the existence of antibodies against non-human sugars and proteins
in healthy individuals (501, 502). Therefore, being algal-derived, it is plausible that QGRFT may be recognized as foreign, triggering an immune response from the body. In
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the murine candidiasis studies described here, we did not assess for ADAs.
Immunogenicity in animal models does not predict that in humans. However, these data
are useful evaluations since immunogenicity in the preclinical models may reveal
potential antibody related toxicities that warrant monitoring in human studies (503). In
the planned Phase 1a study, volunteers will receive a single dose intranasal Q-GRFT
spray. Subsequent exposures will include a multi-dosing regimen. Patient plasma samples
will be collected to evaluate both baseline and subsequent ADAs, with quantification of
specific antibody titers and isotypes/ subclasses. This is important because the initial
exposure primes, while multiple repeat administrations boost the host immune response,
and produce high affinity, high-titer, class switched antibodies (500). If Q-GRFT induces
antibody responses upon administration, epitope de-immunization strategies that reduce
immunogenicity of sequence-modified proteins may be utilized to dampen the effect.
These include rational amino acid substitutions in the peptide sequence without affecting
functionality, and attachment of epitope-masking moieties to decrease immunogenicity
(500, 504).

RECOMMENDATIONS FOR FURTHER STUDY
While our studies have established the efficacy and potential utility of Q-GRFT in
mucosal infections, a number of questions and areas that necessitate further exploration
have been uncovered. It is therefore recommended that further research and experiments
be designed to obtain answers to these questions.
Does Q-GRFT impact the growth of other mucosal fungal infections?
Fungal pathogens A. fumigatus, Cryptococccus and Mucorales are known to cause
mucosal infections that involve oral cavity epithelia, ocular tissues, pulmonary infections,
gastrointestinal tract, and oral lining (505-508), and these often lead to invasive infections
among immunocompromised individuals. The A. fumigatus cell wall consists of
galactomannan in its structure (509), while that of C. neoformans includes mannoproteins
in the outer surface layer (510). Additionally, Mucorales also harbor mannan and
mannoproteins in their cell wall (511). In our in vitro experiments, we have identified α147

mannan as a likely ligand for Q-GRFT interaction in the Candida cell wall structure.
Thus, it would seem possible that Q-GRFT may bind to other fungal pathogens,
especially those that display mannose, and mannan-like structures in their cell wall.
Therefore, in vitro experiments need to be done to determine any inhibitory activity of QGRFT to the growth of other fungal pathogens. Additionally, where effective, animal
studies will be crucial in determining if this activity is preserved in an in vivo setting.
Will Q-GRFT be effective in systemic fungal infections?
Mucosal fungal infections often result in systemic infections. We have
demonstrated that Q-GRFT is efficacious in treating vaginal candidiasis in a murine
model. Additionally, previous studies observed that intravenous administration of a single
dose resulted in detection of GRFT in serum up to 96 hours post-treatment (196).
Designing studies to assess the impact of Q-GRFT on systemic fungal infections,
including candidiasis and other invasive mycoses due to susceptible pathogens will
provide valuable insights into the lectin’s efficacy in related maladies.
What is the impact of Q-GRFT on resident fungal mycobiome in nasal cavity, vagina, gut
and rectum?
In our study, we have demonstrated that Q-GRFT induces death of Candida.
Fungi are often members of the communities that make up commensals in the nasal
cavity, gut, rectum, and vagina environment. Usually, an imbalance in the microbial
community, as seen following antibiotics use (512, 513), leads to overgrowth and
proliferation of Candida (514), with resultant pathogenesis. As mentioned above, QGRFT is currently being developed as a rectal microbicide for the prevention of HIV
infection. We plan to administer Q-GRFT intranasally for COVID-19 prophylaxis in
human subjects. The over-riding question, following the studies performed above, is what
the impact of chronic or recurrent drug use will be on the fungal communities in these
environments? Will this result in death of fungal components with the resultant
overgrowth of bacterial members, which may lead to pathogenesis? Interestingly, chronic
rectal treatment in macaques did not demonstrate any major detrimental changes in the
bacterial microbiome, except the proliferation of Ruminococcaceae and
Christensenellaceae (203). However, this study was not designed to assess the impact of
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GRFT on fungal composition and how this ultimately affected bacterial components.
Studies to assess this scenario may need to be done to answer this question.
Will Q-GRFT’s antifungal effect be maintained in human subjects?
Many drugs show efficacy in animal studies but fail to replicate the similar effects
in human clinical trials. Animal studies are needed to establish if the efficacy of Q-GRFT
in vaginal candidiasis will be maintained in human studies. These studies may be
designed to assess and compare Q-GRFT efficacy with the standard of care for women
with vaginal candidiasis or RVVC. In addition, determining the efficacy in drug-resistant
Candida infections as a single drug, or in combination with other therapeutic antifungals
will enable the determination of its ideal role in vaginal candidiasis.
How does Q-GRFT work in a setting of immune suppression?
From our experiments, it is likely that Q-GRFT binds to C. albicans and results
in the direct killing of the fungal pathogen. Additionally, our animal studies demonstrated
that the inflammatory response was lower following Q-GRFT treatment than in untreated
animals. The innate immune response to Candida infection is responsible for mediating
and mounting a response to clear infection. It is likely that while Q-GRFT reduces the
fungal burden and vaginal colonization, the immune response may eliminate additional
Candida pathogens that may persist. Although our studies were not designed to directly
assess the additional contribution of innate and adaptive immunity during Q-GRFT use,
this is a likely scenario, given that immunocompromised individuals require longer
antifungal treatment durations than immunocompetent individuals (515). Therefore, it is
important to study the efficacy of Q-GRFT in candidiasis, in a setting of
immunosuppression.
Will Q-GRFT be an effective intranasal prophylactic application against SARS-CoV-2
infection? Will the efficacy be maintained for SARS-CoV-2 variants?
We have demonstrated that topical application of corneal and airway epithelium
results in detectable Q-GRFT in these tissues. Whether these results translate into
infection blockade will need to be established in Phase 2 and 3 clinical trials.
Furthermore, Q-GRFT’s efficacy in the setting of multiple emerging SARS-CoV-2
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variants will need to be studied in order to ascertain its potential utility in mucosal
infections.
Can ocular Q-GRFT prevent SARS-CoV-2 infection?
Multiple viruses establish infection through both nasal and ocular tissues (516,
517). Animal and human studies are needed to determine the efficacy of infection
prevention of a Q-GRFT ocular formulation or suspension. This is also an area worth
studying, given the numerous reports suggestive of the ocular route as a portal of SARSCoV-2 infection in humans (228, 229, 518).
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preparation.
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Maryam M. Asgari, Rosalynn M. Nazarian, Victor A. Neel, Alfred Bennett Jenson,
Joongho Joh & Shadmehr Demehri. Immunity to commensal papillomaviruses
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7. Bahr NC, Halupnick R, Linder G, Kiggundu R, Nabeta HW, Williams DA, Musubire AK,
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